Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,17323068,excretion,The mean nickel concentration in blood was 59.6 microg/l and the excretion in urine 700 microg/g creatinine.,Elimination kinetics of metals after an accidental exposure to welding fumes. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17323068/),-1·μg,700,1103,DB01370,Aluminium
,17323068,half-lives,The half-lives were as follows: for aluminium 140 days (urine) and 160 days (plasma); for chromium 40 and 730 days (urine); for nickel 25 and 610 days (urine) as well as 30 and 240 days (blood).,Elimination kinetics of metals after an accidental exposure to welding fumes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17323068/),d,140,1104,DB01370,Aluminium
,17323068,half-lives,The half-lives were as follows: for aluminium 140 days (urine) and 160 days (plasma); for chromium 40 and 730 days (urine); for nickel 25 and 610 days (urine) as well as 30 and 240 days (blood).,Elimination kinetics of metals after an accidental exposure to welding fumes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17323068/),d,160,1105,DB01370,Aluminium
,17323068,half-lives,The half-lives were as follows: for aluminium 140 days (urine) and 160 days (plasma); for chromium 40 and 730 days (urine); for nickel 25 and 610 days (urine) as well as 30 and 240 days (blood).,Elimination kinetics of metals after an accidental exposure to welding fumes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17323068/),d,40,1106,DB01370,Aluminium
,17323068,half-lives,The half-lives were as follows: for aluminium 140 days (urine) and 160 days (plasma); for chromium 40 and 730 days (urine); for nickel 25 and 610 days (urine) as well as 30 and 240 days (blood).,Elimination kinetics of metals after an accidental exposure to welding fumes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17323068/),d,730,1107,DB01370,Aluminium
,17323068,half-lives,The half-lives were as follows: for aluminium 140 days (urine) and 160 days (plasma); for chromium 40 and 730 days (urine); for nickel 25 and 610 days (urine) as well as 30 and 240 days (blood).,Elimination kinetics of metals after an accidental exposure to welding fumes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17323068/),d,25,1108,DB01370,Aluminium
,17323068,half-lives,The half-lives were as follows: for aluminium 140 days (urine) and 160 days (plasma); for chromium 40 and 730 days (urine); for nickel 25 and 610 days (urine) as well as 30 and 240 days (blood).,Elimination kinetics of metals after an accidental exposure to welding fumes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17323068/),d,610,1109,DB01370,Aluminium
,17323068,half-lives,The half-lives were as follows: for aluminium 140 days (urine) and 160 days (plasma); for chromium 40 and 730 days (urine); for nickel 25 and 610 days (urine) as well as 30 and 240 days (blood).,Elimination kinetics of metals after an accidental exposure to welding fumes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17323068/),d,30,1110,DB01370,Aluminium
,17323068,half-lives,The half-lives were as follows: for aluminium 140 days (urine) and 160 days (plasma); for chromium 40 and 730 days (urine); for nickel 25 and 610 days (urine) as well as 30 and 240 days (blood).,Elimination kinetics of metals after an accidental exposure to welding fumes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17323068/),d,240,1111,DB01370,Aluminium
,17323068,renal clearance,The renal clearance of aluminium and nickel was about 2 l/h estimated for the last monitoring day.,Elimination kinetics of metals after an accidental exposure to welding fumes. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17323068/),[l] / [h],2,1112,DB01370,Aluminium
,2720131,AUC,The mean AUC and Cmax from rectal administration were 87 per cent and 62 per cent of the corresponding values achieved after oral administration.,Absorption kinetics of rectally and orally administered ibuprofen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720131/),%,87,1929,DB01370,Aluminium
,2720131,Cmax,The mean AUC and Cmax from rectal administration were 87 per cent and 62 per cent of the corresponding values achieved after oral administration.,Absorption kinetics of rectally and orally administered ibuprofen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720131/),%,62,1930,DB01370,Aluminium
,27671833,C24 h,"However, significant reduction in the trough concentrations of raltegravir was observed: C24 h 0.43 (0.36, 0.51) in the presence of calcium carbonate antacids and 0.42 (0.34, 0.52) in presence of magnesium/aluminium hydroxide, respectively.",Effect of metal-cation antacids on the pharmacokinetics of 1200 mg raltegravir. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27671833/),,0.43,2060,DB01370,Aluminium
,27671833,C24 h,"However, significant reduction in the trough concentrations of raltegravir was observed: C24 h 0.43 (0.36, 0.51) in the presence of calcium carbonate antacids and 0.42 (0.34, 0.52) in presence of magnesium/aluminium hydroxide, respectively.",Effect of metal-cation antacids on the pharmacokinetics of 1200 mg raltegravir. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27671833/),,0.42,2061,DB01370,Aluminium
,3757968,apparent deposition fraction,The apparent deposition fraction was 5.1% after the 1-month exposure.,Pulmonary deposition and clearance of a coal fly ash aerosol by inhalation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3757968/),%,5.1,2144,DB01370,Aluminium
,6860522,systemic bioavailability,"After the oral administration of phenoperidine to two subjects, the systemic bioavailability of the drug was 9.9% and 13.9% respectively.",Effect of antacids on the plasma concentration of phenoperidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6860522/),%,9.9,3519,DB01370,Aluminium
,6860522,systemic bioavailability,"After the oral administration of phenoperidine to two subjects, the systemic bioavailability of the drug was 9.9% and 13.9% respectively.",Effect of antacids on the plasma concentration of phenoperidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6860522/),%,13.9,3520,DB01370,Aluminium
,314299,relative bioavailability,"3 From the AUC-method, a relative bioavailability of 0.60 was calculated.",Effect of aluminum hydroxide on diflunisal absorption. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/314299/),,0.60,4898,DB01370,Aluminium
,10612067,uptake,"We also investigated whether orthosilicic acid promotes the urinary excretion of endogenous Al. Minimum, median uptake of Si from the ingested dose was 50.3% (range: 21.9-74.7%, n = 8) based on urinary analysis following dosing.",Silicic acid: its gastrointestinal uptake and urinary excretion in man and effects on aluminium excretion. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10612067/),%,50.3,5425,DB01370,Aluminium
,10612067,Renal clearance,Renal clearance of Si was 82-96 ml/min suggesting high renal filterability.,Silicic acid: its gastrointestinal uptake and urinary excretion in man and effects on aluminium excretion. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10612067/),[ml] / [min],82-96,5426,DB01370,Aluminium
,3940504,plasma,"Fasting plasma zinc levels, the 2-hour plasma zinc peak, and the area under the plasma zinc curve were significantly lower in patients compared with values in controls (plasma zinc, 92 +/- 4 compared with 108 +/- 3 micrograms/dL, p less than 0.025; 2-hour plasma zinc peak, 159 +/- 8 compared with 228 +/- 17 micrograms/dL, p less than 0.025; and area under the curve, 193 +/- 41 compared with 316 +/- 39 micrograms h/dL, p less than 0.025).",Zinc tolerance test in uremia. Effect of ferrous sulfate and aluminum hydroxide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940504/),[μg] / [dl],159,7621,DB01370,Aluminium
,3940504,peak,"Fasting plasma zinc levels, the 2-hour plasma zinc peak, and the area under the plasma zinc curve were significantly lower in patients compared with values in controls (plasma zinc, 92 +/- 4 compared with 108 +/- 3 micrograms/dL, p less than 0.025; 2-hour plasma zinc peak, 159 +/- 8 compared with 228 +/- 17 micrograms/dL, p less than 0.025; and area under the curve, 193 +/- 41 compared with 316 +/- 39 micrograms h/dL, p less than 0.025).",Zinc tolerance test in uremia. Effect of ferrous sulfate and aluminum hydroxide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940504/),[μg] / [dl],159,7622,DB01370,Aluminium
,3940504,peak,"Fasting plasma zinc levels, the 2-hour plasma zinc peak, and the area under the plasma zinc curve were significantly lower in patients compared with values in controls (plasma zinc, 92 +/- 4 compared with 108 +/- 3 micrograms/dL, p less than 0.025; 2-hour plasma zinc peak, 159 +/- 8 compared with 228 +/- 17 micrograms/dL, p less than 0.025; and area under the curve, 193 +/- 41 compared with 316 +/- 39 micrograms h/dL, p less than 0.025).",Zinc tolerance test in uremia. Effect of ferrous sulfate and aluminum hydroxide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940504/),[μg] / [dl],228,7623,DB01370,Aluminium
,3940504,area under the curve,"Fasting plasma zinc levels, the 2-hour plasma zinc peak, and the area under the plasma zinc curve were significantly lower in patients compared with values in controls (plasma zinc, 92 +/- 4 compared with 108 +/- 3 micrograms/dL, p less than 0.025; 2-hour plasma zinc peak, 159 +/- 8 compared with 228 +/- 17 micrograms/dL, p less than 0.025; and area under the curve, 193 +/- 41 compared with 316 +/- 39 micrograms h/dL, p less than 0.025).",Zinc tolerance test in uremia. Effect of ferrous sulfate and aluminum hydroxide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940504/),[h·μg] / [dl],193,7624,DB01370,Aluminium
,3940504,area under the curve,"Fasting plasma zinc levels, the 2-hour plasma zinc peak, and the area under the plasma zinc curve were significantly lower in patients compared with values in controls (plasma zinc, 92 +/- 4 compared with 108 +/- 3 micrograms/dL, p less than 0.025; 2-hour plasma zinc peak, 159 +/- 8 compared with 228 +/- 17 micrograms/dL, p less than 0.025; and area under the curve, 193 +/- 41 compared with 316 +/- 39 micrograms h/dL, p less than 0.025).",Zinc tolerance test in uremia. Effect of ferrous sulfate and aluminum hydroxide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940504/),[h·μg] / [dl],316,7625,DB01370,Aluminium
,1425718,peak serum levels,"Pharmacokinetics after a single dose of roxithromycin were characterized by high peak serum levels (9.1 +/- 2.1 mg/l) and a long elimination half-life (7.2 +/- 2.5 h), resulting in a large area under the curve (116.9 +/- 32.7 mg h/l).",Pharmacokinetics of roxithromycin and influence of H2-blockers and antacids on gastrointestinal absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425718/),[mg] / [l],9.1,9020,DB01370,Aluminium
,1425718,elimination half-life,"Pharmacokinetics after a single dose of roxithromycin were characterized by high peak serum levels (9.1 +/- 2.1 mg/l) and a long elimination half-life (7.2 +/- 2.5 h), resulting in a large area under the curve (116.9 +/- 32.7 mg h/l).",Pharmacokinetics of roxithromycin and influence of H2-blockers and antacids on gastrointestinal absorption. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425718/),h,7.2,9021,DB01370,Aluminium
,1425718,area under the curve,"Pharmacokinetics after a single dose of roxithromycin were characterized by high peak serum levels (9.1 +/- 2.1 mg/l) and a long elimination half-life (7.2 +/- 2.5 h), resulting in a large area under the curve (116.9 +/- 32.7 mg h/l).",Pharmacokinetics of roxithromycin and influence of H2-blockers and antacids on gastrointestinal absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425718/),[h·mg] / [l],116.9,9022,DB01370,Aluminium
,2724077,elimination half-life,Increasing the administered dose increased the elimination half-life (mean +/- SD) from 1.20 +/- 0.25 to 2.41 +/- 0.26 h.,Kinetics of aluminum in rats I: Dose-dependent elimination from blood after intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2724077/),h,1.20,9118,DB01370,Aluminium
,2724077,elimination half-life,Increasing the administered dose increased the elimination half-life (mean +/- SD) from 1.20 +/- 0.25 to 2.41 +/- 0.26 h.,Kinetics of aluminum in rats I: Dose-dependent elimination from blood after intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2724077/),h,2.41,9119,DB01370,Aluminium
,2724077,systemic clearance,A corresponding decrease in systemic clearance was observed (49.6 +/- 11.0 to 18.4 +/- 4.6 mL/kg.h).,Kinetics of aluminum in rats I: Dose-dependent elimination from blood after intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2724077/),[ml] / [h·kg],49.6,9120,DB01370,Aluminium
,2724077,systemic clearance,A corresponding decrease in systemic clearance was observed (49.6 +/- 11.0 to 18.4 +/- 4.6 mL/kg.h).,Kinetics of aluminum in rats I: Dose-dependent elimination from blood after intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2724077/),[ml] / [h·kg],18.4,9121,DB01370,Aluminium
,2724077,volume of distribution,"Significant differences were also observed in the volume of distribution, the values of which were 78.3 +/- 17.2 and 58.9 +/- 8.5 mL/kg at the low and high doses, respectively.",Kinetics of aluminum in rats I: Dose-dependent elimination from blood after intravenous administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2724077/),[ml] / [kg],78.3,9122,DB01370,Aluminium
,2724077,volume of distribution,"Significant differences were also observed in the volume of distribution, the values of which were 78.3 +/- 17.2 and 58.9 +/- 8.5 mL/kg at the low and high doses, respectively.",Kinetics of aluminum in rats I: Dose-dependent elimination from blood after intravenous administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2724077/),[ml] / [kg],58.9,9123,DB01370,Aluminium
,2724077,blood:plasma ratios,"At both doses, blood:plasma ratios ranged from 0.8 to 1.0, indicating considerable uptake/binding of the element by blood cells.",Kinetics of aluminum in rats I: Dose-dependent elimination from blood after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2724077/),,0.8 to 1.0,9124,DB01370,Aluminium
,1580293,elimination half-life,The elimination half-life of serum aluminum after therapeutic dosing of sucralfate was 13.1 +/- 3.1 days.,Aluminum absorption and excretion following sucralfate therapy in chronic renal insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1580293/),d,13.1,9259,DB01370,Aluminium
,7286040,neutralising capacity,"In 8 healthy subjects the absorption of cimetidine was investigated when given alone, together with 60 ml aluminium/magnesium hydroxide containing antacid (neutralising capacity 26 mmol HCl/10 ml), and together with liquid metoclopramide 14 mg.",Impaired cimetidine absorption due to antacids and metoclopramide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7286040/),[hcl·mM] / [10·ml],26,11176,DB01370,Aluminium
,9416381,recovery,"Multiple linear regression analysis of the spectral absorbance data demonstrated a calculated recovery of tetracycline of 100.9% and, therefore, a lack of in vitro complexation with bismuth.",Reduced tetracycline bioavailability caused by magnesium aluminum silicate in liquid formulations of bismuth subsalicylate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9416381/),%,100.9,11597,DB01370,Aluminium
,26970901,Maximum observed levels,"Maximum observed levels were 1.0 µmol/mol creatinine and 0.8nmol/mol creatinine for 1-OHP and 3-OHBaP, respectively.",Urinary elimination kinetics of 3-hydroxybenzo(a)pyrene and 1-hydroxypyrene of workers in a prebake aluminum electrode production plant: Evaluation of diuresis correction methods for routine biological monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26970901/),[μM] / [mol],1.0,11747,DB01370,Aluminium
,26970901,Maximum observed levels,"Maximum observed levels were 1.0 µmol/mol creatinine and 0.8nmol/mol creatinine for 1-OHP and 3-OHBaP, respectively.",Urinary elimination kinetics of 3-hydroxybenzo(a)pyrene and 1-hydroxypyrene of workers in a prebake aluminum electrode production plant: Evaluation of diuresis correction methods for routine biological monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26970901/),[nM] / [mol],0.8,11748,DB01370,Aluminium
,26970901,Apparent urinary half-life,"Apparent urinary half-life of 1-OHP and 3-OHBaP ranged from 12.0h to 18.2h and from 4.8h to 49.5h, respectively.",Urinary elimination kinetics of 3-hydroxybenzo(a)pyrene and 1-hydroxypyrene of workers in a prebake aluminum electrode production plant: Evaluation of diuresis correction methods for routine biological monitoring. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26970901/),h,12.0,11749,DB01370,Aluminium
,26970901,Apparent urinary half-life,"Apparent urinary half-life of 1-OHP and 3-OHBaP ranged from 12.0h to 18.2h and from 4.8h to 49.5h, respectively.",Urinary elimination kinetics of 3-hydroxybenzo(a)pyrene and 1-hydroxypyrene of workers in a prebake aluminum electrode production plant: Evaluation of diuresis correction methods for routine biological monitoring. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26970901/),h,18.2,11750,DB01370,Aluminium
,26970901,Apparent urinary half-life,"Apparent urinary half-life of 1-OHP and 3-OHBaP ranged from 12.0h to 18.2h and from 4.8h to 49.5h, respectively.",Urinary elimination kinetics of 3-hydroxybenzo(a)pyrene and 1-hydroxypyrene of workers in a prebake aluminum electrode production plant: Evaluation of diuresis correction methods for routine biological monitoring. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26970901/),h,4.8,11751,DB01370,Aluminium
,26970901,Apparent urinary half-life,"Apparent urinary half-life of 1-OHP and 3-OHBaP ranged from 12.0h to 18.2h and from 4.8h to 49.5h, respectively.",Urinary elimination kinetics of 3-hydroxybenzo(a)pyrene and 1-hydroxypyrene of workers in a prebake aluminum electrode production plant: Evaluation of diuresis correction methods for routine biological monitoring. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26970901/),h,49.5,11752,DB01370,Aluminium
,1474531,time to maximum plasma concentration,"At steady state, the time to maximum plasma concentration for 6MNA is 1 to 4 h.",An overview of the clinical pharmacokinetics of nabumetone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1474531/),h,1 to 4,15264,DB01370,Aluminium
,1474531,half-life,6MNA has a very low clearance rate and long half-life (about 24 h).,An overview of the clinical pharmacokinetics of nabumetone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1474531/),h,24,15265,DB01370,Aluminium
,1784003,urinary recoveries,"During the same interval, urinary excretion accounted for 16.7 +/- 2.66 and 8.85 +/- 2.2% of administered dose at the low and high doses, respectively (p less than 0.05); corresponding long term (0 to 13 or 22 days) urinary recoveries were 37.6 +/- 3.67 and 28.4 +/- 1.88% of the injected dose (p less than 0.05), with most (66-70%) of the excretion occurring in the first 24 h.",Kinetics of aluminum in rats. II: Dose-dependent urinary and biliary excretion. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1784003/),,37,16603,DB01370,Aluminium
,1784003,urinary recoveries,"During the same interval, urinary excretion accounted for 16.7 +/- 2.66 and 8.85 +/- 2.2% of administered dose at the low and high doses, respectively (p less than 0.05); corresponding long term (0 to 13 or 22 days) urinary recoveries were 37.6 +/- 3.67 and 28.4 +/- 1.88% of the injected dose (p less than 0.05), with most (66-70%) of the excretion occurring in the first 24 h.",Kinetics of aluminum in rats. II: Dose-dependent urinary and biliary excretion. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1784003/),,28.4,16604,DB01370,Aluminium
,2729939,half-life,"With concomitant antacid therapy, the half-life of intravenous doxycycline was shortened from 16.2 +/- 2.6 to 11.2 +/- 1.2 h (P = 0.003), and total body clearance increased from 37.4 +/- 6.5 to 54.1 +/- 12.3 ml/min (P = 0.008).",Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729939/),h,16.2,17056,DB01370,Aluminium
,2729939,half-life,"With concomitant antacid therapy, the half-life of intravenous doxycycline was shortened from 16.2 +/- 2.6 to 11.2 +/- 1.2 h (P = 0.003), and total body clearance increased from 37.4 +/- 6.5 to 54.1 +/- 12.3 ml/min (P = 0.008).",Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729939/),h,11.2,17057,DB01370,Aluminium
,2729939,total body clearance,"With concomitant antacid therapy, the half-life of intravenous doxycycline was shortened from 16.2 +/- 2.6 to 11.2 +/- 1.2 h (P = 0.003), and total body clearance increased from 37.4 +/- 6.5 to 54.1 +/- 12.3 ml/min (P = 0.008).",Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729939/),[ml] / [min],37.4,17058,DB01370,Aluminium
,2729939,total body clearance,"With concomitant antacid therapy, the half-life of intravenous doxycycline was shortened from 16.2 +/- 2.6 to 11.2 +/- 1.2 h (P = 0.003), and total body clearance increased from 37.4 +/- 6.5 to 54.1 +/- 12.3 ml/min (P = 0.008).",Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729939/),[ml] / [min],54.1,17059,DB01370,Aluminium
,8684530,mean arrival times,"In the 6 patients studied, the mean arrival times of DFO, aluminoxamine (AlO) and ferrioxamine (FO) were, respectively, 193, 1,350 and 126 min, the mean residence times were 1,048, infinite, 1,190 min, respectively.",Estimation of statistical moments for desferrioxamine and its iron and aluminum chelates: contribution to optimisation of therapy in uremic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8684530/),min,193,18189,DB01370,Aluminium
,8684530,mean arrival times,"In the 6 patients studied, the mean arrival times of DFO, aluminoxamine (AlO) and ferrioxamine (FO) were, respectively, 193, 1,350 and 126 min, the mean residence times were 1,048, infinite, 1,190 min, respectively.",Estimation of statistical moments for desferrioxamine and its iron and aluminum chelates: contribution to optimisation of therapy in uremic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8684530/),min,"1,350",18190,DB01370,Aluminium
,8684530,mean arrival times,"In the 6 patients studied, the mean arrival times of DFO, aluminoxamine (AlO) and ferrioxamine (FO) were, respectively, 193, 1,350 and 126 min, the mean residence times were 1,048, infinite, 1,190 min, respectively.",Estimation of statistical moments for desferrioxamine and its iron and aluminum chelates: contribution to optimisation of therapy in uremic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8684530/),min,126,18191,DB01370,Aluminium
,8684530,mean residence times,"In the 6 patients studied, the mean arrival times of DFO, aluminoxamine (AlO) and ferrioxamine (FO) were, respectively, 193, 1,350 and 126 min, the mean residence times were 1,048, infinite, 1,190 min, respectively.",Estimation of statistical moments for desferrioxamine and its iron and aluminum chelates: contribution to optimisation of therapy in uremic patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8684530/),min,"1,048",18192,DB01370,Aluminium
,8684530,mean residence times,"In the 6 patients studied, the mean arrival times of DFO, aluminoxamine (AlO) and ferrioxamine (FO) were, respectively, 193, 1,350 and 126 min, the mean residence times were 1,048, infinite, 1,190 min, respectively.",Estimation of statistical moments for desferrioxamine and its iron and aluminum chelates: contribution to optimisation of therapy in uremic patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8684530/),min,infinite,18193,DB01370,Aluminium
,8684530,mean residence times,"In the 6 patients studied, the mean arrival times of DFO, aluminoxamine (AlO) and ferrioxamine (FO) were, respectively, 193, 1,350 and 126 min, the mean residence times were 1,048, infinite, 1,190 min, respectively.",Estimation of statistical moments for desferrioxamine and its iron and aluminum chelates: contribution to optimisation of therapy in uremic patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8684530/),min,"1,190",18194,DB01370,Aluminium
,7991226,systemic clearance,"The pharmacokinetic studies revealed that systemic clearance, elimination half-life and mean residence time were 42 (+/- 5) ml/hr/kg, 2.2 (+/- 0.5) hr and 3.1 (+/- 0.7) hr [mean +/- SD), respectively.",Pharmacokinetics and distribution of tris(maltolato)aluminum(III) into the central nervous system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7991226/),[ml] / [h·kg],42,18780,DB01370,Aluminium
,7991226,elimination half-life,"The pharmacokinetic studies revealed that systemic clearance, elimination half-life and mean residence time were 42 (+/- 5) ml/hr/kg, 2.2 (+/- 0.5) hr and 3.1 (+/- 0.7) hr [mean +/- SD), respectively.",Pharmacokinetics and distribution of tris(maltolato)aluminum(III) into the central nervous system. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7991226/),h,2.2,18781,DB01370,Aluminium
,7991226,mean residence time,"The pharmacokinetic studies revealed that systemic clearance, elimination half-life and mean residence time were 42 (+/- 5) ml/hr/kg, 2.2 (+/- 0.5) hr and 3.1 (+/- 0.7) hr [mean +/- SD), respectively.",Pharmacokinetics and distribution of tris(maltolato)aluminum(III) into the central nervous system. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7991226/),h,3.1,18782,DB01370,Aluminium
,7991226,steady state volume of distribution (Vss),The steady state volume of distribution (Vss) for Al-maltolate was 130 ml/kg.,Pharmacokinetics and distribution of tris(maltolato)aluminum(III) into the central nervous system. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7991226/),[ml] / [kg],130,18783,DB01370,Aluminium
,7991226,brain/blood ration,"The Al brain/blood ration calculated from Al-maltolate steady state brain and blood MD samples was 0.04, significantly less than those calculated for other Al salts at equimolar Al doses.",Pharmacokinetics and distribution of tris(maltolato)aluminum(III) into the central nervous system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7991226/),,0.04,18784,DB01370,Aluminium
,15886704,half-lives,Pharmacokinetic studies after intraperitoneal administration showed that the serum level of AlPcS(2a) fitted a biexponential model (half-lives of 1.8 and 26.7 h).,Enhanced photodynamic destruction of a transplantable fibrosarcoma using photochemical internalisation of gelonin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15886704/),h,1.8,20194,DB01370,Aluminium
,15886704,half-lives,Pharmacokinetic studies after intraperitoneal administration showed that the serum level of AlPcS(2a) fitted a biexponential model (half-lives of 1.8 and 26.7 h).,Enhanced photodynamic destruction of a transplantable fibrosarcoma using photochemical internalisation of gelonin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15886704/),h,26.7,20195,DB01370,Aluminium
,15886704,depth of necrosis,"In tumours examined histologically 4 days after light delivery, the depth of necrosis was 3-4 mm after PDT, but 7 mm after PCI.",Enhanced photodynamic destruction of a transplantable fibrosarcoma using photochemical internalisation of gelonin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15886704/),mm,3-4,20196,DB01370,Aluminium
,15886704,depth of necrosis,"In tumours examined histologically 4 days after light delivery, the depth of necrosis was 3-4 mm after PDT, but 7 mm after PCI.",Enhanced photodynamic destruction of a transplantable fibrosarcoma using photochemical internalisation of gelonin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15886704/),mm,7,20197,DB01370,Aluminium
,3620295,half-lives,"In controls, rapid and slow phases of decline in plasma DFA concentrations were found, with half-lives of 1.0 h and 6.1 h, respectively.",Pharmacokinetics and renal elimination of desferrioxamine and ferrioxamine in healthy subjects and patients with haemochromatosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3620295/),h,1.0,20364,DB01370,Aluminium
,3620295,half-lives,"In controls, rapid and slow phases of decline in plasma DFA concentrations were found, with half-lives of 1.0 h and 6.1 h, respectively.",Pharmacokinetics and renal elimination of desferrioxamine and ferrioxamine in healthy subjects and patients with haemochromatosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3620295/),h,6.1,20365,DB01370,Aluminium
,3620295,half-life,"In the patients, only a single phase of decline was observed, with a half-life of 5.6 h.",Pharmacokinetics and renal elimination of desferrioxamine and ferrioxamine in healthy subjects and patients with haemochromatosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3620295/),h,5.6,20366,DB01370,Aluminium
,3620295,Total clearances,Total clearances of DFA were 296 ml h-1 kg-1 in controls and 239 ml h-1 kg-1 in patients.,Pharmacokinetics and renal elimination of desferrioxamine and ferrioxamine in healthy subjects and patients with haemochromatosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3620295/),[ml] / [h·kg],296,20367,DB01370,Aluminium
,3620295,Total clearances,Total clearances of DFA were 296 ml h-1 kg-1 in controls and 239 ml h-1 kg-1 in patients.,Pharmacokinetics and renal elimination of desferrioxamine and ferrioxamine in healthy subjects and patients with haemochromatosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3620295/),[ml] / [h·kg],239,20368,DB01370,Aluminium
,3620295,renal clearances,"The amount of FeA eliminated in urine during 6 h was significantly lower in controls (8.0 +/- 4.6 mumol) than in patients (129.2 +/- 40.0 mumol), with respective renal clearances estimated over 6 h of 516 ml h-1 kg-1 and 1,716 ml h-1 kg-1.",Pharmacokinetics and renal elimination of desferrioxamine and ferrioxamine in healthy subjects and patients with haemochromatosis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3620295/),[ml] / [h·kg],516,20369,DB01370,Aluminium
,3620295,renal clearances,"The amount of FeA eliminated in urine during 6 h was significantly lower in controls (8.0 +/- 4.6 mumol) than in patients (129.2 +/- 40.0 mumol), with respective renal clearances estimated over 6 h of 516 ml h-1 kg-1 and 1,716 ml h-1 kg-1.",Pharmacokinetics and renal elimination of desferrioxamine and ferrioxamine in healthy subjects and patients with haemochromatosis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3620295/),[ml] / [h·kg],"1,716",20370,DB01370,Aluminium
,3620295,renal clearance,DFA elimination was similar in both groups and its renal clearance estimated over 6 h was 91 ml h-1 kg-1 in controls and 85 ml h-1 kg-1 in patients.,Pharmacokinetics and renal elimination of desferrioxamine and ferrioxamine in healthy subjects and patients with haemochromatosis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3620295/),[ml] / [h·kg],91,20371,DB01370,Aluminium
,3620295,renal clearance,DFA elimination was similar in both groups and its renal clearance estimated over 6 h was 91 ml h-1 kg-1 in controls and 85 ml h-1 kg-1 in patients.,Pharmacokinetics and renal elimination of desferrioxamine and ferrioxamine in healthy subjects and patients with haemochromatosis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3620295/),[ml] / [h·kg],85,20372,DB01370,Aluminium
,9885302,adsorption capacities,"Other antacids investigated were magnesium trisilicate and aluminium hydroxide and these had Hf-adsorption capacities of 23 and 43%, respectively.","Altered pharmacokinetics of halofantrine by an antacid, magnesium carbonate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9885302/),%,23,21403,DB01370,Aluminium
,9885302,adsorption capacities,"Other antacids investigated were magnesium trisilicate and aluminium hydroxide and these had Hf-adsorption capacities of 23 and 43%, respectively.","Altered pharmacokinetics of halofantrine by an antacid, magnesium carbonate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9885302/),%,43,21404,DB01370,Aluminium
,6737263,half-life,"The nephrectomized group and the control group exhibited differences in the following pharmacokinetic parameters: half-life, 5.0 versus 4.1 h (significant at p less than 0.1); total body clearance, 8.4 versus 13.2 mL/min/kg (significant at p less than 0.1); and volume of distribution, 2.7 versus 3.8 L/kg (significant at p less than 0.1).",Disposition kinetics of ethambutol in nephrectomized dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737263/),h,5.0,21441,DB01370,Aluminium
,6737263,half-life,"The nephrectomized group and the control group exhibited differences in the following pharmacokinetic parameters: half-life, 5.0 versus 4.1 h (significant at p less than 0.1); total body clearance, 8.4 versus 13.2 mL/min/kg (significant at p less than 0.1); and volume of distribution, 2.7 versus 3.8 L/kg (significant at p less than 0.1).",Disposition kinetics of ethambutol in nephrectomized dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737263/),h,4.1,21442,DB01370,Aluminium
,6737263,total body clearance,"The nephrectomized group and the control group exhibited differences in the following pharmacokinetic parameters: half-life, 5.0 versus 4.1 h (significant at p less than 0.1); total body clearance, 8.4 versus 13.2 mL/min/kg (significant at p less than 0.1); and volume of distribution, 2.7 versus 3.8 L/kg (significant at p less than 0.1).",Disposition kinetics of ethambutol in nephrectomized dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737263/),[ml] / [kg·min],8.4,21443,DB01370,Aluminium
,6737263,total body clearance,"The nephrectomized group and the control group exhibited differences in the following pharmacokinetic parameters: half-life, 5.0 versus 4.1 h (significant at p less than 0.1); total body clearance, 8.4 versus 13.2 mL/min/kg (significant at p less than 0.1); and volume of distribution, 2.7 versus 3.8 L/kg (significant at p less than 0.1).",Disposition kinetics of ethambutol in nephrectomized dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737263/),[ml] / [kg·min],13.2,21444,DB01370,Aluminium
,6737263,volume of distribution,"The nephrectomized group and the control group exhibited differences in the following pharmacokinetic parameters: half-life, 5.0 versus 4.1 h (significant at p less than 0.1); total body clearance, 8.4 versus 13.2 mL/min/kg (significant at p less than 0.1); and volume of distribution, 2.7 versus 3.8 L/kg (significant at p less than 0.1).",Disposition kinetics of ethambutol in nephrectomized dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737263/),[l] / [kg],2.7,21445,DB01370,Aluminium
,6737263,volume of distribution,"The nephrectomized group and the control group exhibited differences in the following pharmacokinetic parameters: half-life, 5.0 versus 4.1 h (significant at p less than 0.1); total body clearance, 8.4 versus 13.2 mL/min/kg (significant at p less than 0.1); and volume of distribution, 2.7 versus 3.8 L/kg (significant at p less than 0.1).",Disposition kinetics of ethambutol in nephrectomized dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737263/),[l] / [kg],3.8,21446,DB01370,Aluminium
,9855317,Cmax,"Both fasting conditions produced similar results: mean PZA Cmax 53.4+/-10.4 microg/ml, Tmax 1.43+/-1.06 hours, and AUC(0-infinity) 673+/-79.7 microg x hr/ml.","Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855317/),[μg] / [ml],53.4,23533,DB01370,Aluminium
,9855317,Tmax,"Both fasting conditions produced similar results: mean PZA Cmax 53.4+/-10.4 microg/ml, Tmax 1.43+/-1.06 hours, and AUC(0-infinity) 673+/-79.7 microg x hr/ml.","Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855317/),h,1.43,23534,DB01370,Aluminium
,9855317,AUC(0-infinity),"Both fasting conditions produced similar results: mean PZA Cmax 53.4+/-10.4 microg/ml, Tmax 1.43+/-1.06 hours, and AUC(0-infinity) 673+/-79.7 microg x hr/ml.","Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855317/),[h·μg] / [ml],673,23535,DB01370,Aluminium
,9855317,Cmax,"In the presence of antacids, subjects had a mean Cmax of 55.6+/-9.0 microg/ml, Tmax of 1.43+/-1.23 hours, and AUC(0-infinity) of 628+/-88.4 microg x hr/ml.","Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855317/),[μg] / [ml],55.6,23536,DB01370,Aluminium
,9855317,Tmax,"In the presence of antacids, subjects had a mean Cmax of 55.6+/-9.0 microg/ml, Tmax of 1.43+/-1.23 hours, and AUC(0-infinity) of 628+/-88.4 microg x hr/ml.","Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855317/),h,1.43,23537,DB01370,Aluminium
,9855317,AUC(0-infinity),"In the presence of antacids, subjects had a mean Cmax of 55.6+/-9.0 microg/ml, Tmax of 1.43+/-1.23 hours, and AUC(0-infinity) of 628+/-88.4 microg x hr/ml.","Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855317/),[h·μg] / [ml],628,23538,DB01370,Aluminium
,9855317,Cmax,"In the presence of the high-fat meal, mean Cmax was 45.6+/-9.44 pg/ml, Tmax 3.09+/-1.74 hours, and AUC(0-infinity) 687+/-116 microg x hr/ml.","Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855317/),[pg] / [ml],45.6,23539,DB01370,Aluminium
,9855317,Tmax,"In the presence of the high-fat meal, mean Cmax was 45.6+/-9.44 pg/ml, Tmax 3.09+/-1.74 hours, and AUC(0-infinity) 687+/-116 microg x hr/ml.","Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855317/),h,3.09,23540,DB01370,Aluminium
,9855317,AUC(0-infinity),"In the presence of the high-fat meal, mean Cmax was 45.6+/-9.44 pg/ml, Tmax 3.09+/-1.74 hours, and AUC(0-infinity) 687+/-116 microg x hr/ml.","Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855317/),[h·μg] / [ml],687,23541,DB01370,Aluminium
,1510420,maximum concentrations (Cmax),"When cefprozil was administered alone (treatment A), the mean maximum concentrations (Cmax) of the cis and trans isomers were 9.2 and 1.2 micrograms/ml, respectively.",Effect of antacid on the bioavailability of cefprozil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1510420/),[μg] / [ml],9.2,25238,DB01370,Aluminium
,1510420,maximum concentrations (Cmax),"When cefprozil was administered alone (treatment A), the mean maximum concentrations (Cmax) of the cis and trans isomers were 9.2 and 1.2 micrograms/ml, respectively.",Effect of antacid on the bioavailability of cefprozil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1510420/),[μg] / [ml],1.2,25239,DB01370,Aluminium
,1510420,Cmax,"When cefprozil was coadministered with Maalox (treatment B), the Cmax values of the cis and trans isomers were 8.7 and 1.3 micrograms/ml, respectively.",Effect of antacid on the bioavailability of cefprozil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1510420/),[μg] / [ml],8.7,25240,DB01370,Aluminium
,1510420,Cmax,"When cefprozil was coadministered with Maalox (treatment B), the Cmax values of the cis and trans isomers were 8.7 and 1.3 micrograms/ml, respectively.",Effect of antacid on the bioavailability of cefprozil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1510420/),[μg] / [ml],1.3,25241,DB01370,Aluminium
,1510420,area under the curve from time zero to infinity (AUC0-infinity),"The mean values of the area under the curve from time zero to infinity (AUC0-infinity) were 27.7 and 3.5 micrograms.h/ml for treatment A and 27.5 and 3.5 micrograms.h/ml for treatment B for the cis and trans isomers, respectively.",Effect of antacid on the bioavailability of cefprozil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1510420/),[h·μg] / [ml],27.7,25242,DB01370,Aluminium
,1510420,area under the curve from time zero to infinity (AUC0-infinity),"The mean values of the area under the curve from time zero to infinity (AUC0-infinity) were 27.7 and 3.5 micrograms.h/ml for treatment A and 27.5 and 3.5 micrograms.h/ml for treatment B for the cis and trans isomers, respectively.",Effect of antacid on the bioavailability of cefprozil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1510420/),[h·μg] / [ml],3.5,25243,DB01370,Aluminium
,1510420,area under the curve from time zero to infinity (AUC0-infinity),"The mean values of the area under the curve from time zero to infinity (AUC0-infinity) were 27.7 and 3.5 micrograms.h/ml for treatment A and 27.5 and 3.5 micrograms.h/ml for treatment B for the cis and trans isomers, respectively.",Effect of antacid on the bioavailability of cefprozil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1510420/),[h·μg] / [ml],27.5,25244,DB01370,Aluminium
,1510420,elimination half-life,The respective values of the elimination half-life for the cis and trans isomers were 1.36 and 1.32 h for treatment A and 1.36 and 1.42 h for treatment B.,Effect of antacid on the bioavailability of cefprozil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1510420/),h,1.36,25245,DB01370,Aluminium
,1510420,elimination half-life,The respective values of the elimination half-life for the cis and trans isomers were 1.36 and 1.32 h for treatment A and 1.36 and 1.42 h for treatment B.,Effect of antacid on the bioavailability of cefprozil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1510420/),h,1.32,25246,DB01370,Aluminium
,1510420,elimination half-life,The respective values of the elimination half-life for the cis and trans isomers were 1.36 and 1.32 h for treatment A and 1.36 and 1.42 h for treatment B.,Effect of antacid on the bioavailability of cefprozil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1510420/),h,1.42,25247,DB01370,Aluminium
,1510420,urinary excretion,"Mean urinary excretion was 63 and 60% for treatment A and 58 and 56% for treatment B for the cis and trans isomers, respectively.",Effect of antacid on the bioavailability of cefprozil. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1510420/),%,63,25248,DB01370,Aluminium
,1510420,urinary excretion,"Mean urinary excretion was 63 and 60% for treatment A and 58 and 56% for treatment B for the cis and trans isomers, respectively.",Effect of antacid on the bioavailability of cefprozil. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1510420/),%,60,25249,DB01370,Aluminium
,1510420,urinary excretion,"Mean urinary excretion was 63 and 60% for treatment A and 58 and 56% for treatment B for the cis and trans isomers, respectively.",Effect of antacid on the bioavailability of cefprozil. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1510420/),%,58,25250,DB01370,Aluminium
,1510420,urinary excretion,"Mean urinary excretion was 63 and 60% for treatment A and 58 and 56% for treatment B for the cis and trans isomers, respectively.",Effect of antacid on the bioavailability of cefprozil. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1510420/),%,56,25251,DB01370,Aluminium
,1510420,bioavailability,"For the cis isomer, bioavailability point estimates (90% confidence intervals) of the mean Cmax and AUG0-infinity values for the Maalox treatment relative to those for the reference treatment were 95% (87%, 103%) and 99% (95%, 104%), respectively.",Effect of antacid on the bioavailability of cefprozil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1510420/),%,95,25252,DB01370,Aluminium
,1510420,bioavailability,"For the cis isomer, bioavailability point estimates (90% confidence intervals) of the mean Cmax and AUG0-infinity values for the Maalox treatment relative to those for the reference treatment were 95% (87%, 103%) and 99% (95%, 104%), respectively.",Effect of antacid on the bioavailability of cefprozil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1510420/),%,99,25253,DB01370,Aluminium
,8067750,relative bioavailability,"The relative bioavailability of pefloxacin after the antacid treatment was 44.4% +/- 23.8%, compared with that after a single administration.","Effect of an antacid containing magnesium and aluminum on absorption, metabolism, and mechanism of renal elimination of pefloxacin in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8067750/),%,44.4,27423,DB01370,Aluminium
,8257146,percent relative bioavailability,"Administration of antacid within 5 min before the administration of rufloxacin resulted in a substantial decrease in rufloxacin absorption, with a mean percent relative bioavailability compared with control values of 64% (range, 42 to 77%).",Effects of magnesium-aluminum hydroxide antacid on absorption of rufloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257146/),%,64,27424,DB01370,Aluminium
,8257146,relative bioavailability,"Administration of antacid 4 h after the administration of rufloxacin slightly affected the absorption of the quinolone (mean relative bioavailability, 87%; range, 51 to 110%).",Effects of magnesium-aluminum hydroxide antacid on absorption of rufloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257146/),%,87,27425,DB01370,Aluminium
,15080766,C(max),"Arithmetic mean plasma lumiracoxib concentration-time profiles were similar for all treatments, with a rapid rise in concentration after administration, reaching C(max) values (mean +/- SD) of 9.24 +/- 1.96, 8.81 +/- 2.30, and 10.43 +/- 3.24 mg/L within 2-3 hours for treatments A, B and C, respectively.",Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080766/),[mg] / [l],9.24,28553,DB01370,Aluminium
,15080766,C(max),"Arithmetic mean plasma lumiracoxib concentration-time profiles were similar for all treatments, with a rapid rise in concentration after administration, reaching C(max) values (mean +/- SD) of 9.24 +/- 1.96, 8.81 +/- 2.30, and 10.43 +/- 3.24 mg/L within 2-3 hours for treatments A, B and C, respectively.",Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080766/),[mg] / [l],8.81,28554,DB01370,Aluminium
,15080766,C(max),"Arithmetic mean plasma lumiracoxib concentration-time profiles were similar for all treatments, with a rapid rise in concentration after administration, reaching C(max) values (mean +/- SD) of 9.24 +/- 1.96, 8.81 +/- 2.30, and 10.43 +/- 3.24 mg/L within 2-3 hours for treatments A, B and C, respectively.",Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080766/),[mg] / [l],10.43,28555,DB01370,Aluminium
,15080766,AUC( infinity ),"AUC( infinity ) was similar for the three treatments (36.75 +/- 7.73, 34.88 +/- 8.40 and 35.50 +/- 5.72 mg.",Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080766/),mg,36.75,28556,DB01370,Aluminium
,15080766,AUC( infinity ),"AUC( infinity ) was similar for the three treatments (36.75 +/- 7.73, 34.88 +/- 8.40 and 35.50 +/- 5.72 mg.",Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080766/),mg,34.88,28557,DB01370,Aluminium
,15080766,AUC( infinity ),"AUC( infinity ) was similar for the three treatments (36.75 +/- 7.73, 34.88 +/- 8.40 and 35.50 +/- 5.72 mg.",Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080766/),mg,35.50,28558,DB01370,Aluminium
,1036700,extent of absorption,A minimum value for the extent of absorption of an oral dose was estimated as 21%.,The absorption of [G-3H]-acetylglycyrrhetate after oral administration to rats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1036700/),%,21,28701,DB01370,Aluminium
,24245252,basal spacing,"According to the powder X-ray diffraction pattern, the basal spacing of the intraconazole-layered aluminosilicate nanohybrid increased from 14.7 to 22.7 A depending on the pH of the aqueous suspension.",Heterostructured layered aluminosilicate-itraconazole nanohybrid for drug delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24245252/),a,14.7,28868,DB01370,Aluminium
,24245252,basal spacing,"According to the powder X-ray diffraction pattern, the basal spacing of the intraconazole-layered aluminosilicate nanohybrid increased from 14.7 to 22.7 A depending on the pH of the aqueous suspension.",Heterostructured layered aluminosilicate-itraconazole nanohybrid for drug delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24245252/),a,22.7,28869,DB01370,Aluminium
,24245252,area under the plasma concentration-time curve (AUC,"The pharmacokinetic data for the nanohybrid and Sporanox showed that the mean area under the plasma concentration-time curve (AUC, 2477 +/- 898 ng x hr/mL and 2630 +/- 953 ng x hr/mL, respectively) and maximum concentration (Cmax, 225.4 +/- 77.4 ng x hr/mL and 223.6 +/- 51.9 ng x hr/mL, respectively), were within the bioequivalence (BE) range.",Heterostructured layered aluminosilicate-itraconazole nanohybrid for drug delivery system. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24245252/),[h·ng] / [ml],2477,28870,DB01370,Aluminium
,24245252,area under the plasma concentration-time curve (AUC,"The pharmacokinetic data for the nanohybrid and Sporanox showed that the mean area under the plasma concentration-time curve (AUC, 2477 +/- 898 ng x hr/mL and 2630 +/- 953 ng x hr/mL, respectively) and maximum concentration (Cmax, 225.4 +/- 77.4 ng x hr/mL and 223.6 +/- 51.9 ng x hr/mL, respectively), were within the bioequivalence (BE) range.",Heterostructured layered aluminosilicate-itraconazole nanohybrid for drug delivery system. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24245252/),[h·ng] / [ml],2630,28871,DB01370,Aluminium
,24245252,maximum concentration (Cmax,"The pharmacokinetic data for the nanohybrid and Sporanox showed that the mean area under the plasma concentration-time curve (AUC, 2477 +/- 898 ng x hr/mL and 2630 +/- 953 ng x hr/mL, respectively) and maximum concentration (Cmax, 225.4 +/- 77.4 ng x hr/mL and 223.6 +/- 51.9 ng x hr/mL, respectively), were within the bioequivalence (BE) range.",Heterostructured layered aluminosilicate-itraconazole nanohybrid for drug delivery system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24245252/),[h·ng] / [ml],225.4,28872,DB01370,Aluminium
,24245252,maximum concentration (Cmax,"The pharmacokinetic data for the nanohybrid and Sporanox showed that the mean area under the plasma concentration-time curve (AUC, 2477 +/- 898 ng x hr/mL and 2630 +/- 953 ng x hr/mL, respectively) and maximum concentration (Cmax, 225.4 +/- 77.4 ng x hr/mL and 223.6 +/- 51.9 ng x hr/mL, respectively), were within the bioequivalence (BE) range.",Heterostructured layered aluminosilicate-itraconazole nanohybrid for drug delivery system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24245252/),[h·ng] / [ml],223.6,28873,DB01370,Aluminium
,33428954,shelf life,The estimated shelf life of OF formulation was found to be 3.86 years suggested better stability after fabrication.,Development and statistical optimization of alginate-Neusilin US2 micro-composite beads to elicit gastric stability and sustained action of hesperidin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33428954/),years,3.86,30632,DB01370,Aluminium
,23960758,T 0.5,"In both matrices, rapid degradation of drug favored and the T 0.5 of drug ranged from 9.92 to 12.41 h at 4 °C and from 6.31 to 9.13 h at 20 °C.",A validated HPTLC method for determination of terbutaline sulfate in biological samples: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23960758/),h,9.92 to 12.41,31765,DB01370,Aluminium
,23960758,T 0.5,"In both matrices, rapid degradation of drug favored and the T 0.5 of drug ranged from 9.92 to 12.41 h at 4 °C and from 6.31 to 9.13 h at 20 °C.",A validated HPTLC method for determination of terbutaline sulfate in biological samples: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23960758/),h,6.31 to 9.13,31766,DB01370,Aluminium
,23960758,maximum plasma concentration (Cpmax),"The maximum plasma concentration (Cpmax) was found to be 5875.03 ± 114 ng mL(-1), which is significantly higher than the maximum saliva concentration (Csmax, 1501.69 ± 96 ng mL(-1)).",A validated HPTLC method for determination of terbutaline sulfate in biological samples: Application to pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23960758/),[ng] / [ml],5875.03,31767,DB01370,Aluminium
,23960758,maximum saliva concentration (Csmax,"The maximum plasma concentration (Cpmax) was found to be 5875.03 ± 114 ng mL(-1), which is significantly higher than the maximum saliva concentration (Csmax, 1501.69 ± 96 ng mL(-1)).",A validated HPTLC method for determination of terbutaline sulfate in biological samples: Application to pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23960758/),[ng] / [ml],1501.69,31768,DB01370,Aluminium
,3975904,Al concentration,Baseline pretreatment Al concentration averaged 138 ng/ml in serum and 710 ng/ml in milk.,Aluminum bioavailability and disposition in adult and immature rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3975904/),[ng] / [ml],138,33230,DB01370,Aluminium
,3975904,Al concentration,Baseline pretreatment Al concentration averaged 138 ng/ml in serum and 710 ng/ml in milk.,Aluminum bioavailability and disposition in adult and immature rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3975904/),[ng] / [ml],710,33231,DB01370,Aluminium
,3975904,Systemic bioavailability,Systemic bioavailability of Al after low- (0.7 +/- 0.5% means +/- SD) and high-dose po Al (1.9 +/- 1.7%) was not significantly different.,Aluminum bioavailability and disposition in adult and immature rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3975904/),%,0.7,33232,DB01370,Aluminium
,3975904,Systemic bioavailability,Systemic bioavailability of Al after low- (0.7 +/- 0.5% means +/- SD) and high-dose po Al (1.9 +/- 1.7%) was not significantly different.,Aluminum bioavailability and disposition in adult and immature rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3975904/),%,1.9,33233,DB01370,Aluminium
,3975904,Bioavailability,Bioavailability of sc Al was 27 +/- 7%.,Aluminum bioavailability and disposition in adult and immature rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3975904/),%,27,33234,DB01370,Aluminium
,6491908,Half-lives,Half-lives of ethambutol ranged from 2.26 to 5.20 h when administered alone and 2.18 to 4.00 h when coadministered with the antacid; the difference was not significant (p greater than 0.3).,Absorption and disposition of ethambutol in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6491908/),h,2.26 to 5.20,37481,DB01370,Aluminium
,6491908,Half-lives,Half-lives of ethambutol ranged from 2.26 to 5.20 h when administered alone and 2.18 to 4.00 h when coadministered with the antacid; the difference was not significant (p greater than 0.3).,Absorption and disposition of ethambutol in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6491908/),h,2.18 to 4.00,37482,DB01370,Aluminium
,6491908,clearance,"Mean clearance after the oral administrations (189.2 mL/min/kg) was significantly greater than the mean intravenous clearance (43.7 mL/min/kg) (p less than 0.01), suggesting a first-pass metabolism of ethambutol when administered nonparenterally to rabbits.",Absorption and disposition of ethambutol in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6491908/),[ml] / [kg·min],189.2,37483,DB01370,Aluminium
,6491908,clearance,"Mean clearance after the oral administrations (189.2 mL/min/kg) was significantly greater than the mean intravenous clearance (43.7 mL/min/kg) (p less than 0.01), suggesting a first-pass metabolism of ethambutol when administered nonparenterally to rabbits.",Absorption and disposition of ethambutol in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6491908/),[ml] / [kg·min],43.7,37484,DB01370,Aluminium
,6491908,volume of distribution,"The volume of distribution ranged from 5.5 to 17.8 L/kg, suggesting an extensive distribution of ethambutol outside the central compartment and, possibly, a localized deposit within the body tissues.",Absorption and disposition of ethambutol in rabbits. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6491908/),[l] / [kg],5.5 to 17.8,37485,DB01370,Aluminium
,6491908,bioavailability,Mean bioavailability of ethambutol was approximately 28% and was not affected by the presence of aluminum hydroxide.,Absorption and disposition of ethambutol in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6491908/),%,28,37486,DB01370,Aluminium
,3436066,half-life,"During the interdialysis period, there was a decrease of plasma desferrioxamine concentrations with a mean half-life of 18.7 +/- 5.2 h and an increase in plasma concentrations of aluminium desferrioxamine chelate.",Pharmacokinetics of desferrioxamine and of its iron and aluminium chelates in patients on haemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3436066/),h,18.7,40440,DB01370,Aluminium
,9088581,Cmax,Cmax of sotalol decreased from 1.22 +/- 0.22 mgl-1 (phase 1) to 0.89 +/- 0.29 mgl-1 (phase 2) and increased again to 1.27 +/- 0.18 mgl-1 in phase 3.,Interaction between sotalol and an antacid preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088581/),1/[mgl],1.22,40611,DB01370,Aluminium
,9088581,Cmax,Cmax of sotalol decreased from 1.22 +/- 0.22 mgl-1 (phase 1) to 0.89 +/- 0.29 mgl-1 (phase 2) and increased again to 1.27 +/- 0.18 mgl-1 in phase 3.,Interaction between sotalol and an antacid preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088581/),1/[mgl],0.89,40612,DB01370,Aluminium
,9088581,Cmax,Cmax of sotalol decreased from 1.22 +/- 0.22 mgl-1 (phase 1) to 0.89 +/- 0.29 mgl-1 (phase 2) and increased again to 1.27 +/- 0.18 mgl-1 in phase 3.,Interaction between sotalol and an antacid preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088581/),1/[mgl],1.27,40613,DB01370,Aluminium
,9088581,AUC,"A similar significant change was noted in AUC (15.6 +/- 2.75 mgl-1, 12.3 +/- 3.04 mg h l-1 and 15.0 +/- 2.06 mgl-1) and in the amount of cumulative urinary excretion (79.2 +/- 11.1 mg, 72.1 +/- 11.2 mg and 80.6 +/- 7.9 mg), respectively.",Interaction between sotalol and an antacid preparation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088581/),1/[mgl],15.6,40614,DB01370,Aluminium
,9088581,AUC,"A similar significant change was noted in AUC (15.6 +/- 2.75 mgl-1, 12.3 +/- 3.04 mg h l-1 and 15.0 +/- 2.06 mgl-1) and in the amount of cumulative urinary excretion (79.2 +/- 11.1 mg, 72.1 +/- 11.2 mg and 80.6 +/- 7.9 mg), respectively.",Interaction between sotalol and an antacid preparation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088581/),[h·mg] / [l],12.3,40615,DB01370,Aluminium
,9088581,AUC,"A similar significant change was noted in AUC (15.6 +/- 2.75 mgl-1, 12.3 +/- 3.04 mg h l-1 and 15.0 +/- 2.06 mgl-1) and in the amount of cumulative urinary excretion (79.2 +/- 11.1 mg, 72.1 +/- 11.2 mg and 80.6 +/- 7.9 mg), respectively.",Interaction between sotalol and an antacid preparation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088581/),1/[mgl],15.0,40616,DB01370,Aluminium
,9088581,cumulative urinary excretion,"A similar significant change was noted in AUC (15.6 +/- 2.75 mgl-1, 12.3 +/- 3.04 mg h l-1 and 15.0 +/- 2.06 mgl-1) and in the amount of cumulative urinary excretion (79.2 +/- 11.1 mg, 72.1 +/- 11.2 mg and 80.6 +/- 7.9 mg), respectively.",Interaction between sotalol and an antacid preparation. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088581/),mg,79.2,40617,DB01370,Aluminium
,9088581,cumulative urinary excretion,"A similar significant change was noted in AUC (15.6 +/- 2.75 mgl-1, 12.3 +/- 3.04 mg h l-1 and 15.0 +/- 2.06 mgl-1) and in the amount of cumulative urinary excretion (79.2 +/- 11.1 mg, 72.1 +/- 11.2 mg and 80.6 +/- 7.9 mg), respectively.",Interaction between sotalol and an antacid preparation. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088581/),mg,72.1,40618,DB01370,Aluminium
,9088581,cumulative urinary excretion,"A similar significant change was noted in AUC (15.6 +/- 2.75 mgl-1, 12.3 +/- 3.04 mg h l-1 and 15.0 +/- 2.06 mgl-1) and in the amount of cumulative urinary excretion (79.2 +/- 11.1 mg, 72.1 +/- 11.2 mg and 80.6 +/- 7.9 mg), respectively.",Interaction between sotalol and an antacid preparation. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088581/),mg,80.6,40619,DB01370,Aluminium
,1545356,half-lives,"Blood aluminum concentrations declined in a monoexponential fashion, with half-lives of 0.7 h (portal) and 1.08 h (systemic) (p less than 0.05).",Kinetics of aluminum in rats. III: Effect of route of administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545356/),h,0.7,41743,DB01370,Aluminium
,1545356,half-lives,"Blood aluminum concentrations declined in a monoexponential fashion, with half-lives of 0.7 h (portal) and 1.08 h (systemic) (p less than 0.05).",Kinetics of aluminum in rats. III: Effect of route of administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545356/),h,1.08,41744,DB01370,Aluminium
,1545356,systemic clearances,The corresponding systemic clearances were 48.9 +/- 10.6 and 35.1 +/- 3.64 mL/(h.kg) (p less than 0.05).,Kinetics of aluminum in rats. III: Effect of route of administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545356/),[ml] / [h·kg],48.9,41745,DB01370,Aluminium
,1545356,systemic clearances,The corresponding systemic clearances were 48.9 +/- 10.6 and 35.1 +/- 3.64 mL/(h.kg) (p less than 0.05).,Kinetics of aluminum in rats. III: Effect of route of administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545356/),[ml] / [h·kg],35.1,41746,DB01370,Aluminium
,1545356,systemic availability,"The systemic availability following portal administration was 0.66, indicating a significant ""first-pass"" effect.",Kinetics of aluminum in rats. III: Effect of route of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545356/),,0.66,41747,DB01370,Aluminium
,1545356,recovery,"Biliary aluminum recovery (% dose) was negligible following both routes [0.83 +/- 0.062% (portal) versus 1.3 +/- 0.22% (systemic), p less than 0.05].",Kinetics of aluminum in rats. III: Effect of route of administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545356/),%,0.83,41748,DB01370,Aluminium
,1545356,recovery,"Biliary aluminum recovery (% dose) was negligible following both routes [0.83 +/- 0.062% (portal) versus 1.3 +/- 0.22% (systemic), p less than 0.05].",Kinetics of aluminum in rats. III: Effect of route of administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545356/),%,1.3,41749,DB01370,Aluminium
,1545356,liver recovery,"In contrast, liver recovery of aluminum at 8-h postadministration was higher with the portal route (65.4 +/- 4.1 versus 39.4 +/- 2.52%).",Kinetics of aluminum in rats. III: Effect of route of administration. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545356/),%,65.4,41750,DB01370,Aluminium
,1545356,liver recovery,"In contrast, liver recovery of aluminum at 8-h postadministration was higher with the portal route (65.4 +/- 4.1 versus 39.4 +/- 2.52%).",Kinetics of aluminum in rats. III: Effect of route of administration. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545356/),%,39.4,41751,DB01370,Aluminium
,31500011,relative bioavailability,"In vivo pharmacokinetic study, the relative bioavailability of Sol-TCG-SM exhibited 108.1% and 632.7% compared to TCG-SM and raw TCG powder, respectively.",Statistical approach for solidifying ticagrelor loaded self-microemulsifying drug delivery system with enhanced dissolution and oral bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31500011/),%,108.1,44112,DB01370,Aluminium
,31500011,relative bioavailability,"In vivo pharmacokinetic study, the relative bioavailability of Sol-TCG-SM exhibited 108.1% and 632.7% compared to TCG-SM and raw TCG powder, respectively.",Statistical approach for solidifying ticagrelor loaded self-microemulsifying drug delivery system with enhanced dissolution and oral bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31500011/),%,632.7,44113,DB01370,Aluminium
,24198391,tumor uptake,"(64)Cu-NODAGA-RM1 exhibited tumor uptake values of 3.3 ± 0.38, 3.0 ± 0.76, and 3.5 ± 1.0 percentage injected dose per gram of tissue (%ID/g) at 0.5, 1.5, and 4 h after injection, respectively.",A comparative study of radiolabeled bombesin analogs for the PET imaging of prostate cancer. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24198391/),[%·dose·injected] / [gram·tissue],3.3,44127,DB01370,Aluminium
,24198391,tumor uptake,"(64)Cu-NODAGA-RM1 exhibited tumor uptake values of 3.3 ± 0.38, 3.0 ± 0.76, and 3.5 ± 1.0 percentage injected dose per gram of tissue (%ID/g) at 0.5, 1.5, and 4 h after injection, respectively.",A comparative study of radiolabeled bombesin analogs for the PET imaging of prostate cancer. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24198391/),[%·dose·injected] / [gram·tissue],3.0,44128,DB01370,Aluminium
,24198391,tumor uptake,"(64)Cu-NODAGA-RM1 exhibited tumor uptake values of 3.3 ± 0.38, 3.0 ± 0.76, and 3.5 ± 1.0 percentage injected dose per gram of tissue (%ID/g) at 0.5, 1.5, and 4 h after injection, respectively.",A comparative study of radiolabeled bombesin analogs for the PET imaging of prostate cancer. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24198391/),[%·dose·injected] / [gram·tissue],3.5,44129,DB01370,Aluminium
,24198391,tumor uptake,"(18)F-AlF-NODAGA-RM1 exhibited tumor uptake values of 4.6 ± 1.5, 4.0 ± 0.87, and 3.9 ± 0.48 %ID/g at 0.5, 1, and 2 h, respectively.",A comparative study of radiolabeled bombesin analogs for the PET imaging of prostate cancer. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24198391/),[%id] / [g],4.6,44130,DB01370,Aluminium
,24198391,tumor uptake,"(18)F-AlF-NODAGA-RM1 exhibited tumor uptake values of 4.6 ± 1.5, 4.0 ± 0.87, and 3.9 ± 0.48 %ID/g at 0.5, 1, and 2 h, respectively.",A comparative study of radiolabeled bombesin analogs for the PET imaging of prostate cancer. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24198391/),[%id] / [g],4.0,44131,DB01370,Aluminium
,24198391,tumor uptake,"(18)F-AlF-NODAGA-RM1 exhibited tumor uptake values of 4.6 ± 1.5, 4.0 ± 0.87, and 3.9 ± 0.48 %ID/g at 0.5, 1, and 2 h, respectively.",A comparative study of radiolabeled bombesin analogs for the PET imaging of prostate cancer. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24198391/),[%id] / [g],3.9,44132,DB01370,Aluminium
,17328583,relative bioavailability,"Compared with AZM, AZSR had a slower absorption rate (57% decrease in the mean peak concentration [C(max)] and an approximate 2.5-hour delay in the time to reach C(max) [t(max)]), with a mean relative bioavailability of 82.8%, which met the predefined exposure target (at least 80% bioavailability relative to AZM).",Clinical pharmacokinetics and gastrointestinal tolerability of a novel extended-release microsphere formulation of azithromycin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17328583/),%,82.8,48315,DB01370,Aluminium
,17328583,bioavailability,"Compared with AZM, AZSR had a slower absorption rate (57% decrease in the mean peak concentration [C(max)] and an approximate 2.5-hour delay in the time to reach C(max) [t(max)]), with a mean relative bioavailability of 82.8%, which met the predefined exposure target (at least 80% bioavailability relative to AZM).",Clinical pharmacokinetics and gastrointestinal tolerability of a novel extended-release microsphere formulation of azithromycin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17328583/),%,80,48316,DB01370,Aluminium
,33652037,BEs,"The BEs for blood for daily intake consistent with the MRL, PTWI and TWI were 18, 16 and 8 μg/L, respectively.",Derivation of Biomonitoring Equivalents for aluminium for the interpretation of population-level biomonitoring data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33652037/),[μg] / [l],18,49502,DB01370,Aluminium
,33652037,BEs,"The BEs for blood for daily intake consistent with the MRL, PTWI and TWI were 18, 16 and 8 μg/L, respectively.",Derivation of Biomonitoring Equivalents for aluminium for the interpretation of population-level biomonitoring data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33652037/),[μg] / [l],16,49503,DB01370,Aluminium
,33652037,BEs,"The BEs for blood for daily intake consistent with the MRL, PTWI and TWI were 18, 16 and 8 μg/L, respectively.",Derivation of Biomonitoring Equivalents for aluminium for the interpretation of population-level biomonitoring data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33652037/),[μg] / [l],8,49504,DB01370,Aluminium
,33652037,BEs,"BEs for urine for the same guidance values were 137, 123 and 57 μg/L, respectively.",Derivation of Biomonitoring Equivalents for aluminium for the interpretation of population-level biomonitoring data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33652037/),[μg] / [l],137,49505,DB01370,Aluminium
,33652037,BEs,"BEs for urine for the same guidance values were 137, 123 and 57 μg/L, respectively.",Derivation of Biomonitoring Equivalents for aluminium for the interpretation of population-level biomonitoring data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33652037/),[μg] / [l],123,49506,DB01370,Aluminium
,33652037,BEs,"BEs for urine for the same guidance values were 137, 123 and 57 μg/L, respectively.",Derivation of Biomonitoring Equivalents for aluminium for the interpretation of population-level biomonitoring data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33652037/),[μg] / [l],57,49507,DB01370,Aluminium
,8983932,AUC0-->infinity,The pharmacokinetic parameter values (mean +/- RSD) of piroxicam after administration of droxicam alone were: AUC0-->infinity = 125.5 +/- 25.1 micrograms.,A comparative bioavailability study to estimate the influence of an antacid on droxicam pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983932/),μg,125.5,52962,DB01370,Aluminium
,8983932,Cmax,"h/l, Cmax = 2.08 +/- 19.9 micrograms/l, tmax = 7.08 +/- 36.8 h and t1/2 = 46.3 +/- 27.0 h.",A comparative bioavailability study to estimate the influence of an antacid on droxicam pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983932/),[μg] / [l],2.08,52963,DB01370,Aluminium
,8983932,tmax,"h/l, Cmax = 2.08 +/- 19.9 micrograms/l, tmax = 7.08 +/- 36.8 h and t1/2 = 46.3 +/- 27.0 h.",A comparative bioavailability study to estimate the influence of an antacid on droxicam pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983932/),h,7.08,52964,DB01370,Aluminium
,8983932,t1/2,"h/l, Cmax = 2.08 +/- 19.9 micrograms/l, tmax = 7.08 +/- 36.8 h and t1/2 = 46.3 +/- 27.0 h.",A comparative bioavailability study to estimate the influence of an antacid on droxicam pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983932/),h,46.3,52965,DB01370,Aluminium
,8983932,AUC0-->infinity,"Following administration of droxicam together with the antacid the values obtained for the same parameters were: AUC0-->infinity = 135.1 +/- 24.1 micrograms.h/l. Cmax = 1.85 +/- 23.9 micrograms/l, tmax = 8.17 +/- 34.9 h and t1/2 = 52.0 +/- 22.4 h.",A comparative bioavailability study to estimate the influence of an antacid on droxicam pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983932/),[h·μg] / [l],135.1,52966,DB01370,Aluminium
,8983932,Cmax,"Following administration of droxicam together with the antacid the values obtained for the same parameters were: AUC0-->infinity = 135.1 +/- 24.1 micrograms.h/l. Cmax = 1.85 +/- 23.9 micrograms/l, tmax = 8.17 +/- 34.9 h and t1/2 = 52.0 +/- 22.4 h.",A comparative bioavailability study to estimate the influence of an antacid on droxicam pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983932/),[μg] / [l],1.85,52967,DB01370,Aluminium
,8983932,tmax,"Following administration of droxicam together with the antacid the values obtained for the same parameters were: AUC0-->infinity = 135.1 +/- 24.1 micrograms.h/l. Cmax = 1.85 +/- 23.9 micrograms/l, tmax = 8.17 +/- 34.9 h and t1/2 = 52.0 +/- 22.4 h.",A comparative bioavailability study to estimate the influence of an antacid on droxicam pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983932/),h,8.17,52968,DB01370,Aluminium
,8983932,t1/2,"Following administration of droxicam together with the antacid the values obtained for the same parameters were: AUC0-->infinity = 135.1 +/- 24.1 micrograms.h/l. Cmax = 1.85 +/- 23.9 micrograms/l, tmax = 8.17 +/- 34.9 h and t1/2 = 52.0 +/- 22.4 h.",A comparative bioavailability study to estimate the influence of an antacid on droxicam pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983932/),h,52.0,52969,DB01370,Aluminium
,31573798,Serum concentrations,Serum concentrations were 0.02 μM at 15 min and no more than 0.1 μM at later time points.,Quantifying Intranasally Administered Deferoxamine in Rat Brain Tissue with Mass Spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31573798/),μM,0.02,53151,DB01370,Aluminium
no more,31573798,Serum concentrations,Serum concentrations were 0.02 μM at 15 min and no more than 0.1 μM at later time points.,Quantifying Intranasally Administered Deferoxamine in Rat Brain Tissue with Mass Spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31573798/),μM,0.1,53152,DB01370,Aluminium
,2653697,t1/2,"The t1/2 for enoxacin ranges from 4 to 6 hours, which allows effective twice-daily administration without significant accumulation.",Enoxacin absorption and elimination characteristics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2653697/),h,4 to 6,54494,DB01370,Aluminium
,6688407,maximum plasma concentrations,"After doses of 250, 500, and 1000 mg nabumetone, maximum plasma concentrations of the major metabolite, 6-methoxy-2-naphthylacetic acid, were 9.76, 24.19, and 36.59 micrograms/ml, in nonfasting subjects.","Nabumetone--a novel anti-inflammatory drug: the influence of food, milk, antacids, and analgesics on bioavailability of single oral doses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688407/),[μg] / [ml],9.76,54725,DB01370,Aluminium
,6688407,maximum plasma concentrations,"After doses of 250, 500, and 1000 mg nabumetone, maximum plasma concentrations of the major metabolite, 6-methoxy-2-naphthylacetic acid, were 9.76, 24.19, and 36.59 micrograms/ml, in nonfasting subjects.","Nabumetone--a novel anti-inflammatory drug: the influence of food, milk, antacids, and analgesics on bioavailability of single oral doses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688407/),[μg] / [ml],24.19,54726,DB01370,Aluminium
,6688407,maximum plasma concentrations,"After doses of 250, 500, and 1000 mg nabumetone, maximum plasma concentrations of the major metabolite, 6-methoxy-2-naphthylacetic acid, were 9.76, 24.19, and 36.59 micrograms/ml, in nonfasting subjects.","Nabumetone--a novel anti-inflammatory drug: the influence of food, milk, antacids, and analgesics on bioavailability of single oral doses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688407/),[μg] / [ml],36.59,54727,DB01370,Aluminium
,7795818,retention times,"The retention times for (+)-catechin and the internal standard (deoxyhigenamine) were 6.87 and 8.47 min respectively, without any interference.",Determination of (+)-catechin in plasma by high-performance liquid chromatography using fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7795818/),min,6.87,56207,DB01370,Aluminium
,7795818,retention times,"The retention times for (+)-catechin and the internal standard (deoxyhigenamine) were 6.87 and 8.47 min respectively, without any interference.",Determination of (+)-catechin in plasma by high-performance liquid chromatography using fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7795818/),min,8.47,56208,DB01370,Aluminium
,7795818,recovery,The average recovery was 73.77%.,Determination of (+)-catechin in plasma by high-performance liquid chromatography using fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7795818/),%,73.77,56209,DB01370,Aluminium
,7795818,limit of detection,"The limit of detection and quantitation were 1 ng and 0.02 micrograms/ml, respectively.",Determination of (+)-catechin in plasma by high-performance liquid chromatography using fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7795818/),ng,1,56210,DB01370,Aluminium
,7795818,limit of detection,"The limit of detection and quantitation were 1 ng and 0.02 micrograms/ml, respectively.",Determination of (+)-catechin in plasma by high-performance liquid chromatography using fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7795818/),[μg] / [ml],0.02,56211,DB01370,Aluminium
,2727994,half-lives,"Estimated half-lives were 113 days in spleen, 74 days in liver, 44 days in lung, 42 days in serum, 4.2 days in kidney cortex, and 2.3 days in kidney medulla.",Elevated aluminum persists in serum and tissues of rabbits after a six-hour infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2727994/),d,113,56515,DB01370,Aluminium
,2727994,half-lives,"Estimated half-lives were 113 days in spleen, 74 days in liver, 44 days in lung, 42 days in serum, 4.2 days in kidney cortex, and 2.3 days in kidney medulla.",Elevated aluminum persists in serum and tissues of rabbits after a six-hour infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2727994/),d,74,56516,DB01370,Aluminium
,2727994,half-lives,"Estimated half-lives were 113 days in spleen, 74 days in liver, 44 days in lung, 42 days in serum, 4.2 days in kidney cortex, and 2.3 days in kidney medulla.",Elevated aluminum persists in serum and tissues of rabbits after a six-hour infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2727994/),d,44,56517,DB01370,Aluminium
,2727994,half-lives,"Estimated half-lives were 113 days in spleen, 74 days in liver, 44 days in lung, 42 days in serum, 4.2 days in kidney cortex, and 2.3 days in kidney medulla.",Elevated aluminum persists in serum and tissues of rabbits after a six-hour infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2727994/),d,42,56518,DB01370,Aluminium
,2727994,half-lives,"Estimated half-lives were 113 days in spleen, 74 days in liver, 44 days in lung, 42 days in serum, 4.2 days in kidney cortex, and 2.3 days in kidney medulla.",Elevated aluminum persists in serum and tissues of rabbits after a six-hour infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2727994/),d,4.2,56519,DB01370,Aluminium
,2727994,half-lives,"Estimated half-lives were 113 days in spleen, 74 days in liver, 44 days in lung, 42 days in serum, 4.2 days in kidney cortex, and 2.3 days in kidney medulla.",Elevated aluminum persists in serum and tissues of rabbits after a six-hour infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2727994/),d,2.3,56520,DB01370,Aluminium
exceeding,2727994,half-life,The kidney also demonstrated another half-life greatly exceeding 100 days.,Elevated aluminum persists in serum and tissues of rabbits after a six-hour infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2727994/),d,100,56521,DB01370,Aluminium
,32885750,re-dispersed time,"The re-dispersed time, sedimentation rate and pH value of the suspension were 4 s under a magnetic shaker rotating at 20 r/min, 1 and 5.0, respectively.","Formulation, Characterization and Pharmacokinetics of Long-acting Ceftiofur Hydrochloride Suspension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32885750/),s,4,57409,DB01370,Aluminium
,32885750,withdrawal volume,It could go through 7-gage needle smoothly with withdrawal volume of 9.9 mL/min.,"Formulation, Characterization and Pharmacokinetics of Long-acting Ceftiofur Hydrochloride Suspension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32885750/),[ml] / [min],9.9,57410,DB01370,Aluminium
less,1584315,Al concentrations,Baseline Al concentrations were greater than 2 less than 6 in group 1 and less than 1.5 mumol/l in group 2.,Kinetics of aluminoxamine and feroxamine chelates in dialysis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1584315/),,2,57782,DB01370,Aluminium
less,1584315,Al concentrations,Baseline Al concentrations were greater than 2 less than 6 in group 1 and less than 1.5 mumol/l in group 2.,Kinetics of aluminoxamine and feroxamine chelates in dialysis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1584315/),,6,57783,DB01370,Aluminium
less,1584315,Al concentrations,Baseline Al concentrations were greater than 2 less than 6 in group 1 and less than 1.5 mumol/l in group 2.,Kinetics of aluminoxamine and feroxamine chelates in dialysis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1584315/),[μM] / [l],1.5,57784,DB01370,Aluminium
,10440423,Cmax,"For the fed/fasting study, mean Cmax values (+/-SD) were 2.7+/-0.62 mg/L and 2.1+/-0.96 mg/L for the fasting state and the fed state, respectively and the 90% CI of Cmax ratio was [0.57 - 0.97].",Clopidogrel bioavailability: absence of influence of food or antacids. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440423/),[mg] / [l],2.7,58522,DB01370,Aluminium
,10440423,Cmax,"For the fed/fasting study, mean Cmax values (+/-SD) were 2.7+/-0.62 mg/L and 2.1+/-0.96 mg/L for the fasting state and the fed state, respectively and the 90% CI of Cmax ratio was [0.57 - 0.97].",Clopidogrel bioavailability: absence of influence of food or antacids. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440423/),[mg] / [l],2.1,58523,DB01370,Aluminium
,10440423,AUC(0-obs),"Mean AUC(0-obs) values (AUC to the last observed value) were 7.1+/-1.6 mg.h/L and 7.4+/-1.64 mg.h/L, respectively, and the 90% Cl of AUC ratios were [0.90 - 1.02] and [0.89 - 0.97], respectively.",Clopidogrel bioavailability: absence of influence of food or antacids. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440423/),[h·mg] / [l],7.1,58524,DB01370,Aluminium
,10440423,AUC(0-obs),"Mean AUC(0-obs) values (AUC to the last observed value) were 7.1+/-1.6 mg.h/L and 7.4+/-1.64 mg.h/L, respectively, and the 90% Cl of AUC ratios were [0.90 - 1.02] and [0.89 - 0.97], respectively.",Clopidogrel bioavailability: absence of influence of food or antacids. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440423/),[h·mg] / [l],7.4,58525,DB01370,Aluminium
,10440423,Cmax,"For the antacid study, mean Cmax values were 2.6+/-0.84 mg/L and 2.5+/-0.87 mg/L for the no-antacid regimen and the antacid regimen, respectively, and the 90% CI of Cmax ratio was [0.74 - 1.16].",Clopidogrel bioavailability: absence of influence of food or antacids. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440423/),[mg] / [l],2.6,58526,DB01370,Aluminium
,10440423,Cmax,"For the antacid study, mean Cmax values were 2.6+/-0.84 mg/L and 2.5+/-0.87 mg/L for the no-antacid regimen and the antacid regimen, respectively, and the 90% CI of Cmax ratio was [0.74 - 1.16].",Clopidogrel bioavailability: absence of influence of food or antacids. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440423/),[mg] / [l],2.5,58527,DB01370,Aluminium
,10440423,AUC(0-obs),"Mean AUC(0-obs) values were 6.3+/-1.34 mg.h/L and 5.8+/-1.33 mg.h/L, respectively, and the 90% CI of AUC ratios was [0.89+/-0.97].",Clopidogrel bioavailability: absence of influence of food or antacids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440423/),[h·mg] / [l],6.3,58528,DB01370,Aluminium
,10440423,AUC(0-obs),"Mean AUC(0-obs) values were 6.3+/-1.34 mg.h/L and 5.8+/-1.33 mg.h/L, respectively, and the 90% CI of AUC ratios was [0.89+/-0.97].",Clopidogrel bioavailability: absence of influence of food or antacids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440423/),[h·mg] / [l],5.8,58529,DB01370,Aluminium
,11606803,half-life,"In the absence of DFO treatments, brain (26)Al concentration decreased with a half-life of approximately 150 days.","Entry, half-life, and desferrioxamine-accelerated clearance of brain aluminum after a single (26)Al exposure. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11606803/),d,150,61696,DB01370,Aluminium
,11606803,half-life,The brain Al half-life in the DFO-treated rats was approximately 55 days.,"Entry, half-life, and desferrioxamine-accelerated clearance of brain aluminum after a single (26)Al exposure. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11606803/),d,55,61697,DB01370,Aluminium
,1354432,maximum concentrations,The maximum concentrations were 1.19 +/- 0.32 mg/liter after 0.1 g of cefpodoxime proxetil and 2.54 +/- 0.64 mg/liter after 0.2 g of cefpodoxime proxetil.,Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1354432/),[mg] / [l],1.19,68026,DB01370,Aluminium
,1354432,maximum concentrations,The maximum concentrations were 1.19 +/- 0.32 mg/liter after 0.1 g of cefpodoxime proxetil and 2.54 +/- 0.64 mg/liter after 0.2 g of cefpodoxime proxetil.,Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1354432/),[mg] / [l],2.54,68027,DB01370,Aluminium
,1354432,elimination half-lives,The elimination half-lives were 149 min for 0.1 g and 172 min for 0.2 g of cefpodoxime proxetil.,Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1354432/),min,149,68028,DB01370,Aluminium
,1354432,elimination half-lives,The elimination half-lives were 149 min for 0.1 g and 172 min for 0.2 g of cefpodoxime proxetil.,Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1354432/),min,172,68029,DB01370,Aluminium
,1354432,AUC,Combination with Maalox 70 caused a reduction in the AUC from 14.0 +/- 3.9 to 8.44 +/- 1.85 mg.h/liter.,Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1354432/),[h·mg] / [l],14.0,68030,DB01370,Aluminium
,1354432,AUC,Combination with Maalox 70 caused a reduction in the AUC from 14.0 +/- 3.9 to 8.44 +/- 1.85 mg.h/liter.,Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1354432/),[h·mg] / [l],8.44,68031,DB01370,Aluminium
,1354432,AUC,"After famotidine, the AUC decreased to 8.36 +/- 2.0 mg . h/liter.",Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1354432/),[h·mg] / [l],8.36,68032,DB01370,Aluminium
,6631559,half-life,In pharmacokinetic analyses of the data calculation of the half-life of fluoride from plasma data and from the urinary excretion rate yielded almost identical results; 5.78 hours (plasma) and 5.11 hours (urine).,"The relationship between plasma fluoride, urinary excretion rate and urine fluoride concentration in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6631559/),h,5.78,68414,DB01370,Aluminium
,6631559,half-life,In pharmacokinetic analyses of the data calculation of the half-life of fluoride from plasma data and from the urinary excretion rate yielded almost identical results; 5.78 hours (plasma) and 5.11 hours (urine).,"The relationship between plasma fluoride, urinary excretion rate and urine fluoride concentration in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6631559/),h,5.11,68415,DB01370,Aluminium
,4039147,Cmax,Cmax (means +/- SEM) decreased from 40.6 +/- 2.9 to 36.25 +/- 1.4 micrograms/ml; the mean area under the plasma level time curve was somewhat higher after additional administration of aluminium hydroxide (n. s.).,The influence of aluminium hydroxide on the bioavailability of feprazone. Single dose study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039147/),[μg] / [ml],40.6,70861,DB01370,Aluminium
,4039147,Cmax,Cmax (means +/- SEM) decreased from 40.6 +/- 2.9 to 36.25 +/- 1.4 micrograms/ml; the mean area under the plasma level time curve was somewhat higher after additional administration of aluminium hydroxide (n. s.).,The influence of aluminium hydroxide on the bioavailability of feprazone. Single dose study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039147/),[μg] / [ml],36.25,70862,DB01370,Aluminium
,2878076,duration of action,"Alftentanil reaches its peak effect within 1 min after injection, and its duration of action is very short; at 2 times its MED50, 9r has a duration of action of 11 min.","Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2878076/),min,11,70928,DB01370,Aluminium
,8097694,systemic clearance,"The mean (+/- SD) systemic clearance, steady-state volume of distribution, mean residence time, mean oral absorption time, and systemic availability for CP20 and CP94 were 0.8 +/- 0.3 and 2.1 +/- 1.4 liter/hr/kg; 1.2 +/- 0.5 and 1.2 +/- 0.5 liter/kg; 1.7 +/- 0.7 and 0.7 +/- 0.3 hr; 0.9 +/- 1.6 and 0.6 +/- 0.5 hr; and 72 +/- 20 and 57 +/- 27%, respectively.",Pharmacokinetics of representative 3-hydroxypyridin-4-ones in rabbits: CP20 and CP94. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097694/),[l] / [h·kg],0.8,74993,DB01370,Aluminium
,8097694,steady-state volume of distribution,"The mean (+/- SD) systemic clearance, steady-state volume of distribution, mean residence time, mean oral absorption time, and systemic availability for CP20 and CP94 were 0.8 +/- 0.3 and 2.1 +/- 1.4 liter/hr/kg; 1.2 +/- 0.5 and 1.2 +/- 0.5 liter/kg; 1.7 +/- 0.7 and 0.7 +/- 0.3 hr; 0.9 +/- 1.6 and 0.6 +/- 0.5 hr; and 72 +/- 20 and 57 +/- 27%, respectively.",Pharmacokinetics of representative 3-hydroxypyridin-4-ones in rabbits: CP20 and CP94. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097694/),[l] / [h·kg],2.1,74994,DB01370,Aluminium
,8097694,mean residence time,"The mean (+/- SD) systemic clearance, steady-state volume of distribution, mean residence time, mean oral absorption time, and systemic availability for CP20 and CP94 were 0.8 +/- 0.3 and 2.1 +/- 1.4 liter/hr/kg; 1.2 +/- 0.5 and 1.2 +/- 0.5 liter/kg; 1.7 +/- 0.7 and 0.7 +/- 0.3 hr; 0.9 +/- 1.6 and 0.6 +/- 0.5 hr; and 72 +/- 20 and 57 +/- 27%, respectively.",Pharmacokinetics of representative 3-hydroxypyridin-4-ones in rabbits: CP20 and CP94. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097694/),[l] / [h·kg],2.1,74995,DB01370,Aluminium
,8097694,mean residence time,"The mean (+/- SD) systemic clearance, steady-state volume of distribution, mean residence time, mean oral absorption time, and systemic availability for CP20 and CP94 were 0.8 +/- 0.3 and 2.1 +/- 1.4 liter/hr/kg; 1.2 +/- 0.5 and 1.2 +/- 0.5 liter/kg; 1.7 +/- 0.7 and 0.7 +/- 0.3 hr; 0.9 +/- 1.6 and 0.6 +/- 0.5 hr; and 72 +/- 20 and 57 +/- 27%, respectively.",Pharmacokinetics of representative 3-hydroxypyridin-4-ones in rabbits: CP20 and CP94. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097694/),h,1.7,74996,DB01370,Aluminium
,8097694,mean residence time,"The mean (+/- SD) systemic clearance, steady-state volume of distribution, mean residence time, mean oral absorption time, and systemic availability for CP20 and CP94 were 0.8 +/- 0.3 and 2.1 +/- 1.4 liter/hr/kg; 1.2 +/- 0.5 and 1.2 +/- 0.5 liter/kg; 1.7 +/- 0.7 and 0.7 +/- 0.3 hr; 0.9 +/- 1.6 and 0.6 +/- 0.5 hr; and 72 +/- 20 and 57 +/- 27%, respectively.",Pharmacokinetics of representative 3-hydroxypyridin-4-ones in rabbits: CP20 and CP94. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097694/),h,0.9,74997,DB01370,Aluminium
,8097694,mean oral absorption time,"The mean (+/- SD) systemic clearance, steady-state volume of distribution, mean residence time, mean oral absorption time, and systemic availability for CP20 and CP94 were 0.8 +/- 0.3 and 2.1 +/- 1.4 liter/hr/kg; 1.2 +/- 0.5 and 1.2 +/- 0.5 liter/kg; 1.7 +/- 0.7 and 0.7 +/- 0.3 hr; 0.9 +/- 1.6 and 0.6 +/- 0.5 hr; and 72 +/- 20 and 57 +/- 27%, respectively.",Pharmacokinetics of representative 3-hydroxypyridin-4-ones in rabbits: CP20 and CP94. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097694/),[l] / [h·kg],2.1,74998,DB01370,Aluminium
,8097694,mean oral absorption time,"The mean (+/- SD) systemic clearance, steady-state volume of distribution, mean residence time, mean oral absorption time, and systemic availability for CP20 and CP94 were 0.8 +/- 0.3 and 2.1 +/- 1.4 liter/hr/kg; 1.2 +/- 0.5 and 1.2 +/- 0.5 liter/kg; 1.7 +/- 0.7 and 0.7 +/- 0.3 hr; 0.9 +/- 1.6 and 0.6 +/- 0.5 hr; and 72 +/- 20 and 57 +/- 27%, respectively.",Pharmacokinetics of representative 3-hydroxypyridin-4-ones in rabbits: CP20 and CP94. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097694/),[l] / [kg],1.2,74999,DB01370,Aluminium
,8097694,mean oral absorption time,"The mean (+/- SD) systemic clearance, steady-state volume of distribution, mean residence time, mean oral absorption time, and systemic availability for CP20 and CP94 were 0.8 +/- 0.3 and 2.1 +/- 1.4 liter/hr/kg; 1.2 +/- 0.5 and 1.2 +/- 0.5 liter/kg; 1.7 +/- 0.7 and 0.7 +/- 0.3 hr; 0.9 +/- 1.6 and 0.6 +/- 0.5 hr; and 72 +/- 20 and 57 +/- 27%, respectively.",Pharmacokinetics of representative 3-hydroxypyridin-4-ones in rabbits: CP20 and CP94. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097694/),h,1.7,75000,DB01370,Aluminium
,8097694,mean oral absorption time,"The mean (+/- SD) systemic clearance, steady-state volume of distribution, mean residence time, mean oral absorption time, and systemic availability for CP20 and CP94 were 0.8 +/- 0.3 and 2.1 +/- 1.4 liter/hr/kg; 1.2 +/- 0.5 and 1.2 +/- 0.5 liter/kg; 1.7 +/- 0.7 and 0.7 +/- 0.3 hr; 0.9 +/- 1.6 and 0.6 +/- 0.5 hr; and 72 +/- 20 and 57 +/- 27%, respectively.",Pharmacokinetics of representative 3-hydroxypyridin-4-ones in rabbits: CP20 and CP94. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097694/),h,0.9,75001,DB01370,Aluminium
,8097694,systemic availability,"The mean (+/- SD) systemic clearance, steady-state volume of distribution, mean residence time, mean oral absorption time, and systemic availability for CP20 and CP94 were 0.8 +/- 0.3 and 2.1 +/- 1.4 liter/hr/kg; 1.2 +/- 0.5 and 1.2 +/- 0.5 liter/kg; 1.7 +/- 0.7 and 0.7 +/- 0.3 hr; 0.9 +/- 1.6 and 0.6 +/- 0.5 hr; and 72 +/- 20 and 57 +/- 27%, respectively.",Pharmacokinetics of representative 3-hydroxypyridin-4-ones in rabbits: CP20 and CP94. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097694/),h,0.6,75002,DB01370,Aluminium
,8097694,systemic availability,"The mean (+/- SD) systemic clearance, steady-state volume of distribution, mean residence time, mean oral absorption time, and systemic availability for CP20 and CP94 were 0.8 +/- 0.3 and 2.1 +/- 1.4 liter/hr/kg; 1.2 +/- 0.5 and 1.2 +/- 0.5 liter/kg; 1.7 +/- 0.7 and 0.7 +/- 0.3 hr; 0.9 +/- 1.6 and 0.6 +/- 0.5 hr; and 72 +/- 20 and 57 +/- 27%, respectively.",Pharmacokinetics of representative 3-hydroxypyridin-4-ones in rabbits: CP20 and CP94. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097694/),%,72,75003,DB01370,Aluminium
,8097694,systemic availability,"The mean (+/- SD) systemic clearance, steady-state volume of distribution, mean residence time, mean oral absorption time, and systemic availability for CP20 and CP94 were 0.8 +/- 0.3 and 2.1 +/- 1.4 liter/hr/kg; 1.2 +/- 0.5 and 1.2 +/- 0.5 liter/kg; 1.7 +/- 0.7 and 0.7 +/- 0.3 hr; 0.9 +/- 1.6 and 0.6 +/- 0.5 hr; and 72 +/- 20 and 57 +/- 27%, respectively.",Pharmacokinetics of representative 3-hydroxypyridin-4-ones in rabbits: CP20 and CP94. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097694/),%,57,75004,DB01370,Aluminium
,19139573,Drug,"Drug recovery from plasma, saliva and gingival fluid averaged 97.7%.","An HPTLC method for the determination of minocycline in human plasma, saliva, and gingival fluid after single step liquid extraction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19139573/),%,97.7,77364,DB01370,Aluminium
,19139573,recovery,"Drug recovery from plasma, saliva and gingival fluid averaged 97.7%.","An HPTLC method for the determination of minocycline in human plasma, saliva, and gingival fluid after single step liquid extraction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19139573/),%,97.7,77365,DB01370,Aluminium
,19139573,half-life of drug,"In all the three matrices, rapid degradation of drug occurred and the half-life of drug ranged from 9.9 to 16.1 h at 4 degrees C and from 6.3 to 11.5 h at 20 degrees C.","An HPTLC method for the determination of minocycline in human plasma, saliva, and gingival fluid after single step liquid extraction. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19139573/),h,9.9 to 16.1,77366,DB01370,Aluminium
,19139573,half-life of drug,"In all the three matrices, rapid degradation of drug occurred and the half-life of drug ranged from 9.9 to 16.1 h at 4 degrees C and from 6.3 to 11.5 h at 20 degrees C.","An HPTLC method for the determination of minocycline in human plasma, saliva, and gingival fluid after single step liquid extraction. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19139573/),h,6.3 to 11.5,77367,DB01370,Aluminium
,12392584,bioavailability,"The bioavailability (90% confidence intervals) of Ro 64-0802 following administration of oseltamivir together with Maalox suspension vs administration of oseltamivir alone, was 90% (83.6, 96.9%) for C(max) and 94.1% (91.4, 96.9%) for AUC(0, infinity); similarly, for Titralac tablets, the equivalent values were 95.1% (88.3, 102%) for C(max) and 94.7% (91.9, 97.5%) for AUC(0, infinity).",Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12392584/),%,90,78477,DB01370,Aluminium
,12392584,bioavailability,"The bioavailability (90% confidence intervals) of Ro 64-0802 following administration of oseltamivir together with Maalox suspension vs administration of oseltamivir alone, was 90% (83.6, 96.9%) for C(max) and 94.1% (91.4, 96.9%) for AUC(0, infinity); similarly, for Titralac tablets, the equivalent values were 95.1% (88.3, 102%) for C(max) and 94.7% (91.9, 97.5%) for AUC(0, infinity).",Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12392584/),%,94.1,78478,DB01370,Aluminium
,12392584,bioavailability,"The bioavailability (90% confidence intervals) of Ro 64-0802 following administration of oseltamivir together with Maalox suspension vs administration of oseltamivir alone, was 90% (83.6, 96.9%) for C(max) and 94.1% (91.4, 96.9%) for AUC(0, infinity); similarly, for Titralac tablets, the equivalent values were 95.1% (88.3, 102%) for C(max) and 94.7% (91.9, 97.5%) for AUC(0, infinity).",Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12392584/),%,95.1,78479,DB01370,Aluminium
,12392584,bioavailability,"The bioavailability (90% confidence intervals) of Ro 64-0802 following administration of oseltamivir together with Maalox suspension vs administration of oseltamivir alone, was 90% (83.6, 96.9%) for C(max) and 94.1% (91.4, 96.9%) for AUC(0, infinity); similarly, for Titralac tablets, the equivalent values were 95.1% (88.3, 102%) for C(max) and 94.7% (91.9, 97.5%) for AUC(0, infinity).",Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12392584/),%,94.7,78480,DB01370,Aluminium
,1820883,MRT,"Ibuprofen absorption was much slower with aluminium hydroxide capsules (MRT 5.3, Tmax 3.1 h, Cmax 25.6 mg l-1, lag time 37.5 min) than with sodium bicarbonate capsules of the previous study (MRT 2.6 h, tmax 0.4 h, Cmax 51.4 mg l-1), lag time 0 min).",Effects of pH regulators used as additives on the bioavailability of ibuprofen from hard gelatin capsules. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820883/),,5.3,78792,DB01370,Aluminium
,1820883,Tmax,"Ibuprofen absorption was much slower with aluminium hydroxide capsules (MRT 5.3, Tmax 3.1 h, Cmax 25.6 mg l-1, lag time 37.5 min) than with sodium bicarbonate capsules of the previous study (MRT 2.6 h, tmax 0.4 h, Cmax 51.4 mg l-1), lag time 0 min).",Effects of pH regulators used as additives on the bioavailability of ibuprofen from hard gelatin capsules. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820883/),h,3.1,78793,DB01370,Aluminium
,1820883,Cmax,"Ibuprofen absorption was much slower with aluminium hydroxide capsules (MRT 5.3, Tmax 3.1 h, Cmax 25.6 mg l-1, lag time 37.5 min) than with sodium bicarbonate capsules of the previous study (MRT 2.6 h, tmax 0.4 h, Cmax 51.4 mg l-1), lag time 0 min).",Effects of pH regulators used as additives on the bioavailability of ibuprofen from hard gelatin capsules. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820883/),[mg] / [l],25.6,78794,DB01370,Aluminium
,1820883,lag time,"Ibuprofen absorption was much slower with aluminium hydroxide capsules (MRT 5.3, Tmax 3.1 h, Cmax 25.6 mg l-1, lag time 37.5 min) than with sodium bicarbonate capsules of the previous study (MRT 2.6 h, tmax 0.4 h, Cmax 51.4 mg l-1), lag time 0 min).",Effects of pH regulators used as additives on the bioavailability of ibuprofen from hard gelatin capsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820883/),min,37.5,78795,DB01370,Aluminium
,1820883,MRT,"Ibuprofen absorption was much slower with aluminium hydroxide capsules (MRT 5.3, Tmax 3.1 h, Cmax 25.6 mg l-1, lag time 37.5 min) than with sodium bicarbonate capsules of the previous study (MRT 2.6 h, tmax 0.4 h, Cmax 51.4 mg l-1), lag time 0 min).",Effects of pH regulators used as additives on the bioavailability of ibuprofen from hard gelatin capsules. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820883/),h,2.6,78796,DB01370,Aluminium
,1820883,tmax,"Ibuprofen absorption was much slower with aluminium hydroxide capsules (MRT 5.3, Tmax 3.1 h, Cmax 25.6 mg l-1, lag time 37.5 min) than with sodium bicarbonate capsules of the previous study (MRT 2.6 h, tmax 0.4 h, Cmax 51.4 mg l-1), lag time 0 min).",Effects of pH regulators used as additives on the bioavailability of ibuprofen from hard gelatin capsules. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820883/),h,0.4,78797,DB01370,Aluminium
,1820883,Cmax,"Ibuprofen absorption was much slower with aluminium hydroxide capsules (MRT 5.3, Tmax 3.1 h, Cmax 25.6 mg l-1, lag time 37.5 min) than with sodium bicarbonate capsules of the previous study (MRT 2.6 h, tmax 0.4 h, Cmax 51.4 mg l-1), lag time 0 min).",Effects of pH regulators used as additives on the bioavailability of ibuprofen from hard gelatin capsules. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820883/),[mg] / [l],51.4,78798,DB01370,Aluminium
,1820883,lag time,"Ibuprofen absorption was much slower with aluminium hydroxide capsules (MRT 5.3, Tmax 3.1 h, Cmax 25.6 mg l-1, lag time 37.5 min) than with sodium bicarbonate capsules of the previous study (MRT 2.6 h, tmax 0.4 h, Cmax 51.4 mg l-1), lag time 0 min).",Effects of pH regulators used as additives on the bioavailability of ibuprofen from hard gelatin capsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820883/),min,0,78799,DB01370,Aluminium
,1820883,MRT,"The corresponding values for calcium carbonate and tartaric acid capsules were: MRT 3.7 h and 3.9 h, Tmax 1.7 h and 2.0 h, Cmax 32.2 mg l-1 and 30.8 mg l-1 and lag time 3.1 min and 7.6 min.",Effects of pH regulators used as additives on the bioavailability of ibuprofen from hard gelatin capsules. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820883/),h,3.7,78800,DB01370,Aluminium
,1820883,MRT,"The corresponding values for calcium carbonate and tartaric acid capsules were: MRT 3.7 h and 3.9 h, Tmax 1.7 h and 2.0 h, Cmax 32.2 mg l-1 and 30.8 mg l-1 and lag time 3.1 min and 7.6 min.",Effects of pH regulators used as additives on the bioavailability of ibuprofen from hard gelatin capsules. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820883/),h,3.9,78801,DB01370,Aluminium
,1820883,Tmax,"The corresponding values for calcium carbonate and tartaric acid capsules were: MRT 3.7 h and 3.9 h, Tmax 1.7 h and 2.0 h, Cmax 32.2 mg l-1 and 30.8 mg l-1 and lag time 3.1 min and 7.6 min.",Effects of pH regulators used as additives on the bioavailability of ibuprofen from hard gelatin capsules. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820883/),h,1.7,78802,DB01370,Aluminium
,1820883,Tmax,"The corresponding values for calcium carbonate and tartaric acid capsules were: MRT 3.7 h and 3.9 h, Tmax 1.7 h and 2.0 h, Cmax 32.2 mg l-1 and 30.8 mg l-1 and lag time 3.1 min and 7.6 min.",Effects of pH regulators used as additives on the bioavailability of ibuprofen from hard gelatin capsules. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820883/),h,2.0,78803,DB01370,Aluminium
,1820883,Cmax,"The corresponding values for calcium carbonate and tartaric acid capsules were: MRT 3.7 h and 3.9 h, Tmax 1.7 h and 2.0 h, Cmax 32.2 mg l-1 and 30.8 mg l-1 and lag time 3.1 min and 7.6 min.",Effects of pH regulators used as additives on the bioavailability of ibuprofen from hard gelatin capsules. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820883/),[mg] / [l],32.2,78804,DB01370,Aluminium
,1820883,Cmax,"The corresponding values for calcium carbonate and tartaric acid capsules were: MRT 3.7 h and 3.9 h, Tmax 1.7 h and 2.0 h, Cmax 32.2 mg l-1 and 30.8 mg l-1 and lag time 3.1 min and 7.6 min.",Effects of pH regulators used as additives on the bioavailability of ibuprofen from hard gelatin capsules. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820883/),[mg] / [l],30.8,78805,DB01370,Aluminium
,1820883,lag time,"The corresponding values for calcium carbonate and tartaric acid capsules were: MRT 3.7 h and 3.9 h, Tmax 1.7 h and 2.0 h, Cmax 32.2 mg l-1 and 30.8 mg l-1 and lag time 3.1 min and 7.6 min.",Effects of pH regulators used as additives on the bioavailability of ibuprofen from hard gelatin capsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820883/),min,3.1,78806,DB01370,Aluminium
,1820883,lag time,"The corresponding values for calcium carbonate and tartaric acid capsules were: MRT 3.7 h and 3.9 h, Tmax 1.7 h and 2.0 h, Cmax 32.2 mg l-1 and 30.8 mg l-1 and lag time 3.1 min and 7.6 min.",Effects of pH regulators used as additives on the bioavailability of ibuprofen from hard gelatin capsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820883/),min,7.6,78807,DB01370,Aluminium
,1503446,relative bioavailability,The relative bioavailability of Cipro when given with calcium carbonate was approximately 60% of the control value.,Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1503446/),%,60,82780,DB01370,Aluminium
,1503446,relative bioavailability,"When Cipro was given with aluminum hydroxide, the relative bioavailability was approximately 15%.",Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1503446/),%,15,82781,DB01370,Aluminium
,16433897,Bioavailability (F),Bioavailability (F) of heroin inhalation was estimated as 52% (95% CI 44-61%).,"Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16433897/),%,52,85351,DB01370,Aluminium
,16433897,Cl/F,"Cl/F was 930 l/hr (95% CI 799-1061 l/hr) after intravenous administration, and 1939 l/hr (95% CI 1661-2217 l/hr) after inhalation.","Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16433897/),[l] / [h],930,85352,DB01370,Aluminium
,16433897,Cl/F,"Cl/F was 930 l/hr (95% CI 799-1061 l/hr) after intravenous administration, and 1939 l/hr (95% CI 1661-2217 l/hr) after inhalation.","Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16433897/),[l] / [h],1939,85353,DB01370,Aluminium
,16433897,reaction time,"After heroin administration, the reaction time was significantly prolonged with 28+/-5.3 msec.","Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16433897/),ms,28,85354,DB01370,Aluminium
,9112830,AUC,"The in-vivo study showed that the oral administration of Riopan 1 h after administration of Indocid capsules to fed dogs resulted in a significant (p < 0.05) reduction in plasma concentrations of indomethacin, a non-significant (p > 0.05) change in Cmax, significantly (p < 0.05) shorter Tmax and significantly reduced AUC where it decreased from 15.06 +/- 5.65 to 9.52 +/- 3.69 micrograms h/ml resulted in a relative bioavailability of 63.21% after Riopan administration.",Effect of antacid magaldrate oral suspension on in-vitro and in-vivo availability of indomethacin in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9112830/),,15.06,87500,DB01370,Aluminium
,9112830,AUC,"The in-vivo study showed that the oral administration of Riopan 1 h after administration of Indocid capsules to fed dogs resulted in a significant (p < 0.05) reduction in plasma concentrations of indomethacin, a non-significant (p > 0.05) change in Cmax, significantly (p < 0.05) shorter Tmax and significantly reduced AUC where it decreased from 15.06 +/- 5.65 to 9.52 +/- 3.69 micrograms h/ml resulted in a relative bioavailability of 63.21% after Riopan administration.",Effect of antacid magaldrate oral suspension on in-vitro and in-vivo availability of indomethacin in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9112830/),,9.52,87501,DB01370,Aluminium
,9112830,relative bioavailability,"The in-vivo study showed that the oral administration of Riopan 1 h after administration of Indocid capsules to fed dogs resulted in a significant (p < 0.05) reduction in plasma concentrations of indomethacin, a non-significant (p > 0.05) change in Cmax, significantly (p < 0.05) shorter Tmax and significantly reduced AUC where it decreased from 15.06 +/- 5.65 to 9.52 +/- 3.69 micrograms h/ml resulted in a relative bioavailability of 63.21% after Riopan administration.",Effect of antacid magaldrate oral suspension on in-vitro and in-vivo availability of indomethacin in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9112830/),%,63.21,87502,DB01370,Aluminium
,3435126,Peak concentrations,"Peak concentrations in serum noted in the absence of antacids ranged from 2.9 to 6.4 micrograms/ml, and peak concentrations in dialysate in the absence of antacids ranged from 1.8 to 4.5 micrograms/ml.",Effects of antacids and dialysate dwell times on multiple-dose pharmacokinetics of oral ciprofloxacin in patients on continuous ambulatory peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435126/),[μg] / [ml],2.9 to 6.4,88327,DB01370,Aluminium
,3435126,peak concentrations,"Peak concentrations in serum noted in the absence of antacids ranged from 2.9 to 6.4 micrograms/ml, and peak concentrations in dialysate in the absence of antacids ranged from 1.8 to 4.5 micrograms/ml.",Effects of antacids and dialysate dwell times on multiple-dose pharmacokinetics of oral ciprofloxacin in patients on continuous ambulatory peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435126/),[μg] / [ml],1.8 to 4.5,88328,DB01370,Aluminium
,3435126,D/S,"At 4 h D/S was 0.57 +/- 0.07 (mean +/- standard error of the mean; n = 9), and at 8 h it was 0.75 +/- 0.04 (n = 26).",Effects of antacids and dialysate dwell times on multiple-dose pharmacokinetics of oral ciprofloxacin in patients on continuous ambulatory peritoneal dialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435126/),,0.57,88329,DB01370,Aluminium
,3435126,D/S,"At 4 h D/S was 0.57 +/- 0.07 (mean +/- standard error of the mean; n = 9), and at 8 h it was 0.75 +/- 0.04 (n = 26).",Effects of antacids and dialysate dwell times on multiple-dose pharmacokinetics of oral ciprofloxacin in patients on continuous ambulatory peritoneal dialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435126/),,0.75,88330,DB01370,Aluminium
,6872853,Cmax,"Cmax was higher in subjects when treated with the antacid (10.45 +/- 3.03 vs. 8.30 +/- 2.90 micrograms/ml, p less than 0.05) than when given theophylline alone.",Effect of antacid on bioavailability of a sustained-release theophylline preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6872853/),[μg] / [ml],10.45,89099,DB01370,Aluminium
,6872853,Cmax,"Cmax was higher in subjects when treated with the antacid (10.45 +/- 3.03 vs. 8.30 +/- 2.90 micrograms/ml, p less than 0.05) than when given theophylline alone.",Effect of antacid on bioavailability of a sustained-release theophylline preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6872853/),[μg] / [ml],8.30,89100,DB01370,Aluminium
,6872853,tmax,"The mean tmax for the two treatments did not differ (10.4 +/- 1.67 h-combination vs. 10.8 +/- 1.1 h-theophylline, p greater than 0.05).",Effect of antacid on bioavailability of a sustained-release theophylline preparation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6872853/),h,10.4,89101,DB01370,Aluminium
,6872853,tmax,"The mean tmax for the two treatments did not differ (10.4 +/- 1.67 h-combination vs. 10.8 +/- 1.1 h-theophylline, p greater than 0.05).",Effect of antacid on bioavailability of a sustained-release theophylline preparation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6872853/),h,10.8,89102,DB01370,Aluminium
,6872853,AUC,"Likewise, mean AUC was unchanged by the coadministration of antacid (140.65 +/- 41.6 micrograms/ml.h--combination vs. 155.13 +/- 46.6 micrograms/h--theophylline, p greater than 0.05).",Effect of antacid on bioavailability of a sustained-release theophylline preparation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6872853/),[μg] / [h·ml],140.65,89103,DB01370,Aluminium
,6872853,AUC,"Likewise, mean AUC was unchanged by the coadministration of antacid (140.65 +/- 41.6 micrograms/ml.h--combination vs. 155.13 +/- 46.6 micrograms/h--theophylline, p greater than 0.05).",Effect of antacid on bioavailability of a sustained-release theophylline preparation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6872853/),[μg] / [h],155.13,89104,DB01370,Aluminium
,3418776,peak level,Al levels in serum of all patients increased in average from 28.6 micrograms/l immediately before to a peak level of 41.6 micrograms,Elimination of absorbed aluminum in patients undergoing continuous ambulatory peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3418776/),μg,41.6,90668,DB01370,Aluminium
,3418776,Elimination,Elimination across the peritoneum increased from 5.6 micrograms Al during the first 4 h to peak levels of 12.9 micrograms between hour 8 and 12 and decreased to 8.1 micrograms during the last 12 h.,Elimination of absorbed aluminum in patients undergoing continuous ambulatory peritoneal dialysis. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3418776/),μg,5.6,90669,DB01370,Aluminium
,3418776,Elimination,Elimination across the peritoneum increased from 5.6 micrograms Al during the first 4 h to peak levels of 12.9 micrograms between hour 8 and 12 and decreased to 8.1 micrograms during the last 12 h.,Elimination of absorbed aluminum in patients undergoing continuous ambulatory peritoneal dialysis. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3418776/),μg,8.1,90670,DB01370,Aluminium
,3418776,peak levels,Elimination across the peritoneum increased from 5.6 micrograms Al during the first 4 h to peak levels of 12.9 micrograms between hour 8 and 12 and decreased to 8.1 micrograms during the last 12 h.,Elimination of absorbed aluminum in patients undergoing continuous ambulatory peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3418776/),μg,12.9,90671,DB01370,Aluminium
,3418776,peak levels,Elimination across the peritoneum increased from 5.6 micrograms Al during the first 4 h to peak levels of 12.9 micrograms between hour 8 and 12 and decreased to 8.1 micrograms during the last 12 h.,Elimination of absorbed aluminum in patients undergoing continuous ambulatory peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3418776/),μg,8.1,90672,DB01370,Aluminium
,3418776,Al clearance,The Al clearance of the peritoneum was 0.43 ml/min.,Elimination of absorbed aluminum in patients undergoing continuous ambulatory peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3418776/),[ml] / [min],0.43,90673,DB01370,Aluminium
,3418776,renal Al excretion,In the 6 patients with residual diuresis the renal Al excretion was higher than the peritoneal removal (48.1 micrograms/24 h vs. 24.8 micrograms/24 h).,Elimination of absorbed aluminum in patients undergoing continuous ambulatory peritoneal dialysis. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3418776/),[μg] / [24·h],48.1,90674,DB01370,Aluminium
,3418776,renal Al excretion,In the 6 patients with residual diuresis the renal Al excretion was higher than the peritoneal removal (48.1 micrograms/24 h vs. 24.8 micrograms/24 h).,Elimination of absorbed aluminum in patients undergoing continuous ambulatory peritoneal dialysis. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3418776/),[μg] / [24·h],24.8,90675,DB01370,Aluminium
,3418776,renal Al clearance,The renal Al clearance amounted to 1.6 ml/min.,Elimination of absorbed aluminum in patients undergoing continuous ambulatory peritoneal dialysis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3418776/),[ml] / [min],1.6,90676,DB01370,Aluminium
,3418776,gastrointestinal absorption quotient,Assuming a gastrointestinal absorption quotient of 0.1% it is concluded that Al removal by CAPD in patients receiving 342 mg Al/day is not sufficient to prevent Al accumulation.,Elimination of absorbed aluminum in patients undergoing continuous ambulatory peritoneal dialysis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3418776/),%,0.1,90677,DB01370,Aluminium
,1831005,relative extents of absorption (Frel),"The mean +/- SD relative extents of absorption (Frel) of clonidine following dermal pretreatment with hydrocortisone and magnesium-aluminum hydroxide in respect to the transdermal patch alone were 94.84 +/- 45.69% and 97.65 +/- 59.65%, respectively.",Skin pretreatment and the use of transdermal clonidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1831005/),%,94.84,92589,DB01370,Aluminium
,1831005,relative extents of absorption (Frel),"The mean +/- SD relative extents of absorption (Frel) of clonidine following dermal pretreatment with hydrocortisone and magnesium-aluminum hydroxide in respect to the transdermal patch alone were 94.84 +/- 45.69% and 97.65 +/- 59.65%, respectively.",Skin pretreatment and the use of transdermal clonidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1831005/),%,97.65,92590,DB01370,Aluminium
,9267685,relative bioavailabilities,"The mean relative bioavailabilities of sertindole administered as tablets after fasting, with food, and with Maalox are 99, 104, and 98%, respectively, compared to sertindole solution.","Effects of food, antacid, and dosage form on the pharmacokinetics and relative bioavailability of sertindole in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9267685/),%,99,95019,DB01370,Aluminium
,9267685,relative bioavailabilities,"The mean relative bioavailabilities of sertindole administered as tablets after fasting, with food, and with Maalox are 99, 104, and 98%, respectively, compared to sertindole solution.","Effects of food, antacid, and dosage form on the pharmacokinetics and relative bioavailability of sertindole in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9267685/),%,104,95020,DB01370,Aluminium
,9267685,relative bioavailabilities,"The mean relative bioavailabilities of sertindole administered as tablets after fasting, with food, and with Maalox are 99, 104, and 98%, respectively, compared to sertindole solution.","Effects of food, antacid, and dosage form on the pharmacokinetics and relative bioavailability of sertindole in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9267685/),%,98,95021,DB01370,Aluminium
,770046,absorption half-time,"The antacid prolonged the mean chlordiazepoxide absorption half-time from 11 to 24 min, and in 6 of 10 subjects delayed achievement of the peak blood concentration by from 0.5 to 3.0 hrs.",Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/770046/),min,11 to 24,96327,DB01370,Aluminium
,770046,apparent elimination half-life,The apparent elimination half-life of chlordiazepoxide (8.4 and 8.2 hr) was not significantly affected.,Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/770046/),h,8.4,96328,DB01370,Aluminium
,770046,apparent elimination half-life,The apparent elimination half-life of chlordiazepoxide (8.4 and 8.2 hr) was not significantly affected.,Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/770046/),h,8.2,96329,DB01370,Aluminium
,2751741,biological half-life,There was no significant difference in the biological half-life of pirenzepine between the two treatments (10.1-9.4 h).,Effect of an aluminium-hydroxide containing antacid on the oral bioavailability of pirenzepine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751741/),h,10.1-9.4,98974,DB01370,Aluminium
,1646724,AUC,"Sodium bicarbonate significantly increased the AUC of plasma glipizide from 0 to 0.5 h, 0 to 1 h, and from 0 to 2 h (six-, four- and twofold, respectively).",Differential effects of sodium bicarbonate and aluminium hydroxide on the absorption and activity of glipizide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1646724/),h,0,99733,DB01370,Aluminium
,1646724,time to peak concentration (tmax),The time to peak concentration (tmax) fell from 2.5 h during the control phase to 1.0 h during the sodium bicarbonate phase.,Differential effects of sodium bicarbonate and aluminium hydroxide on the absorption and activity of glipizide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1646724/),h,2.5,99734,DB01370,Aluminium
,1646724,time to peak concentration (tmax),The time to peak concentration (tmax) fell from 2.5 h during the control phase to 1.0 h during the sodium bicarbonate phase.,Differential effects of sodium bicarbonate and aluminium hydroxide on the absorption and activity of glipizide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1646724/),h,1.0,99735,DB01370,Aluminium
,16809799,absolute bioavailability,"The absolute bioavailability of lanthanum [administered as La2(CO3)3] was extremely low (0.00127% +/- 0.00080%), with individual values in the range of 0.00015% to 0.00224%.",Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16809799/),%,0.00127,103016,DB01370,Aluminium
,16809799,absolute bioavailability,"The absolute bioavailability of lanthanum [administered as La2(CO3)3] was extremely low (0.00127% +/- 0.00080%), with individual values in the range of 0.00015% to 0.00224%.",Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16809799/),%,0.00015,103017,DB01370,Aluminium
,16809799,absolute bioavailability,"The absolute bioavailability of lanthanum [administered as La2(CO3)3] was extremely low (0.00127% +/- 0.00080%), with individual values in the range of 0.00015% to 0.00224%.",Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16809799/),%,0.00224,103018,DB01370,Aluminium
,16809799,Renal clearance,Renal clearance was negligible following oral administration (1.36 +/- 1.43 mL/min).,Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16809799/),[ml] / [min],1.36,103019,DB01370,Aluminium
,16809799,renal clearance,"Intravenous administration confirmed low renal clearance (0.95 +/- 0.60 mL/min), just 1.7% of total plasma clearance.",Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16809799/),[ml] / [min],0.95,103020,DB01370,Aluminium
,10564839,lung bioavailability,"Following intratracheal instillation of the drug solution, the lung bioavailability was found to be approximately 75% in dogs.","Pulmonary delivery of a dopamine D-1 agonist, ABT-431, in dogs and humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10564839/),%,75,105157,DB01370,Aluminium
,10564839,C(max),"Using tracheostomized beagle dogs, the C(max) following tracheal administration of 5 mg aerosolized ABT-431 was found to be 13.3+/-0.9 ng ml(-1) and the AUC(0-24) was estimated at 33.2+/-10.6 h ng ml(-1).","Pulmonary delivery of a dopamine D-1 agonist, ABT-431, in dogs and humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10564839/),[ng] / [ml],13.3,105158,DB01370,Aluminium
,10564839,AUC(0-24),"Using tracheostomized beagle dogs, the C(max) following tracheal administration of 5 mg aerosolized ABT-431 was found to be 13.3+/-0.9 ng ml(-1) and the AUC(0-24) was estimated at 33.2+/-10.6 h ng ml(-1).","Pulmonary delivery of a dopamine D-1 agonist, ABT-431, in dogs and humans. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10564839/),[h·ng] / [ml],33.2,105159,DB01370,Aluminium
,10564839,lung bioavailability,The lung bioavailability of the aerosolized drug was 34% compared to intravenous injection in dogs.,"Pulmonary delivery of a dopamine D-1 agonist, ABT-431, in dogs and humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10564839/),%,34,105160,DB01370,Aluminium
,4076324,bioavailability,"The bioavailability of paracetamol was not altered by either antacid, but they both delayed the time to peak plasma concentration (0.85 h; 1.43 h; 1.25 h, without antacid, with Dimalan and with Maalox respectively).",Effect of two antacids on the bioavailability of paracetamol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4076324/),h,0.85,107270,DB01370,Aluminium
,4076324,bioavailability,"The bioavailability of paracetamol was not altered by either antacid, but they both delayed the time to peak plasma concentration (0.85 h; 1.43 h; 1.25 h, without antacid, with Dimalan and with Maalox respectively).",Effect of two antacids on the bioavailability of paracetamol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4076324/),h,1.43,107271,DB01370,Aluminium
,4076324,bioavailability,"The bioavailability of paracetamol was not altered by either antacid, but they both delayed the time to peak plasma concentration (0.85 h; 1.43 h; 1.25 h, without antacid, with Dimalan and with Maalox respectively).",Effect of two antacids on the bioavailability of paracetamol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4076324/),h,1.25,107272,DB01370,Aluminium
,4076324,time to peak plasma concentration,"The bioavailability of paracetamol was not altered by either antacid, but they both delayed the time to peak plasma concentration (0.85 h; 1.43 h; 1.25 h, without antacid, with Dimalan and with Maalox respectively).",Effect of two antacids on the bioavailability of paracetamol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4076324/),h,0.85,107273,DB01370,Aluminium
,4076324,time to peak plasma concentration,"The bioavailability of paracetamol was not altered by either antacid, but they both delayed the time to peak plasma concentration (0.85 h; 1.43 h; 1.25 h, without antacid, with Dimalan and with Maalox respectively).",Effect of two antacids on the bioavailability of paracetamol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4076324/),h,1.43,107274,DB01370,Aluminium
,4076324,time to peak plasma concentration,"The bioavailability of paracetamol was not altered by either antacid, but they both delayed the time to peak plasma concentration (0.85 h; 1.43 h; 1.25 h, without antacid, with Dimalan and with Maalox respectively).",Effect of two antacids on the bioavailability of paracetamol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4076324/),h,1.25,107275,DB01370,Aluminium
,29902922,contact angles,"Results revealed that superamphiphobic substrates were successfully prepared showing a rough micro-sized hierarchical structured surface upon observing with scanning electron microscope and were confirmed by high contact angles of 151.60 ± 2.42 and 142.80°±05.23° for water and olive oil, respectively.","Ultrahigh verapamil-loaded controlled release polymeric beads using superamphiphobic substrate: D-optimal statistical design, in vitro and in vivo performance. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29902922/),°,151.60,109147,DB01370,Aluminium
,29902922,contact angles,"Results revealed that superamphiphobic substrates were successfully prepared showing a rough micro-sized hierarchical structured surface upon observing with scanning electron microscope and were confirmed by high contact angles of 151.60 ± 2.42 and 142.80°±05.23° for water and olive oil, respectively.","Ultrahigh verapamil-loaded controlled release polymeric beads using superamphiphobic substrate: D-optimal statistical design, in vitro and in vivo performance. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29902922/),°,142.80,109148,DB01370,Aluminium
,29902922,Q12 h,All the prepared systems exhibited a controlled release behavior with Q12 h ranging between 5.46 and 95.90%w/w.,"Ultrahigh verapamil-loaded controlled release polymeric beads using superamphiphobic substrate: D-optimal statistical design, in vitro and in vivo performance. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29902922/),[%w] / [w],5.46 and 95.90,109149,DB01370,Aluminium
,2610494,areas under the concentration-time curve (AUCs),"The areas under the concentration-time curve (AUCs) of ciprofloxacin for regimens A and D were not significantly different (14.5 +/- 2.3 versus 15.7 +/- 2.8 micrograms.h/ml, mean +/- standard deviation).",Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2610494/),[h·μg] / [ml],14.5,110179,DB01370,Aluminium
,2610494,areas under the concentration-time curve (AUCs),"The areas under the concentration-time curve (AUCs) of ciprofloxacin for regimens A and D were not significantly different (14.5 +/- 2.3 versus 15.7 +/- 2.8 micrograms.h/ml, mean +/- standard deviation).",Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2610494/),[h·μg] / [ml],15.7,110180,DB01370,Aluminium
,2610494,AUCs,The AUCs for regimen B (5.4 +/- 1.7 micrograms.h/ml) and regimen C (11.3 +/- 2.4 micrograms.h/ml) were significantly different from the AUCs for regimens A and D.,Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2610494/),[h·μg] / [ml],5.4,110181,DB01370,Aluminium
,2610494,AUCs,The AUCs for regimen B (5.4 +/- 1.7 micrograms.h/ml) and regimen C (11.3 +/- 2.4 micrograms.h/ml) were significantly different from the AUCs for regimens A and D.,Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2610494/),[h·μg] / [ml],11.3,110182,DB01370,Aluminium
,28870,peak measured concentration,"Mean kinetic variables for DMDZ in CZP-water and CZP-magnesium aluminum hydroxide treatment conditions, respectively, were: peak measured concentration, 273 and 188 ng/ml (p 0.001); time of peak concentration, 1.8 and 2.8 hr after dose (p less than 0.01); apparent absorption half-life, 14.8 and 30.7 min (p less than 0.02); area under the 48-hr plasma concentration curve, 6,028 and 5,433 ng/ml X hr (p less than 0.02).",Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28870/),[ng] / [ml],273,115120,DB01370,Aluminium
,28870,peak measured concentration,"Mean kinetic variables for DMDZ in CZP-water and CZP-magnesium aluminum hydroxide treatment conditions, respectively, were: peak measured concentration, 273 and 188 ng/ml (p 0.001); time of peak concentration, 1.8 and 2.8 hr after dose (p less than 0.01); apparent absorption half-life, 14.8 and 30.7 min (p less than 0.02); area under the 48-hr plasma concentration curve, 6,028 and 5,433 ng/ml X hr (p less than 0.02).",Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28870/),[ng] / [ml],188,115121,DB01370,Aluminium
,28870,time of peak concentration,"Mean kinetic variables for DMDZ in CZP-water and CZP-magnesium aluminum hydroxide treatment conditions, respectively, were: peak measured concentration, 273 and 188 ng/ml (p 0.001); time of peak concentration, 1.8 and 2.8 hr after dose (p less than 0.01); apparent absorption half-life, 14.8 and 30.7 min (p less than 0.02); area under the 48-hr plasma concentration curve, 6,028 and 5,433 ng/ml X hr (p less than 0.02).",Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28870/),h,1.8,115122,DB01370,Aluminium
,28870,time of peak concentration,"Mean kinetic variables for DMDZ in CZP-water and CZP-magnesium aluminum hydroxide treatment conditions, respectively, were: peak measured concentration, 273 and 188 ng/ml (p 0.001); time of peak concentration, 1.8 and 2.8 hr after dose (p less than 0.01); apparent absorption half-life, 14.8 and 30.7 min (p less than 0.02); area under the 48-hr plasma concentration curve, 6,028 and 5,433 ng/ml X hr (p less than 0.02).",Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28870/),h,2.8,115123,DB01370,Aluminium
,28870,apparent absorption half-life,"Mean kinetic variables for DMDZ in CZP-water and CZP-magnesium aluminum hydroxide treatment conditions, respectively, were: peak measured concentration, 273 and 188 ng/ml (p 0.001); time of peak concentration, 1.8 and 2.8 hr after dose (p less than 0.01); apparent absorption half-life, 14.8 and 30.7 min (p less than 0.02); area under the 48-hr plasma concentration curve, 6,028 and 5,433 ng/ml X hr (p less than 0.02).",Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28870/),min,14.8,115124,DB01370,Aluminium
,28870,apparent absorption half-life,"Mean kinetic variables for DMDZ in CZP-water and CZP-magnesium aluminum hydroxide treatment conditions, respectively, were: peak measured concentration, 273 and 188 ng/ml (p 0.001); time of peak concentration, 1.8 and 2.8 hr after dose (p less than 0.01); apparent absorption half-life, 14.8 and 30.7 min (p less than 0.02); area under the 48-hr plasma concentration curve, 6,028 and 5,433 ng/ml X hr (p less than 0.02).",Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28870/),min,30.7,115125,DB01370,Aluminium
,28870,area under the 48-hr plasma concentration curve,"Mean kinetic variables for DMDZ in CZP-water and CZP-magnesium aluminum hydroxide treatment conditions, respectively, were: peak measured concentration, 273 and 188 ng/ml (p 0.001); time of peak concentration, 1.8 and 2.8 hr after dose (p less than 0.01); apparent absorption half-life, 14.8 and 30.7 min (p less than 0.02); area under the 48-hr plasma concentration curve, 6,028 and 5,433 ng/ml X hr (p less than 0.02).",Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28870/),[ng] / [h·ml],"6,028",115126,DB01370,Aluminium
,28870,area under the 48-hr plasma concentration curve,"Mean kinetic variables for DMDZ in CZP-water and CZP-magnesium aluminum hydroxide treatment conditions, respectively, were: peak measured concentration, 273 and 188 ng/ml (p 0.001); time of peak concentration, 1.8 and 2.8 hr after dose (p less than 0.01); apparent absorption half-life, 14.8 and 30.7 min (p less than 0.02); area under the 48-hr plasma concentration curve, 6,028 and 5,433 ng/ml X hr (p less than 0.02).",Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28870/),[ng] / [h·ml],"5,433",115127,DB01370,Aluminium
,16584286,bioavailability,"The bioavailability of inhaled heroin was estimated to be 53% (95% CI 43.7, 62.3).",Population pharmacokinetics of heroin and its major metabolites. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584286/),%,53,116470,DB01370,Aluminium
,16584286,terminal half-lives,"The terminal half-lives of heroin and 6-acetylmorphine were estimated to be 7.6 and 21.8 minutes, respectively.",Population pharmacokinetics of heroin and its major metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584286/),min,7.6,116471,DB01370,Aluminium
,16584286,terminal half-lives,"The terminal half-lives of heroin and 6-acetylmorphine were estimated to be 7.6 and 21.8 minutes, respectively.",Population pharmacokinetics of heroin and its major metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584286/),min,21.8,116472,DB01370,Aluminium
,16584286,clearances,"The clearances of morphine and the morphine-glucuronides were estimated to be 73.6 L/h (95% CI 62.8, 84.4) and between 6 and 10 L/h, respectively.",Population pharmacokinetics of heroin and its major metabolites. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584286/),[l] / [h],73.6,116473,DB01370,Aluminium
,8877335,total Al load,The total Al load for each antacid and patient was 512 mg daily for a total of 15360 mg during the 30-day treatment.,Absence of gastrointestinal absorption or urinary excretion of aluminium from an allantoinate complex contained in two antacid formulations in patients with normal renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877335/),mg,512,117187,DB01370,Aluminium
,1328941,interdialytic half-life,"The interdialytic half-life of ferrioxamine was 2.2 h in normal volunteers, 13.3 h in dialysis patients without haemosiderosis, and 24.6 h in patients with haemosiderosis.",Pharmacokinetics of aluminoxamine and ferrioxamine and dose finding of desferrioxamine in haemodialysis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1328941/),h,2.2,117306,DB01370,Aluminium
,1328941,interdialytic half-life,"The interdialytic half-life of ferrioxamine was 2.2 h in normal volunteers, 13.3 h in dialysis patients without haemosiderosis, and 24.6 h in patients with haemosiderosis.",Pharmacokinetics of aluminoxamine and ferrioxamine and dose finding of desferrioxamine in haemodialysis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1328941/),h,13.3,117307,DB01370,Aluminium
,1328941,interdialytic half-life,"The interdialytic half-life of ferrioxamine was 2.2 h in normal volunteers, 13.3 h in dialysis patients without haemosiderosis, and 24.6 h in patients with haemosiderosis.",Pharmacokinetics of aluminoxamine and ferrioxamine and dose finding of desferrioxamine in haemodialysis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1328941/),h,24.6,117308,DB01370,Aluminium
,1328941,peak serum concentrations,"The peak serum concentrations after these doses were 4.1 +/- 2.9, 6.4 +/- 2.9, and 10.7 +/- 7.1 mumol/l for ferrioxamine and 2.8 +/- 1.5, 3.1 +/- 1.5, and 4.2 +/- 1.7 mumol/l for aluminoxamine.",Pharmacokinetics of aluminoxamine and ferrioxamine and dose finding of desferrioxamine in haemodialysis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1328941/),[μM] / [l],4.1,117309,DB01370,Aluminium
,1328941,peak serum concentrations,"The peak serum concentrations after these doses were 4.1 +/- 2.9, 6.4 +/- 2.9, and 10.7 +/- 7.1 mumol/l for ferrioxamine and 2.8 +/- 1.5, 3.1 +/- 1.5, and 4.2 +/- 1.7 mumol/l for aluminoxamine.",Pharmacokinetics of aluminoxamine and ferrioxamine and dose finding of desferrioxamine in haemodialysis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1328941/),[μM] / [l],6.4,117310,DB01370,Aluminium
,1328941,peak serum concentrations,"The peak serum concentrations after these doses were 4.1 +/- 2.9, 6.4 +/- 2.9, and 10.7 +/- 7.1 mumol/l for ferrioxamine and 2.8 +/- 1.5, 3.1 +/- 1.5, and 4.2 +/- 1.7 mumol/l for aluminoxamine.",Pharmacokinetics of aluminoxamine and ferrioxamine and dose finding of desferrioxamine in haemodialysis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1328941/),[μM] / [l],10.7,117311,DB01370,Aluminium
,1328941,peak serum concentrations,"The peak serum concentrations after these doses were 4.1 +/- 2.9, 6.4 +/- 2.9, and 10.7 +/- 7.1 mumol/l for ferrioxamine and 2.8 +/- 1.5, 3.1 +/- 1.5, and 4.2 +/- 1.7 mumol/l for aluminoxamine.",Pharmacokinetics of aluminoxamine and ferrioxamine and dose finding of desferrioxamine in haemodialysis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1328941/),[μM] / [l],2.8,117312,DB01370,Aluminium
,1328941,peak serum concentrations,"The peak serum concentrations after these doses were 4.1 +/- 2.9, 6.4 +/- 2.9, and 10.7 +/- 7.1 mumol/l for ferrioxamine and 2.8 +/- 1.5, 3.1 +/- 1.5, and 4.2 +/- 1.7 mumol/l for aluminoxamine.",Pharmacokinetics of aluminoxamine and ferrioxamine and dose finding of desferrioxamine in haemodialysis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1328941/),[μM] / [l],3.1,117313,DB01370,Aluminium
,1328941,peak serum concentrations,"The peak serum concentrations after these doses were 4.1 +/- 2.9, 6.4 +/- 2.9, and 10.7 +/- 7.1 mumol/l for ferrioxamine and 2.8 +/- 1.5, 3.1 +/- 1.5, and 4.2 +/- 1.7 mumol/l for aluminoxamine.",Pharmacokinetics of aluminoxamine and ferrioxamine and dose finding of desferrioxamine in haemodialysis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1328941/),[μM] / [l],4.2,117314,DB01370,Aluminium
,11401178,half-life,"After intravenous administration of cilomilast, plasma concentrations increased in an approximately dose-proportional manner; the half-life, approximately 6.5 hours, was dose independent.",Bioavailability of the oral selective phosphodiesterase 4 inhibitor cilomilast. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11401178/),h,6.5,118928,DB01370,Aluminium
,11401178,absolute bioavailability,"After oral dosing, the absolute bioavailability was consistently close to 100%.",Bioavailability of the oral selective phosphodiesterase 4 inhibitor cilomilast. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11401178/),%,100,118929,DB01370,Aluminium
,11401178,absolute bioavailability,The absolute bioavailability of oral cilomilast was 100%; it was not adversely affected by time of dosing or coadministration with food or antacid.,Bioavailability of the oral selective phosphodiesterase 4 inhibitor cilomilast. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11401178/),%,100,118930,DB01370,Aluminium
,10223915,peak concentration (Cmax),"Pharmacokinetics of a single 400-mg dose of gatifloxacin alone were characterized as follows (mean +/- standard deviation): peak concentration (Cmax), 3.8 +/- 0. 5 (treatment A) and 3.4 +/- 0.9 (treatment D) microgram/ml; time to Cmax, 1.4 +/- 0.8 (treatment A) and 1.7 +/- 0.7 (treatment D) h; area under the curve from time zero to infinity (AUC0-infinity), 33. 5 +/- 5.9 (treatment A) and 31.4 +/- 3.4 (treatment D) microgram.",Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223915/),[μg] / [ml],3.8,119998,DB01370,Aluminium
,10223915,peak concentration (Cmax),"Pharmacokinetics of a single 400-mg dose of gatifloxacin alone were characterized as follows (mean +/- standard deviation): peak concentration (Cmax), 3.8 +/- 0. 5 (treatment A) and 3.4 +/- 0.9 (treatment D) microgram/ml; time to Cmax, 1.4 +/- 0.8 (treatment A) and 1.7 +/- 0.7 (treatment D) h; area under the curve from time zero to infinity (AUC0-infinity), 33. 5 +/- 5.9 (treatment A) and 31.4 +/- 3.4 (treatment D) microgram.",Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223915/),[μg] / [ml],3.4,119999,DB01370,Aluminium
,10223915,time to Cmax,"Pharmacokinetics of a single 400-mg dose of gatifloxacin alone were characterized as follows (mean +/- standard deviation): peak concentration (Cmax), 3.8 +/- 0. 5 (treatment A) and 3.4 +/- 0.9 (treatment D) microgram/ml; time to Cmax, 1.4 +/- 0.8 (treatment A) and 1.7 +/- 0.7 (treatment D) h; area under the curve from time zero to infinity (AUC0-infinity), 33. 5 +/- 5.9 (treatment A) and 31.4 +/- 3.4 (treatment D) microgram.",Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223915/),h,1.4,120000,DB01370,Aluminium
,10223915,time to Cmax,"Pharmacokinetics of a single 400-mg dose of gatifloxacin alone were characterized as follows (mean +/- standard deviation): peak concentration (Cmax), 3.8 +/- 0. 5 (treatment A) and 3.4 +/- 0.9 (treatment D) microgram/ml; time to Cmax, 1.4 +/- 0.8 (treatment A) and 1.7 +/- 0.7 (treatment D) h; area under the curve from time zero to infinity (AUC0-infinity), 33. 5 +/- 5.9 (treatment A) and 31.4 +/- 3.4 (treatment D) microgram.",Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223915/),h,1.7,120001,DB01370,Aluminium
,10223915,area under the curve from time zero to infinity (AUC0-infinity),"Pharmacokinetics of a single 400-mg dose of gatifloxacin alone were characterized as follows (mean +/- standard deviation): peak concentration (Cmax), 3.8 +/- 0. 5 (treatment A) and 3.4 +/- 0.9 (treatment D) microgram/ml; time to Cmax, 1.4 +/- 0.8 (treatment A) and 1.7 +/- 0.7 (treatment D) h; area under the curve from time zero to infinity (AUC0-infinity), 33. 5 +/- 5.9 (treatment A) and 31.4 +/- 3.4 (treatment D) microgram.",Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223915/),μg,33. 5,120002,DB01370,Aluminium
,10223915,area under the curve from time zero to infinity (AUC0-infinity),"Pharmacokinetics of a single 400-mg dose of gatifloxacin alone were characterized as follows (mean +/- standard deviation): peak concentration (Cmax), 3.8 +/- 0. 5 (treatment A) and 3.4 +/- 0.9 (treatment D) microgram/ml; time to Cmax, 1.4 +/- 0.8 (treatment A) and 1.7 +/- 0.7 (treatment D) h; area under the curve from time zero to infinity (AUC0-infinity), 33. 5 +/- 5.9 (treatment A) and 31.4 +/- 3.4 (treatment D) microgram.",Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223915/),μg,31.4,120003,DB01370,Aluminium
,10223915,urine recovery,"h/ml; urine recovery, (83 +/- 6)% (treatment A) and (84 +/- 8)% (treatment D).",Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223915/),%,83,120004,DB01370,Aluminium
,10223915,urine recovery,"h/ml; urine recovery, (83 +/- 6)% (treatment A) and (84 +/- 8)% (treatment D).",Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223915/),%,84,120005,DB01370,Aluminium
,10223915,AUC0-infinity,AUC0-infinity was significantly reduced from 33.5 +/- 5.9 to 19.4 +/- 6.9 microgram.,Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223915/),μg,33.5,120006,DB01370,Aluminium
,10223915,AUC0-infinity,AUC0-infinity was significantly reduced from 33.5 +/- 5.9 to 19.4 +/- 6.9 microgram.,Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223915/),μg,19.4,120007,DB01370,Aluminium
,10223915,AUC0-infinity,"If aluminum magnesium hydroxide was given 2 h after gatifloxacin (treatment E), there was no significant reduction of concentration in serum but AUC0-infinity was significantly reduced from 31.4 +/- 3.4 to 25.9 +/- 5.3 microgram.",Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223915/),μg,31.4,120008,DB01370,Aluminium
,10223915,AUC0-infinity,"If aluminum magnesium hydroxide was given 2 h after gatifloxacin (treatment E), there was no significant reduction of concentration in serum but AUC0-infinity was significantly reduced from 31.4 +/- 3.4 to 25.9 +/- 5.3 microgram.",Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223915/),μg,25.9,120009,DB01370,Aluminium
,30302509,total plasma clearance,High and dose-independent total plasma clearance (6.6 mL/min/kg) was observed after IV administration corresponding to 60-82% of normal rat GFR.,"Aluminium toxicokinetics after intramuscular, subcutaneous, and intravenous injection of Al citrate solution in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30302509/),[ml] / [kg·min],6.6,122403,DB01370,Aluminium
,30302509,bioavailability,Fast and complete absorption of Al was observed at each dose level after both SC and IM administration (bioavailability estimates: 88 and 110%).,"Aluminium toxicokinetics after intramuscular, subcutaneous, and intravenous injection of Al citrate solution in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30302509/),%,88,122404,DB01370,Aluminium
,30302509,bioavailability,Fast and complete absorption of Al was observed at each dose level after both SC and IM administration (bioavailability estimates: 88 and 110%).,"Aluminium toxicokinetics after intramuscular, subcutaneous, and intravenous injection of Al citrate solution in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30302509/),%,110,122405,DB01370,Aluminium
,30302509,absorption half-lives,Estimates for the first-order absorption rate constant ka correspond to absorption half-lives of 36 min (SC) and ≤ 13 min (IM).,"Aluminium toxicokinetics after intramuscular, subcutaneous, and intravenous injection of Al citrate solution in rats. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30302509/),min,36,122406,DB01370,Aluminium
≤,30302509,absorption half-lives,Estimates for the first-order absorption rate constant ka correspond to absorption half-lives of 36 min (SC) and ≤ 13 min (IM).,"Aluminium toxicokinetics after intramuscular, subcutaneous, and intravenous injection of Al citrate solution in rats. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30302509/),min,13,122407,DB01370,Aluminium
,12134955,peak percentage,"When total body distribution was considered, the recovery of radioactivity was greater for the endothelium than for plasma (peak percentage of the dose was 65% at 15 min, 20% at 3 min, 5% from 20 to 240 min for the vena cava, aortic endothelium, and plasma, respectively).",Tissue distribution of [14C]sucrose octasulfate following oral administration to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12134955/),%,65,126566,DB01370,Aluminium
,12134955,peak percentage,"When total body distribution was considered, the recovery of radioactivity was greater for the endothelium than for plasma (peak percentage of the dose was 65% at 15 min, 20% at 3 min, 5% from 20 to 240 min for the vena cava, aortic endothelium, and plasma, respectively).",Tissue distribution of [14C]sucrose octasulfate following oral administration to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12134955/),%,20,126567,DB01370,Aluminium
,12134955,peak percentage,"When total body distribution was considered, the recovery of radioactivity was greater for the endothelium than for plasma (peak percentage of the dose was 65% at 15 min, 20% at 3 min, 5% from 20 to 240 min for the vena cava, aortic endothelium, and plasma, respectively).",Tissue distribution of [14C]sucrose octasulfate following oral administration to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12134955/),%,5,126568,DB01370,Aluminium
,2624820,peak serum concentration,"Meals were found to decrease the peak serum concentration of NaF from 122 micrograms/L during fasting (after baseline subtraction) to 71 and 88 micrograms/L with breakfast and lunch respectively, and to slow its absorption rate with Tmax increasing from 3.3 to 7.3 and 11.2 hours, without altering its bioavailability.",Influence of food and antacid administration on fluoride bioavailability from enteric-coated sodium fluoride tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2624820/),[μg] / [l],122,127760,DB01370,Aluminium
,2624820,peak serum concentration,"Meals were found to decrease the peak serum concentration of NaF from 122 micrograms/L during fasting (after baseline subtraction) to 71 and 88 micrograms/L with breakfast and lunch respectively, and to slow its absorption rate with Tmax increasing from 3.3 to 7.3 and 11.2 hours, without altering its bioavailability.",Influence of food and antacid administration on fluoride bioavailability from enteric-coated sodium fluoride tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2624820/),[μg] / [l],71,127761,DB01370,Aluminium
,2624820,peak serum concentration,"Meals were found to decrease the peak serum concentration of NaF from 122 micrograms/L during fasting (after baseline subtraction) to 71 and 88 micrograms/L with breakfast and lunch respectively, and to slow its absorption rate with Tmax increasing from 3.3 to 7.3 and 11.2 hours, without altering its bioavailability.",Influence of food and antacid administration on fluoride bioavailability from enteric-coated sodium fluoride tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2624820/),[μg] / [l],88,127762,DB01370,Aluminium
,2624820,Tmax,"Meals were found to decrease the peak serum concentration of NaF from 122 micrograms/L during fasting (after baseline subtraction) to 71 and 88 micrograms/L with breakfast and lunch respectively, and to slow its absorption rate with Tmax increasing from 3.3 to 7.3 and 11.2 hours, without altering its bioavailability.",Influence of food and antacid administration on fluoride bioavailability from enteric-coated sodium fluoride tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2624820/),h,3.3,127763,DB01370,Aluminium
,2624820,Tmax,"Meals were found to decrease the peak serum concentration of NaF from 122 micrograms/L during fasting (after baseline subtraction) to 71 and 88 micrograms/L with breakfast and lunch respectively, and to slow its absorption rate with Tmax increasing from 3.3 to 7.3 and 11.2 hours, without altering its bioavailability.",Influence of food and antacid administration on fluoride bioavailability from enteric-coated sodium fluoride tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2624820/),h,7.3,127764,DB01370,Aluminium
,2624820,Tmax,"Meals were found to decrease the peak serum concentration of NaF from 122 micrograms/L during fasting (after baseline subtraction) to 71 and 88 micrograms/L with breakfast and lunch respectively, and to slow its absorption rate with Tmax increasing from 3.3 to 7.3 and 11.2 hours, without altering its bioavailability.",Influence of food and antacid administration on fluoride bioavailability from enteric-coated sodium fluoride tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2624820/),h,11.2,127765,DB01370,Aluminium
,2624820,AUC,"Antacid impaired the bioavailability of NaF by 80% when administered simultaneously, with AUC decreasing from 987 to 155 micrograms.h/L, but had no significant effect when taken 2 h before NaF.",Influence of food and antacid administration on fluoride bioavailability from enteric-coated sodium fluoride tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2624820/),[h·μg] / [l],987,127766,DB01370,Aluminium
,2624820,AUC,"Antacid impaired the bioavailability of NaF by 80% when administered simultaneously, with AUC decreasing from 987 to 155 micrograms.h/L, but had no significant effect when taken 2 h before NaF.",Influence of food and antacid administration on fluoride bioavailability from enteric-coated sodium fluoride tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2624820/),[h·μg] / [l],155,127767,DB01370,Aluminium
,7233492,area under the curve,"Coadministration of naproxen with Mylanta in the single-dose experiment did not significantly affect the area under the curve (579 vs. 580 microgram/ml X hr with and without Mylanta, respectively), time to peak serum concentration (2.5 vs. 2.6 hr), peak serum concentration (37.2 vs. 34.8 microgram/ml) or plasma half-life (16.1 vs. 16.4 hr).",Effect of Mylanta on naproxen bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7233492/),[μg] / [h·ml],579,132691,DB01370,Aluminium
,7233492,area under the curve,"Coadministration of naproxen with Mylanta in the single-dose experiment did not significantly affect the area under the curve (579 vs. 580 microgram/ml X hr with and without Mylanta, respectively), time to peak serum concentration (2.5 vs. 2.6 hr), peak serum concentration (37.2 vs. 34.8 microgram/ml) or plasma half-life (16.1 vs. 16.4 hr).",Effect of Mylanta on naproxen bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7233492/),[μg] / [h·ml],580,132692,DB01370,Aluminium
,7233492,time to peak serum concentration,"Coadministration of naproxen with Mylanta in the single-dose experiment did not significantly affect the area under the curve (579 vs. 580 microgram/ml X hr with and without Mylanta, respectively), time to peak serum concentration (2.5 vs. 2.6 hr), peak serum concentration (37.2 vs. 34.8 microgram/ml) or plasma half-life (16.1 vs. 16.4 hr).",Effect of Mylanta on naproxen bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7233492/),h,2.5,132693,DB01370,Aluminium
,7233492,time to peak serum concentration,"Coadministration of naproxen with Mylanta in the single-dose experiment did not significantly affect the area under the curve (579 vs. 580 microgram/ml X hr with and without Mylanta, respectively), time to peak serum concentration (2.5 vs. 2.6 hr), peak serum concentration (37.2 vs. 34.8 microgram/ml) or plasma half-life (16.1 vs. 16.4 hr).",Effect of Mylanta on naproxen bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7233492/),h,2.6,132694,DB01370,Aluminium
,7233492,peak serum concentration,"Coadministration of naproxen with Mylanta in the single-dose experiment did not significantly affect the area under the curve (579 vs. 580 microgram/ml X hr with and without Mylanta, respectively), time to peak serum concentration (2.5 vs. 2.6 hr), peak serum concentration (37.2 vs. 34.8 microgram/ml) or plasma half-life (16.1 vs. 16.4 hr).",Effect of Mylanta on naproxen bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7233492/),[μg] / [ml],37.2,132695,DB01370,Aluminium
,7233492,peak serum concentration,"Coadministration of naproxen with Mylanta in the single-dose experiment did not significantly affect the area under the curve (579 vs. 580 microgram/ml X hr with and without Mylanta, respectively), time to peak serum concentration (2.5 vs. 2.6 hr), peak serum concentration (37.2 vs. 34.8 microgram/ml) or plasma half-life (16.1 vs. 16.4 hr).",Effect of Mylanta on naproxen bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7233492/),[μg] / [ml],34.8,132696,DB01370,Aluminium
,7233492,plasma half-life,"Coadministration of naproxen with Mylanta in the single-dose experiment did not significantly affect the area under the curve (579 vs. 580 microgram/ml X hr with and without Mylanta, respectively), time to peak serum concentration (2.5 vs. 2.6 hr), peak serum concentration (37.2 vs. 34.8 microgram/ml) or plasma half-life (16.1 vs. 16.4 hr).",Effect of Mylanta on naproxen bioavailability. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7233492/),h,16.1,132697,DB01370,Aluminium
,7233492,plasma half-life,"Coadministration of naproxen with Mylanta in the single-dose experiment did not significantly affect the area under the curve (579 vs. 580 microgram/ml X hr with and without Mylanta, respectively), time to peak serum concentration (2.5 vs. 2.6 hr), peak serum concentration (37.2 vs. 34.8 microgram/ml) or plasma half-life (16.1 vs. 16.4 hr).",Effect of Mylanta on naproxen bioavailability. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7233492/),h,16.4,132698,DB01370,Aluminium
,7233492,trough level naproxen concentrations at steady state,There was no significant difference between trough level naproxen concentrations at steady state (29.6 microgram/ml with Mylanta vs. 30.7 microgram/ml without Mylanta).,Effect of Mylanta on naproxen bioavailability. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7233492/),[μg] / [ml],29.6,132699,DB01370,Aluminium
,7233492,trough level naproxen concentrations at steady state,There was no significant difference between trough level naproxen concentrations at steady state (29.6 microgram/ml with Mylanta vs. 30.7 microgram/ml without Mylanta).,Effect of Mylanta on naproxen bioavailability. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7233492/),[μg] / [ml],30.7,132700,DB01370,Aluminium
up to,8415915,tumor-over-subcutis ratios,Phthalocyanines chelated with aluminum gave the highest fluorescence signal with tumor-over-subcutis ratios of up to a value of 4.,In vivo fluorescence kinetics of phthalocyanines in a skin-fold observation chamber model: role of central metal ion and degree of sulfonation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8415915/),,4,134594,DB01370,Aluminium
well over,8415915,retention times,They also displayed the longest retention times in the vascular system of well over 7 h.,In vivo fluorescence kinetics of phthalocyanines in a skin-fold observation chamber model: role of central metal ion and degree of sulfonation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8415915/),h,7,134595,DB01370,Aluminium
,8453847,maximum concentration,The average maximum concentration of ciprofloxacin alone was 3.38 +/- 0.63 (SD) micrograms/ml compared with 0.25 +/- 0.21 (SD) micrograms/ml when ciprofloxacin was administered with the didanosine placebo (p < 0.0001).,Cations in the didanosine tablet reduce ciprofloxacin bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453847/),[μg] / [ml],3.38,135141,DB01370,Aluminium
,8453847,maximum concentration,The average maximum concentration of ciprofloxacin alone was 3.38 +/- 0.63 (SD) micrograms/ml compared with 0.25 +/- 0.21 (SD) micrograms/ml when ciprofloxacin was administered with the didanosine placebo (p < 0.0001).,Cations in the didanosine tablet reduce ciprofloxacin bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453847/),[μg] / [ml],0.25,135142,DB01370,Aluminium
,8453847,area under the plasma drug concentration-time curve from time 0 to the last measurable concentration,The mean (+/- SD) area under the plasma drug concentration-time curve from time 0 to the last measurable concentration for ciprofloxacin alone was 15.50 +/- 2.69 micrograms.hr/ml compared with 0.26 +/- 0.21 micrograms.hr/ml when ciprofloxacin was coadministered with the didanosine-placebo (p < 0.0001).,Cations in the didanosine tablet reduce ciprofloxacin bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453847/),[h·μg] / [ml],15.50,135143,DB01370,Aluminium
,8453847,area under the plasma drug concentration-time curve from time 0 to the last measurable concentration,The mean (+/- SD) area under the plasma drug concentration-time curve from time 0 to the last measurable concentration for ciprofloxacin alone was 15.50 +/- 2.69 micrograms.hr/ml compared with 0.26 +/- 0.21 micrograms.hr/ml when ciprofloxacin was coadministered with the didanosine-placebo (p < 0.0001).,Cations in the didanosine tablet reduce ciprofloxacin bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453847/),[h·μg] / [ml],0.26,135144,DB01370,Aluminium
,8453847,time to maximum concentration,The mean time to maximum concentration of ciprofloxacin alone decreased from 1.56 +/- 0.62 to 0.75 +/- 0.38 hours with buffer administration (p = 0.0012).,Cations in the didanosine tablet reduce ciprofloxacin bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453847/),h,1.56,135145,DB01370,Aluminium
,8453847,time to maximum concentration,The mean time to maximum concentration of ciprofloxacin alone decreased from 1.56 +/- 0.62 to 0.75 +/- 0.38 hours with buffer administration (p = 0.0012).,Cations in the didanosine tablet reduce ciprofloxacin bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453847/),h,0.75,135146,DB01370,Aluminium
,1826901,elimination half-life,"Thereafter, the plasma level of AIPCS4 decreased exponentially with an elimination half-life of 1.5 hr.",Sensitizer for photodynamic therapy of cancer: a comparison of the tissue distribution of Photofrin II and aluminum phthalocyanine tetrasulfonate in nude mice bearing a human malignant tumor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1826901/),h,1.5,137948,DB01370,Aluminium
,1826901,half-life,"The kinetics of elimination of P-II from the plasma were consistent with a 2-compartment model, with 90% of sensitizer lost with a half-life of about 5 hr, and the remaining fraction with a half-life of 30 hr.",Sensitizer for photodynamic therapy of cancer: a comparison of the tissue distribution of Photofrin II and aluminum phthalocyanine tetrasulfonate in nude mice bearing a human malignant tumor. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1826901/),h,5,137949,DB01370,Aluminium
,1826901,half-life,"The kinetics of elimination of P-II from the plasma were consistent with a 2-compartment model, with 90% of sensitizer lost with a half-life of about 5 hr, and the remaining fraction with a half-life of 30 hr.",Sensitizer for photodynamic therapy of cancer: a comparison of the tissue distribution of Photofrin II and aluminum phthalocyanine tetrasulfonate in nude mice bearing a human malignant tumor. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1826901/),h,30,137950,DB01370,Aluminium
,1826901,half-life,"On the other hand, the concentrations of APICS4 in most tissues as well as in the tumor peaked at about 30 min, then decreased with a half-life of between 1.5 and 3 hr.",Sensitizer for photodynamic therapy of cancer: a comparison of the tissue distribution of Photofrin II and aluminum phthalocyanine tetrasulfonate in nude mice bearing a human malignant tumor. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1826901/),h,1.5 and 3,137951,DB01370,Aluminium
,1826901,tumor/skin concentration ratio,The tumor/skin concentration ratio was about 1 for both drugs (1-24 hr after injection).,Sensitizer for photodynamic therapy of cancer: a comparison of the tissue distribution of Photofrin II and aluminum phthalocyanine tetrasulfonate in nude mice bearing a human malignant tumor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1826901/),,1,137952,DB01370,Aluminium
,1826901,tumor/muscle concentration ratio,"The tumor/muscle concentration ratio was about 2 for P-II at all sampling times, and maximally 10 (at 18 hr after injection) for AIPCS4.",Sensitizer for photodynamic therapy of cancer: a comparison of the tissue distribution of Photofrin II and aluminum phthalocyanine tetrasulfonate in nude mice bearing a human malignant tumor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1826901/),,2,137953,DB01370,Aluminium
,1826901,tumor/muscle concentration ratio,"The tumor/muscle concentration ratio was about 2 for P-II at all sampling times, and maximally 10 (at 18 hr after injection) for AIPCS4.",Sensitizer for photodynamic therapy of cancer: a comparison of the tissue distribution of Photofrin II and aluminum phthalocyanine tetrasulfonate in nude mice bearing a human malignant tumor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1826901/),,10,137954,DB01370,Aluminium
,11352441,area under the plasma concentration-time curve extrapolated to infinity (AUCinfinity),"Coadministration of moxifloxacin with ranitidine showed lack of interaction for area under the plasma concentration-time curve extrapolated to infinity (AUCinfinity) [35.5 versus 34.3 mg/L x h with versus without ranitidine; relative bioavailability 103%, 90% confidence interval (CI) 97.7 to 109.3%] and maximum plasma concentration (Cmax) [2.98 versus 2.76 mg/L with versus without ranitidine; ratio 107.9%, 90% CI 90.5 to 128.6%].",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),[mg] / [h·l],35.5,142404,DB01370,Aluminium
,11352441,area under the plasma concentration-time curve extrapolated to infinity (AUCinfinity),"Coadministration of moxifloxacin with ranitidine showed lack of interaction for area under the plasma concentration-time curve extrapolated to infinity (AUCinfinity) [35.5 versus 34.3 mg/L x h with versus without ranitidine; relative bioavailability 103%, 90% confidence interval (CI) 97.7 to 109.3%] and maximum plasma concentration (Cmax) [2.98 versus 2.76 mg/L with versus without ranitidine; ratio 107.9%, 90% CI 90.5 to 128.6%].",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),[mg] / [h·l],34.3,142405,DB01370,Aluminium
,11352441,relative bioavailability,"Coadministration of moxifloxacin with ranitidine showed lack of interaction for area under the plasma concentration-time curve extrapolated to infinity (AUCinfinity) [35.5 versus 34.3 mg/L x h with versus without ranitidine; relative bioavailability 103%, 90% confidence interval (CI) 97.7 to 109.3%] and maximum plasma concentration (Cmax) [2.98 versus 2.76 mg/L with versus without ranitidine; ratio 107.9%, 90% CI 90.5 to 128.6%].",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),%,103,142406,DB01370,Aluminium
,11352441,maximum plasma concentration (Cmax),"Coadministration of moxifloxacin with ranitidine showed lack of interaction for area under the plasma concentration-time curve extrapolated to infinity (AUCinfinity) [35.5 versus 34.3 mg/L x h with versus without ranitidine; relative bioavailability 103%, 90% confidence interval (CI) 97.7 to 109.3%] and maximum plasma concentration (Cmax) [2.98 versus 2.76 mg/L with versus without ranitidine; ratio 107.9%, 90% CI 90.5 to 128.6%].",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),[mg] / [l],2.98,142407,DB01370,Aluminium
,11352441,maximum plasma concentration (Cmax),"Coadministration of moxifloxacin with ranitidine showed lack of interaction for area under the plasma concentration-time curve extrapolated to infinity (AUCinfinity) [35.5 versus 34.3 mg/L x h with versus without ranitidine; relative bioavailability 103%, 90% confidence interval (CI) 97.7 to 109.3%] and maximum plasma concentration (Cmax) [2.98 versus 2.76 mg/L with versus without ranitidine; ratio 107.9%, 90% CI 90.5 to 128.6%].",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),[mg] / [l],2.76,142408,DB01370,Aluminium
,11352441,AUCinfinity,"When moxifloxacin was given simultaneously with Maalox 70, AUCinfinity ( 14.7 mg/L x h) and Cmax (1.00 mg/L) were reduced by approximately 60%.",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),[mg] / [h·l],14.7,142409,DB01370,Aluminium
,11352441,Cmax,"When moxifloxacin was given simultaneously with Maalox 70, AUCinfinity ( 14.7 mg/L x h) and Cmax (1.00 mg/L) were reduced by approximately 60%.",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),[mg] / [l],1.00,142410,DB01370,Aluminium
,11352441,AUCinfinity,"When the antacid was given 4 hours before or 2 hours after the fluoroquinolone, AUCinfinity values (28.0 and 26.7 versus 34.3 mg/L x h) were moderately reduced (by <27%), terminal elimination half-life values declined by approximately 24% (9.4 and 9.3 versus 12.3 hours) compared with moxifloxacin alone and Cmax values were almost unchanged (2.55 and 2.38 versus 2.57 mg/L).",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),[mg] / [h·l],28.0,142411,DB01370,Aluminium
,11352441,AUCinfinity,"When the antacid was given 4 hours before or 2 hours after the fluoroquinolone, AUCinfinity values (28.0 and 26.7 versus 34.3 mg/L x h) were moderately reduced (by <27%), terminal elimination half-life values declined by approximately 24% (9.4 and 9.3 versus 12.3 hours) compared with moxifloxacin alone and Cmax values were almost unchanged (2.55 and 2.38 versus 2.57 mg/L).",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),[mg] / [h·l],26.7,142412,DB01370,Aluminium
,11352441,AUCinfinity,"When the antacid was given 4 hours before or 2 hours after the fluoroquinolone, AUCinfinity values (28.0 and 26.7 versus 34.3 mg/L x h) were moderately reduced (by <27%), terminal elimination half-life values declined by approximately 24% (9.4 and 9.3 versus 12.3 hours) compared with moxifloxacin alone and Cmax values were almost unchanged (2.55 and 2.38 versus 2.57 mg/L).",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),[mg] / [h·l],34.3,142413,DB01370,Aluminium
,11352441,terminal elimination half-life,"When the antacid was given 4 hours before or 2 hours after the fluoroquinolone, AUCinfinity values (28.0 and 26.7 versus 34.3 mg/L x h) were moderately reduced (by <27%), terminal elimination half-life values declined by approximately 24% (9.4 and 9.3 versus 12.3 hours) compared with moxifloxacin alone and Cmax values were almost unchanged (2.55 and 2.38 versus 2.57 mg/L).",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),h,9.4,142414,DB01370,Aluminium
,11352441,terminal elimination half-life,"When the antacid was given 4 hours before or 2 hours after the fluoroquinolone, AUCinfinity values (28.0 and 26.7 versus 34.3 mg/L x h) were moderately reduced (by <27%), terminal elimination half-life values declined by approximately 24% (9.4 and 9.3 versus 12.3 hours) compared with moxifloxacin alone and Cmax values were almost unchanged (2.55 and 2.38 versus 2.57 mg/L).",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),h,9.3,142415,DB01370,Aluminium
,11352441,terminal elimination half-life,"When the antacid was given 4 hours before or 2 hours after the fluoroquinolone, AUCinfinity values (28.0 and 26.7 versus 34.3 mg/L x h) were moderately reduced (by <27%), terminal elimination half-life values declined by approximately 24% (9.4 and 9.3 versus 12.3 hours) compared with moxifloxacin alone and Cmax values were almost unchanged (2.55 and 2.38 versus 2.57 mg/L).",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),h,12.3,142416,DB01370,Aluminium
,11352441,Cmax,"When the antacid was given 4 hours before or 2 hours after the fluoroquinolone, AUCinfinity values (28.0 and 26.7 versus 34.3 mg/L x h) were moderately reduced (by <27%), terminal elimination half-life values declined by approximately 24% (9.4 and 9.3 versus 12.3 hours) compared with moxifloxacin alone and Cmax values were almost unchanged (2.55 and 2.38 versus 2.57 mg/L).",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),[mg] / [l],2.55,142417,DB01370,Aluminium
,11352441,Cmax,"When the antacid was given 4 hours before or 2 hours after the fluoroquinolone, AUCinfinity values (28.0 and 26.7 versus 34.3 mg/L x h) were moderately reduced (by <27%), terminal elimination half-life values declined by approximately 24% (9.4 and 9.3 versus 12.3 hours) compared with moxifloxacin alone and Cmax values were almost unchanged (2.55 and 2.38 versus 2.57 mg/L).",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),[mg] / [l],2.38,142418,DB01370,Aluminium
,11352441,Cmax,"When the antacid was given 4 hours before or 2 hours after the fluoroquinolone, AUCinfinity values (28.0 and 26.7 versus 34.3 mg/L x h) were moderately reduced (by <27%), terminal elimination half-life values declined by approximately 24% (9.4 and 9.3 versus 12.3 hours) compared with moxifloxacin alone and Cmax values were almost unchanged (2.55 and 2.38 versus 2.57 mg/L).",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),[mg] / [l],2.57,142419,DB01370,Aluminium
,11352441,bioavailabilities,"The mean bioavailabilities corrected for the elimination rate constants (lambdaz) were 101% (antacid given 4 hours before moxifloxacin) and 98% (antacid given 2 hours after moxifloxacin), indicating that Maalox 70 may interfere with the gastrointestinal recirculation of moxifloxacin.",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),%,101,142420,DB01370,Aluminium
,11352441,bioavailabilities,"The mean bioavailabilities corrected for the elimination rate constants (lambdaz) were 101% (antacid given 4 hours before moxifloxacin) and 98% (antacid given 2 hours after moxifloxacin), indicating that Maalox 70 may interfere with the gastrointestinal recirculation of moxifloxacin.",Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352441/),%,98,142421,DB01370,Aluminium
,15896236,Tmax,Tmax for treatment A was 3.0 +/- 0.4 and 5.1 +/- 2.7 h for treatment B.,Reduced oral itraconazole bioavailability by antacid suspension. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15896236/),h,3.0,142622,DB01370,Aluminium
,15896236,Tmax,Tmax for treatment A was 3.0 +/- 0.4 and 5.1 +/- 2.7 h for treatment B.,Reduced oral itraconazole bioavailability by antacid suspension. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15896236/),h,5.1,142623,DB01370,Aluminium
,15896236,Cmax,Cmax and AUC0-infinity of treatments A and B were 146.3 +/- 70.5 vs.,Reduced oral itraconazole bioavailability by antacid suspension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15896236/),,146.3,142624,DB01370,Aluminium
,1820900,limit of detection,"Lansoprazole and metabolite (sulfone (AG 1813), sulfide (AG 1777) and hydroxylated (AG 1908) metabolites) plasma concentrations were determined using a specific high pressure liquid chromatographic assay procedure, with a limit of detection of 2 ng/ml.",The effect of food and antacids on lansoprazole absorption and disposition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820900/),[ng] / [ml],2,145096,DB01370,Aluminium
,1820900,time to peak,"The time to peak was significantly later with food (p less than 0.001) and its magnitude was significantly decreased (600 +/- 330 ng/ml vs 1151 +/- 344 ng/ml, p less than 0.001).",The effect of food and antacids on lansoprazole absorption and disposition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820900/),[ng] / [ml],600,145097,DB01370,Aluminium
,1820900,time to peak,"The time to peak was significantly later with food (p less than 0.001) and its magnitude was significantly decreased (600 +/- 330 ng/ml vs 1151 +/- 344 ng/ml, p less than 0.001).",The effect of food and antacids on lansoprazole absorption and disposition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820900/),[ng] / [ml],1151,145098,DB01370,Aluminium
,1820900,bioavailability,"The bioavailability of lansoprazole was significantly decreased by food, about 27%, (p less than 0.05) and slightly decreased by concomitant administration of antacids (NS), the effect was more pronounced in male subjects (p less than 0.05).",The effect of food and antacids on lansoprazole absorption and disposition. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820900/),%,27,145099,DB01370,Aluminium
,7784344,AUC,"The mean plasma silicon AUC values (+/- S.D.) were 9.5 +/- 4.5, 7.7 +/- 1.6, 8.8 +/- 3.0, 6.1 +/- 1.9 mg.hr/L and the mean plasma silicon Cmax values (+/- S.D.) were 1.07 +/- 1.06, 0.67 +/- 0.27, 0.75 +/- 0.31, 0.44 +/- 0.17 mg/L for Zeolite A, sodium aluminosilicate, magnesium trisilicate, and aluminum hydroxide respectively.","Pharmacokinetic study of zeolite A, sodium aluminosilicate, magnesium silicate, and aluminum hydroxide in dogs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7784344/),[h·mg] / [l],9.5,148588,DB01370,Aluminium
,7784344,AUC,"The mean plasma silicon AUC values (+/- S.D.) were 9.5 +/- 4.5, 7.7 +/- 1.6, 8.8 +/- 3.0, 6.1 +/- 1.9 mg.hr/L and the mean plasma silicon Cmax values (+/- S.D.) were 1.07 +/- 1.06, 0.67 +/- 0.27, 0.75 +/- 0.31, 0.44 +/- 0.17 mg/L for Zeolite A, sodium aluminosilicate, magnesium trisilicate, and aluminum hydroxide respectively.","Pharmacokinetic study of zeolite A, sodium aluminosilicate, magnesium silicate, and aluminum hydroxide in dogs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7784344/),[h·mg] / [l],7.7,148589,DB01370,Aluminium
,7784344,AUC,"The mean plasma silicon AUC values (+/- S.D.) were 9.5 +/- 4.5, 7.7 +/- 1.6, 8.8 +/- 3.0, 6.1 +/- 1.9 mg.hr/L and the mean plasma silicon Cmax values (+/- S.D.) were 1.07 +/- 1.06, 0.67 +/- 0.27, 0.75 +/- 0.31, 0.44 +/- 0.17 mg/L for Zeolite A, sodium aluminosilicate, magnesium trisilicate, and aluminum hydroxide respectively.","Pharmacokinetic study of zeolite A, sodium aluminosilicate, magnesium silicate, and aluminum hydroxide in dogs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7784344/),[h·mg] / [l],8.8,148590,DB01370,Aluminium
,7784344,AUC,"The mean plasma silicon AUC values (+/- S.D.) were 9.5 +/- 4.5, 7.7 +/- 1.6, 8.8 +/- 3.0, 6.1 +/- 1.9 mg.hr/L and the mean plasma silicon Cmax values (+/- S.D.) were 1.07 +/- 1.06, 0.67 +/- 0.27, 0.75 +/- 0.31, 0.44 +/- 0.17 mg/L for Zeolite A, sodium aluminosilicate, magnesium trisilicate, and aluminum hydroxide respectively.","Pharmacokinetic study of zeolite A, sodium aluminosilicate, magnesium silicate, and aluminum hydroxide in dogs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7784344/),[h·mg] / [l],6.1,148591,DB01370,Aluminium
,7784344,Cmax,"The mean plasma silicon AUC values (+/- S.D.) were 9.5 +/- 4.5, 7.7 +/- 1.6, 8.8 +/- 3.0, 6.1 +/- 1.9 mg.hr/L and the mean plasma silicon Cmax values (+/- S.D.) were 1.07 +/- 1.06, 0.67 +/- 0.27, 0.75 +/- 0.31, 0.44 +/- 0.17 mg/L for Zeolite A, sodium aluminosilicate, magnesium trisilicate, and aluminum hydroxide respectively.","Pharmacokinetic study of zeolite A, sodium aluminosilicate, magnesium silicate, and aluminum hydroxide in dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7784344/),[mg] / [l],1.07,148592,DB01370,Aluminium
,7784344,Cmax,"The mean plasma silicon AUC values (+/- S.D.) were 9.5 +/- 4.5, 7.7 +/- 1.6, 8.8 +/- 3.0, 6.1 +/- 1.9 mg.hr/L and the mean plasma silicon Cmax values (+/- S.D.) were 1.07 +/- 1.06, 0.67 +/- 0.27, 0.75 +/- 0.31, 0.44 +/- 0.17 mg/L for Zeolite A, sodium aluminosilicate, magnesium trisilicate, and aluminum hydroxide respectively.","Pharmacokinetic study of zeolite A, sodium aluminosilicate, magnesium silicate, and aluminum hydroxide in dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7784344/),[mg] / [l],0.67,148593,DB01370,Aluminium
,7784344,Cmax,"The mean plasma silicon AUC values (+/- S.D.) were 9.5 +/- 4.5, 7.7 +/- 1.6, 8.8 +/- 3.0, 6.1 +/- 1.9 mg.hr/L and the mean plasma silicon Cmax values (+/- S.D.) were 1.07 +/- 1.06, 0.67 +/- 0.27, 0.75 +/- 0.31, 0.44 +/- 0.17 mg/L for Zeolite A, sodium aluminosilicate, magnesium trisilicate, and aluminum hydroxide respectively.","Pharmacokinetic study of zeolite A, sodium aluminosilicate, magnesium silicate, and aluminum hydroxide in dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7784344/),[mg] / [l],0.75,148594,DB01370,Aluminium
,7784344,Cmax,"The mean plasma silicon AUC values (+/- S.D.) were 9.5 +/- 4.5, 7.7 +/- 1.6, 8.8 +/- 3.0, 6.1 +/- 1.9 mg.hr/L and the mean plasma silicon Cmax values (+/- S.D.) were 1.07 +/- 1.06, 0.67 +/- 0.27, 0.75 +/- 0.31, 0.44 +/- 0.17 mg/L for Zeolite A, sodium aluminosilicate, magnesium trisilicate, and aluminum hydroxide respectively.","Pharmacokinetic study of zeolite A, sodium aluminosilicate, magnesium silicate, and aluminum hydroxide in dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7784344/),[mg] / [l],0.44,148595,DB01370,Aluminium
,7784344,Tmax,"The mean plasma silicon Tmax values (+/- S.D.) were 7.9 +/- 6.4, 5.8 +/- 4.6, 6.9 +/- 6.3 and 8.5 +/- 3.4 hrs for Zeolite A, sodium aluminosilicate, magnesium trisilicate and aluminum Hydroxide respectively.","Pharmacokinetic study of zeolite A, sodium aluminosilicate, magnesium silicate, and aluminum hydroxide in dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7784344/),h,7.9,148596,DB01370,Aluminium
,7784344,Tmax,"The mean plasma silicon Tmax values (+/- S.D.) were 7.9 +/- 6.4, 5.8 +/- 4.6, 6.9 +/- 6.3 and 8.5 +/- 3.4 hrs for Zeolite A, sodium aluminosilicate, magnesium trisilicate and aluminum Hydroxide respectively.","Pharmacokinetic study of zeolite A, sodium aluminosilicate, magnesium silicate, and aluminum hydroxide in dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7784344/),h,5.8,148597,DB01370,Aluminium
,7784344,Tmax,"The mean plasma silicon Tmax values (+/- S.D.) were 7.9 +/- 6.4, 5.8 +/- 4.6, 6.9 +/- 6.3 and 8.5 +/- 3.4 hrs for Zeolite A, sodium aluminosilicate, magnesium trisilicate and aluminum Hydroxide respectively.","Pharmacokinetic study of zeolite A, sodium aluminosilicate, magnesium silicate, and aluminum hydroxide in dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7784344/),h,6.9,148598,DB01370,Aluminium
,7784344,Tmax,"The mean plasma silicon Tmax values (+/- S.D.) were 7.9 +/- 6.4, 5.8 +/- 4.6, 6.9 +/- 6.3 and 8.5 +/- 3.4 hrs for Zeolite A, sodium aluminosilicate, magnesium trisilicate and aluminum Hydroxide respectively.","Pharmacokinetic study of zeolite A, sodium aluminosilicate, magnesium silicate, and aluminum hydroxide in dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7784344/),h,8.5,148599,DB01370,Aluminium
,16949191,bioavailability (F),"Oral Al bioavailability (F) from biscuit containing 1% or 2% acidic (26)Al-SALP averaged approximately 0.11% and 0.13%; significantly less than from water, which was previously shown to be approximately 0.3%.","Aluminum bioavailability from the approved food additive leavening agent acidic sodium aluminum phosphate, incorporated into a baked good, is lower than from water. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16949191/),%,0.11,150455,DB01370,Aluminium
,16949191,bioavailability (F),"Oral Al bioavailability (F) from biscuit containing 1% or 2% acidic (26)Al-SALP averaged approximately 0.11% and 0.13%; significantly less than from water, which was previously shown to be approximately 0.3%.","Aluminum bioavailability from the approved food additive leavening agent acidic sodium aluminum phosphate, incorporated into a baked good, is lower than from water. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16949191/),%,0.13,150456,DB01370,Aluminium
,16949191,bioavailability (F),"Oral Al bioavailability (F) from biscuit containing 1% or 2% acidic (26)Al-SALP averaged approximately 0.11% and 0.13%; significantly less than from water, which was previously shown to be approximately 0.3%.","Aluminum bioavailability from the approved food additive leavening agent acidic sodium aluminum phosphate, incorporated into a baked good, is lower than from water. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16949191/),%,0.3,150457,DB01370,Aluminium
,16949191,time to maximum serum,"The time to maximum serum (26)Al concentration was 4.2 and 6h after consumption of biscuit containing 1% or 2% (26)Al-acidic SALP, respectively, compared to 1-2h following (26)Al in water.","Aluminum bioavailability from the approved food additive leavening agent acidic sodium aluminum phosphate, incorporated into a baked good, is lower than from water. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16949191/),h,4.2,150458,DB01370,Aluminium
,16949191,time to maximum serum,"The time to maximum serum (26)Al concentration was 4.2 and 6h after consumption of biscuit containing 1% or 2% (26)Al-acidic SALP, respectively, compared to 1-2h following (26)Al in water.","Aluminum bioavailability from the approved food additive leavening agent acidic sodium aluminum phosphate, incorporated into a baked good, is lower than from water. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16949191/),h,6,150459,DB01370,Aluminium
,16949191,time to maximum serum,"The time to maximum serum (26)Al concentration was 4.2 and 6h after consumption of biscuit containing 1% or 2% (26)Al-acidic SALP, respectively, compared to 1-2h following (26)Al in water.","Aluminum bioavailability from the approved food additive leavening agent acidic sodium aluminum phosphate, incorporated into a baked good, is lower than from water. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16949191/),h,1-2,150460,DB01370,Aluminium
,16949191,F,"These results of oral Al bioavailability from acidic (26)Al-SALP in a biscuit (F approximately 0.1%) and results from (26)Al in water (F approximately 0.3%) x the contributions of food and drinking water to the typical human's daily Al intake ( approximately 5-10mg from food and 0.1mg from water, respectively) suggest food provides approximately 25-fold more Al to systemic circulation, and potential Al body burden, than does drinking water.","Aluminum bioavailability from the approved food additive leavening agent acidic sodium aluminum phosphate, incorporated into a baked good, is lower than from water. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16949191/),%,0.1,150461,DB01370,Aluminium
,16949191,F,"These results of oral Al bioavailability from acidic (26)Al-SALP in a biscuit (F approximately 0.1%) and results from (26)Al in water (F approximately 0.3%) x the contributions of food and drinking water to the typical human's daily Al intake ( approximately 5-10mg from food and 0.1mg from water, respectively) suggest food provides approximately 25-fold more Al to systemic circulation, and potential Al body burden, than does drinking water.","Aluminum bioavailability from the approved food additive leavening agent acidic sodium aluminum phosphate, incorporated into a baked good, is lower than from water. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16949191/),%,0.3,150462,DB01370,Aluminium
,972657,excre,"Cumulative six-day urinary digoxin excretion (expressed as the percentage of a 0.75-mg dose recovered) was: control, 40.1+/-3.0 (S.E.); aluminum hydroxide, 30.7+/-2.9; magnesium hydroxide, 27.1+/-2.4; magnesium trisilicate, 29.1+/-1.7; and kaolin-pectin 23.4+/-2.0.",Decreased bioavailability of digoxin due to antacids and kaolin-pectin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/972657/),,40.1,152845,DB01370,Aluminium
,972657,excre,"Cumulative six-day urinary digoxin excretion (expressed as the percentage of a 0.75-mg dose recovered) was: control, 40.1+/-3.0 (S.E.); aluminum hydroxide, 30.7+/-2.9; magnesium hydroxide, 27.1+/-2.4; magnesium trisilicate, 29.1+/-1.7; and kaolin-pectin 23.4+/-2.0.",Decreased bioavailability of digoxin due to antacids and kaolin-pectin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/972657/),,30.7,152846,DB01370,Aluminium
,972657,excre,"Cumulative six-day urinary digoxin excretion (expressed as the percentage of a 0.75-mg dose recovered) was: control, 40.1+/-3.0 (S.E.); aluminum hydroxide, 30.7+/-2.9; magnesium hydroxide, 27.1+/-2.4; magnesium trisilicate, 29.1+/-1.7; and kaolin-pectin 23.4+/-2.0.",Decreased bioavailability of digoxin due to antacids and kaolin-pectin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/972657/),,27.1,152847,DB01370,Aluminium
,972657,excre,"Cumulative six-day urinary digoxin excretion (expressed as the percentage of a 0.75-mg dose recovered) was: control, 40.1+/-3.0 (S.E.); aluminum hydroxide, 30.7+/-2.9; magnesium hydroxide, 27.1+/-2.4; magnesium trisilicate, 29.1+/-1.7; and kaolin-pectin 23.4+/-2.0.",Decreased bioavailability of digoxin due to antacids and kaolin-pectin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/972657/),,29.1,152848,DB01370,Aluminium
,972657,excre,"Cumulative six-day urinary digoxin excretion (expressed as the percentage of a 0.75-mg dose recovered) was: control, 40.1+/-3.0 (S.E.); aluminum hydroxide, 30.7+/-2.9; magnesium hydroxide, 27.1+/-2.4; magnesium trisilicate, 29.1+/-1.7; and kaolin-pectin 23.4+/-2.0.",Decreased bioavailability of digoxin due to antacids and kaolin-pectin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/972657/),,23.4,152849,DB01370,Aluminium
,8287631,peak (Cmax),Plasma sparfloxacin concentrations reach a peak (Cmax) of approximately 0.7 mg/L at 3 to 5 hours after a 200mg oral dose.,Clinical pharmacokinetics of sparfloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8287631/),[mg] / [l],0.7,152908,DB01370,Aluminium
,8287631,elimination half-life (t1/2),"This is followed by a monophasic slow decrease, with an elimination half-life (t1/2) of 15 to 20 hours.",Clinical pharmacokinetics of sparfloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8287631/),h,15 to 20,152909,DB01370,Aluminium
,8031961,peak serum aluminium,"A peak serum aluminium of 54.5 micrograms/l was reached at 30 min, returning to the initial value of 6.8 micrograms/l at 3 h after the oral intake.",The kinetics of aluminium-containing antacid absorption in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031961/),[μg] / [l],54.5,155913,DB01370,Aluminium
,8031961,peak serum aluminium,"A peak serum aluminium of 54.5 micrograms/l was reached at 30 min, returning to the initial value of 6.8 micrograms/l at 3 h after the oral intake.",The kinetics of aluminium-containing antacid absorption in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031961/),[μg] / [l],6.8,155914,DB01370,Aluminium
,4025553,Fractional excretion (FE),Fractional excretion (FE) of A1 was 39.4 +/- 4.2% in these hydropenic experiments (FENa = 0.3 +/- 0.1%).,Renal handling of aluminum in the rat: clearance and micropuncture studies. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025553/),%,39.4,156489,DB01370,Aluminium
,4025553,FENa,Fractional excretion (FE) of A1 was 39.4 +/- 4.2% in these hydropenic experiments (FENa = 0.3 +/- 0.1%).,Renal handling of aluminum in the rat: clearance and micropuncture studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025553/),%,0.3,156490,DB01370,Aluminium
,4025553,FENa,"The natriuresis produced by volume expansion (FENa = 1.0, 3.0, 8.4, and 7.9%) and furosemide (FENa = 4.2, 6.0, 6.6, and 6.7%) were comparable.",Renal handling of aluminum in the rat: clearance and micropuncture studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025553/),%,1.0,156491,DB01370,Aluminium
,4025553,FENa,"The natriuresis produced by volume expansion (FENa = 1.0, 3.0, 8.4, and 7.9%) and furosemide (FENa = 4.2, 6.0, 6.6, and 6.7%) were comparable.",Renal handling of aluminum in the rat: clearance and micropuncture studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025553/),%,3.0,156492,DB01370,Aluminium
,4025553,FENa,"The natriuresis produced by volume expansion (FENa = 1.0, 3.0, 8.4, and 7.9%) and furosemide (FENa = 4.2, 6.0, 6.6, and 6.7%) were comparable.",Renal handling of aluminum in the rat: clearance and micropuncture studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025553/),%,8.4,156493,DB01370,Aluminium
,4025553,FENa,"The natriuresis produced by volume expansion (FENa = 1.0, 3.0, 8.4, and 7.9%) and furosemide (FENa = 4.2, 6.0, 6.6, and 6.7%) were comparable.",Renal handling of aluminum in the rat: clearance and micropuncture studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025553/),%,7.9,156494,DB01370,Aluminium
,4025553,FENa,"The natriuresis produced by volume expansion (FENa = 1.0, 3.0, 8.4, and 7.9%) and furosemide (FENa = 4.2, 6.0, 6.6, and 6.7%) were comparable.",Renal handling of aluminum in the rat: clearance and micropuncture studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025553/),%,4.2,156495,DB01370,Aluminium
,4025553,FENa,"The natriuresis produced by volume expansion (FENa = 1.0, 3.0, 8.4, and 7.9%) and furosemide (FENa = 4.2, 6.0, 6.6, and 6.7%) were comparable.",Renal handling of aluminum in the rat: clearance and micropuncture studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025553/),%,6.0,156496,DB01370,Aluminium
,4025553,FENa,"The natriuresis produced by volume expansion (FENa = 1.0, 3.0, 8.4, and 7.9%) and furosemide (FENa = 4.2, 6.0, 6.6, and 6.7%) were comparable.",Renal handling of aluminum in the rat: clearance and micropuncture studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025553/),%,6.6,156497,DB01370,Aluminium
,4025553,FENa,"The natriuresis produced by volume expansion (FENa = 1.0, 3.0, 8.4, and 7.9%) and furosemide (FENa = 4.2, 6.0, 6.6, and 6.7%) were comparable.",Renal handling of aluminum in the rat: clearance and micropuncture studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025553/),%,6.7,156498,DB01370,Aluminium
,31981708,t50%,"This formulation exhibited pH-dependent swelling, negligible drug release in simulated gastric fluid and sustained-release pattern in simulated small intestinal fluid with a mean t50% of 26.5 h.",Colon-targeting of progesterone using hybrid polymeric microspheres improves its bioavailability and in vivo biological efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31981708/),h,26.5,159827,DB01370,Aluminium
,6500763,Plasma protein binding,Plasma protein binding of isofezolac was very high (99%) and did not influence salicylic acid binding.,The effect of antacid and aspirin on the bioavailability of isofezolac in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6500763/),%,99,159966,DB01370,Aluminium
,7252799,KA,"The pharmacokinetic parameters (mean +/- SD) KA, K, AUC, and F/V for theophylline from the rapid release theophylline anhydrous tablets were 2.1 +/- 1.3 hr-1, 0.15 +/- 0.06 hr-1, 89.2 +/0 39 microgram hr/ml, and 0.0023 +/- 0.002 kg/ml, respectively; from the anhydrous timed-release capsules, they were 0.27 +/- 0.08 hr-1, 0.20 +/- 0.07 hr-1, 79.0 +/- 27 microgram hr/ml, and 0.0030 +/- 0.007 kg/ml, respectively.",Effect of antacid on bioavailability of theophylline from rapid and timed-release drug products. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7252799/),1/[h],2.1,161072,DB01370,Aluminium
,7252799,F/V,"The pharmacokinetic parameters (mean +/- SD) KA, K, AUC, and F/V for theophylline from the rapid release theophylline anhydrous tablets were 2.1 +/- 1.3 hr-1, 0.15 +/- 0.06 hr-1, 89.2 +/0 39 microgram hr/ml, and 0.0023 +/- 0.002 kg/ml, respectively; from the anhydrous timed-release capsules, they were 0.27 +/- 0.08 hr-1, 0.20 +/- 0.07 hr-1, 79.0 +/- 27 microgram hr/ml, and 0.0030 +/- 0.007 kg/ml, respectively.",Effect of antacid on bioavailability of theophylline from rapid and timed-release drug products. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7252799/),[kg] / [ml],0.0023,161073,DB01370,Aluminium
,7252799,F/V,"The pharmacokinetic parameters (mean +/- SD) KA, K, AUC, and F/V for theophylline from the rapid release theophylline anhydrous tablets were 2.1 +/- 1.3 hr-1, 0.15 +/- 0.06 hr-1, 89.2 +/0 39 microgram hr/ml, and 0.0023 +/- 0.002 kg/ml, respectively; from the anhydrous timed-release capsules, they were 0.27 +/- 0.08 hr-1, 0.20 +/- 0.07 hr-1, 79.0 +/- 27 microgram hr/ml, and 0.0030 +/- 0.007 kg/ml, respectively.",Effect of antacid on bioavailability of theophylline from rapid and timed-release drug products. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7252799/),1/[h],0.27,161074,DB01370,Aluminium
,7252799,F/V,"The pharmacokinetic parameters (mean +/- SD) KA, K, AUC, and F/V for theophylline from the rapid release theophylline anhydrous tablets were 2.1 +/- 1.3 hr-1, 0.15 +/- 0.06 hr-1, 89.2 +/0 39 microgram hr/ml, and 0.0023 +/- 0.002 kg/ml, respectively; from the anhydrous timed-release capsules, they were 0.27 +/- 0.08 hr-1, 0.20 +/- 0.07 hr-1, 79.0 +/- 27 microgram hr/ml, and 0.0030 +/- 0.007 kg/ml, respectively.",Effect of antacid on bioavailability of theophylline from rapid and timed-release drug products. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7252799/),1/[h],0.20,161075,DB01370,Aluminium
,7252799,F/V,"The pharmacokinetic parameters (mean +/- SD) KA, K, AUC, and F/V for theophylline from the rapid release theophylline anhydrous tablets were 2.1 +/- 1.3 hr-1, 0.15 +/- 0.06 hr-1, 89.2 +/0 39 microgram hr/ml, and 0.0023 +/- 0.002 kg/ml, respectively; from the anhydrous timed-release capsules, they were 0.27 +/- 0.08 hr-1, 0.20 +/- 0.07 hr-1, 79.0 +/- 27 microgram hr/ml, and 0.0030 +/- 0.007 kg/ml, respectively.",Effect of antacid on bioavailability of theophylline from rapid and timed-release drug products. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7252799/),[h·μg] / [ml],79.0,161076,DB01370,Aluminium
,22317823,LD50,The estimated LD50 at 24 h was 3.45 g Al/kg body weight (b.wt.).,"Lethality, accumulation and toxicokinetics of aluminum in some tissues of male albino rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22317823/),[al·g] / [kg],3.45,161856,DB01370,Aluminium
,2082311,half-life for absorption,It is absorbed rapidly (half-life for absorption 3.8 min) after oral (fasting) and intramuscular administration; food delays but does not reduce its absorption.,"Ketorolac tromethamine pharmacokinetics and metabolism after intravenous, intramuscular, and oral administration in humans and animals. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2082311/),min,3.8,162671,DB01370,Aluminium
,2082311,plasma elimination half-life,"The mean plasma elimination half-life is 5-6 hours, and ketorolac is not extensively distributed outside the vascular compartment (Vd beta 15 L).","Ketorolac tromethamine pharmacokinetics and metabolism after intravenous, intramuscular, and oral administration in humans and animals. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2082311/),h,5-6,162672,DB01370,Aluminium
,2082311,Vd beta,"The mean plasma elimination half-life is 5-6 hours, and ketorolac is not extensively distributed outside the vascular compartment (Vd beta 15 L).","Ketorolac tromethamine pharmacokinetics and metabolism after intravenous, intramuscular, and oral administration in humans and animals. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2082311/),l,15,162673,DB01370,Aluminium
,7590531,half-life,"The half-life of aluminium in tibias (38 v. 58 v. 173 days in growing, mature and ageing rats, respectively) and kidneys (9 v. 12 v. 16 days) lengthened with age.","Tissue aluminium distribution in growing, mature and ageing rats: relationship to changes in gut, kidney and bone metabolism. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7590531/),d,38,165257,DB01370,Aluminium
,7590531,half-life,"The half-life of aluminium in tibias (38 v. 58 v. 173 days in growing, mature and ageing rats, respectively) and kidneys (9 v. 12 v. 16 days) lengthened with age.","Tissue aluminium distribution in growing, mature and ageing rats: relationship to changes in gut, kidney and bone metabolism. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7590531/),d,58,165258,DB01370,Aluminium
,7590531,half-life,"The half-life of aluminium in tibias (38 v. 58 v. 173 days in growing, mature and ageing rats, respectively) and kidneys (9 v. 12 v. 16 days) lengthened with age.","Tissue aluminium distribution in growing, mature and ageing rats: relationship to changes in gut, kidney and bone metabolism. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7590531/),d,173,165259,DB01370,Aluminium
,7590531,half-life,"The half-life of aluminium in tibias (38 v. 58 v. 173 days in growing, mature and ageing rats, respectively) and kidneys (9 v. 12 v. 16 days) lengthened with age.","Tissue aluminium distribution in growing, mature and ageing rats: relationship to changes in gut, kidney and bone metabolism. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7590531/),d,9,165260,DB01370,Aluminium
,7590531,half-life,"The half-life of aluminium in tibias (38 v. 58 v. 173 days in growing, mature and ageing rats, respectively) and kidneys (9 v. 12 v. 16 days) lengthened with age.","Tissue aluminium distribution in growing, mature and ageing rats: relationship to changes in gut, kidney and bone metabolism. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7590531/),d,12,165261,DB01370,Aluminium
,7590531,half-life,"The half-life of aluminium in tibias (38 v. 58 v. 173 days in growing, mature and ageing rats, respectively) and kidneys (9 v. 12 v. 16 days) lengthened with age.","Tissue aluminium distribution in growing, mature and ageing rats: relationship to changes in gut, kidney and bone metabolism. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7590531/),d,16,165262,DB01370,Aluminium
,1444308,relative bioavailability,"When aluminum hydroxide, ferrous sulfate, and magnesium oxide were coadministered with DR-3355, the relative bioavailability of DR-3355 was decreased to 56, 81, and 78%, respectively, of that for DR-3355 (100 mg) alone.","Effects of antacids, ferrous sulfate, and ranitidine on absorption of DR-3355 in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1444308/),%,56,166262,DB01370,Aluminium
,1444308,relative bioavailability,"When aluminum hydroxide, ferrous sulfate, and magnesium oxide were coadministered with DR-3355, the relative bioavailability of DR-3355 was decreased to 56, 81, and 78%, respectively, of that for DR-3355 (100 mg) alone.","Effects of antacids, ferrous sulfate, and ranitidine on absorption of DR-3355 in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1444308/),%,81,166263,DB01370,Aluminium
,1444308,relative bioavailability,"When aluminum hydroxide, ferrous sulfate, and magnesium oxide were coadministered with DR-3355, the relative bioavailability of DR-3355 was decreased to 56, 81, and 78%, respectively, of that for DR-3355 (100 mg) alone.","Effects of antacids, ferrous sulfate, and ranitidine on absorption of DR-3355 in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1444308/),%,78,166264,DB01370,Aluminium
,6749509,elimination half life,After oral administration elimination half life of atenolol is calculated from 6 to 9 h by different authors.,Clinical pharmacokinetics of atenolol--a review. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6749509/),h,6 to 9,169734,DB01370,Aluminium
,6749509,elimination half life,In patients with impaired renal function elimination half life of atenolol gradually increases to values of 36 h in uraemic patients (glomerular filtration rate (GFR) less than 10 ml/min).,Clinical pharmacokinetics of atenolol--a review. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6749509/),h,36,169735,DB01370,Aluminium
,7328486,bioavailability,The bioavailability of aspirin from an aspirin aluminum tablet was nearly 60% of that from an aspirin tablet.,The bioavailabilities of aspirin from an aspirin aluminum and an aspirin tablet and the effects of food and aluminum hydroxide gel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7328486/),%,60,170172,DB01370,Aluminium
,16638738,time to maximum concentration (t(max)),"In the presence of food, time to maximum concentration (t(max)) was delayed by 1.25 hours; maximum concentration (C(max)) and area under the curve (AUC) were increased, with reduced interindividual variability at higher doses of BAY 59-7939.","Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16638738/),h,1.25,170198,DB01370,Aluminium
,16638738,Time to maximum PT,"Time to maximum PT prolongation was delayed by 0.5 to 1.5 hours after food, with no relevant influence of food type.","Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16638738/),h,0.5,170199,DB01370,Aluminium
,16638738,Time to maximum PT,"Time to maximum PT prolongation was delayed by 0.5 to 1.5 hours after food, with no relevant influence of food type.","Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16638738/),h,1.5,170200,DB01370,Aluminium
,15525560,oral clearance,"From the population analysis (one-compartment model), the mean oral clearance was 76.7 l/h (CV=74.2%) and mean apparent volume of distribution was 1470 l (CV=36.3%).","Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15525560/),[l] / [h],76.7,170952,DB01370,Aluminium
,15525560,apparent volume of distribution,"From the population analysis (one-compartment model), the mean oral clearance was 76.7 l/h (CV=74.2%) and mean apparent volume of distribution was 1470 l (CV=36.3%).","Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15525560/),l,1470,170953,DB01370,Aluminium
,15525560,first-order absorption rate constant,The first-order absorption rate constant ranged from 0.716 to 1.33 h(-1) (pooled CV=61.7%).,"Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15525560/),1/[h],0.716 to 1.33,170954,DB01370,Aluminium
,15525560,bioavailability,"Estimates of bioavailability compared to fasting administration were 145% (90% CI, 107-183%) for administration with high fat food, 82.0% (63.2-101%) for administration with orange juice, and 78.5% (55.1-102%) for administration with antacid.","Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15525560/),%,145,170955,DB01370,Aluminium
,15525560,bioavailability,"Estimates of bioavailability compared to fasting administration were 145% (90% CI, 107-183%) for administration with high fat food, 82.0% (63.2-101%) for administration with orange juice, and 78.5% (55.1-102%) for administration with antacid.","Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15525560/),%,82.0,170956,DB01370,Aluminium
,15525560,bioavailability,"Estimates of bioavailability compared to fasting administration were 145% (90% CI, 107-183%) for administration with high fat food, 82.0% (63.2-101%) for administration with orange juice, and 78.5% (55.1-102%) for administration with antacid.","Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15525560/),%,78.5,170957,DB01370,Aluminium
,32620699,recovery,"The typical digestion time was 45 min for titanium foil and 75 min for TiO2 The average scandium recovery was 94% ± 3%, and the average titanium recoveries from digested titanium foil and TiO2 after precipitation as TiO2 were 108% ± 8% and 104% ± 5% of initial mass, respectively.",Cyclotron Production and Separation of Scandium Radionuclides from Natural Titanium Metal and Titanium Dioxide Targets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32620699/),%,94,173929,DB01370,Aluminium
,32620699,recoveries,"The typical digestion time was 45 min for titanium foil and 75 min for TiO2 The average scandium recovery was 94% ± 3%, and the average titanium recoveries from digested titanium foil and TiO2 after precipitation as TiO2 were 108% ± 8% and 104% ± 5% of initial mass, respectively.",Cyclotron Production and Separation of Scandium Radionuclides from Natural Titanium Metal and Titanium Dioxide Targets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32620699/),%,108,173930,DB01370,Aluminium
,32620699,recoveries,"The typical digestion time was 45 min for titanium foil and 75 min for TiO2 The average scandium recovery was 94% ± 3%, and the average titanium recoveries from digested titanium foil and TiO2 after precipitation as TiO2 were 108% ± 8% and 104% ± 5% of initial mass, respectively.",Cyclotron Production and Separation of Scandium Radionuclides from Natural Titanium Metal and Titanium Dioxide Targets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32620699/),%,104,173931,DB01370,Aluminium
,21819285,volume of central compartment (V1),"Mean parameter estimates for volume of central compartment (V1), CL, volume of peripheral compartment (V2), volume of distribution at steady-state (Vss), and intercompartmental clearance (Q) were 168 L, 8.99 L/day, 12 000 L, 12 168 L, and 4.93 L/day, respectively.",Aluminum toxicokinetics in peritoneal dialysis patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21819285/),l,168,174049,DB01370,Aluminium
,21819285,volume of distribution at steady-state (Vss),"Mean parameter estimates for volume of central compartment (V1), CL, volume of peripheral compartment (V2), volume of distribution at steady-state (Vss), and intercompartmental clearance (Q) were 168 L, 8.99 L/day, 12 000 L, 12 168 L, and 4.93 L/day, respectively.",Aluminum toxicokinetics in peritoneal dialysis patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21819285/),l,12 000,174050,DB01370,Aluminium
,21819285,intercompartmental clearance (Q),"Mean parameter estimates for volume of central compartment (V1), CL, volume of peripheral compartment (V2), volume of distribution at steady-state (Vss), and intercompartmental clearance (Q) were 168 L, 8.99 L/day, 12 000 L, 12 168 L, and 4.93 L/day, respectively.",Aluminum toxicokinetics in peritoneal dialysis patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21819285/),[l] / [d],4.93,174051,DB01370,Aluminium
,21819285,distributional half-life,"Al distributional half-life was 8.5 days, while the terminal elimination half-life was 7.2 years.",Aluminum toxicokinetics in peritoneal dialysis patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21819285/),d,8.5,174052,DB01370,Aluminium
,21819285,terminal elimination half-life,"Al distributional half-life was 8.5 days, while the terminal elimination half-life was 7.2 years.",Aluminum toxicokinetics in peritoneal dialysis patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21819285/),years,7.2,174053,DB01370,Aluminium
,33078092,IC50,"The optimization efforts led to potent compounds 42 and 53‒55 with IC50 values of 41, 44, 32, and 42 nmol/L, respectively.","Design, synthesis, molecular modeling, and biological evaluation of acrylamide derivatives as potent inhibitors of human dihydroorotate dehydrogenase for the treatment of rheumatoid arthritis. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33078092/),[nM] / [l],41,177259,DB01370,Aluminium
,33078092,IC50,"The optimization efforts led to potent compounds 42 and 53‒55 with IC50 values of 41, 44, 32, and 42 nmol/L, respectively.","Design, synthesis, molecular modeling, and biological evaluation of acrylamide derivatives as potent inhibitors of human dihydroorotate dehydrogenase for the treatment of rheumatoid arthritis. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33078092/),[nM] / [l],44,177260,DB01370,Aluminium
,33078092,IC50,"The optimization efforts led to potent compounds 42 and 53‒55 with IC50 values of 41, 44, 32, and 42 nmol/L, respectively.","Design, synthesis, molecular modeling, and biological evaluation of acrylamide derivatives as potent inhibitors of human dihydroorotate dehydrogenase for the treatment of rheumatoid arthritis. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33078092/),[nM] / [l],32,177261,DB01370,Aluminium
,33078092,IC50,"The optimization efforts led to potent compounds 42 and 53‒55 with IC50 values of 41, 44, 32, and 42 nmol/L, respectively.","Design, synthesis, molecular modeling, and biological evaluation of acrylamide derivatives as potent inhibitors of human dihydroorotate dehydrogenase for the treatment of rheumatoid arthritis. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33078092/),[nM] / [l],42,177262,DB01370,Aluminium
,30052317,area under the curve (AUC),"In blood samples after i.v. administration, 26 Al was readily detected (mean area under the curve (AUC) = 1,273 ± 466 hours×fg/mL).",Assessment of Dermal Absorption of Aluminum from a Representative Antiperspirant Formulation Using a 26 Al Microtracer Approach. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30052317/),[fg·h] / [ml],"1,273",177731,DB01370,Aluminium
,30052317,Fabs,"From the urinary excretion data, a conservative estimated range for dermal Fabs of 0.002-0.06% was calculated, with a mean estimate of 0.0094%.",Assessment of Dermal Absorption of Aluminum from a Representative Antiperspirant Formulation Using a 26 Al Microtracer Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30052317/),%,0.002-0.06,177732,DB01370,Aluminium
,7547087,AUC,"However, co-administration with the antacid significantly decreased both the mean rate and extent of absorption of tenidap compared with the fasting state: AUC, 420.93 micrograms ml-1 h (antacid), 476.31 micrograms ml-1 h (fasting) (P = 0.026); Cmax 14.3 micrograms ml-1 (antacid), 18.0 micrograms ml-1 (fasting) (P = 0.001); tmax 4.5 h (antacid), 2.9 h (fasting) (P < 0.001).",Pharmacokinetics of tenidap sodium administered with food or antacid in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7547087/),[h·μg] / [ml],420.93,178327,DB01370,Aluminium
,7547087,AUC,"However, co-administration with the antacid significantly decreased both the mean rate and extent of absorption of tenidap compared with the fasting state: AUC, 420.93 micrograms ml-1 h (antacid), 476.31 micrograms ml-1 h (fasting) (P = 0.026); Cmax 14.3 micrograms ml-1 (antacid), 18.0 micrograms ml-1 (fasting) (P = 0.001); tmax 4.5 h (antacid), 2.9 h (fasting) (P < 0.001).",Pharmacokinetics of tenidap sodium administered with food or antacid in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7547087/),[h·μg] / [ml],476.31,178328,DB01370,Aluminium
,7547087,Cmax,"However, co-administration with the antacid significantly decreased both the mean rate and extent of absorption of tenidap compared with the fasting state: AUC, 420.93 micrograms ml-1 h (antacid), 476.31 micrograms ml-1 h (fasting) (P = 0.026); Cmax 14.3 micrograms ml-1 (antacid), 18.0 micrograms ml-1 (fasting) (P = 0.001); tmax 4.5 h (antacid), 2.9 h (fasting) (P < 0.001).",Pharmacokinetics of tenidap sodium administered with food or antacid in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7547087/),[μg] / [ml],14.3,178329,DB01370,Aluminium
,7547087,Cmax,"However, co-administration with the antacid significantly decreased both the mean rate and extent of absorption of tenidap compared with the fasting state: AUC, 420.93 micrograms ml-1 h (antacid), 476.31 micrograms ml-1 h (fasting) (P = 0.026); Cmax 14.3 micrograms ml-1 (antacid), 18.0 micrograms ml-1 (fasting) (P = 0.001); tmax 4.5 h (antacid), 2.9 h (fasting) (P < 0.001).",Pharmacokinetics of tenidap sodium administered with food or antacid in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7547087/),[μg] / [ml],18.0,178330,DB01370,Aluminium
,7547087,tmax,"However, co-administration with the antacid significantly decreased both the mean rate and extent of absorption of tenidap compared with the fasting state: AUC, 420.93 micrograms ml-1 h (antacid), 476.31 micrograms ml-1 h (fasting) (P = 0.026); Cmax 14.3 micrograms ml-1 (antacid), 18.0 micrograms ml-1 (fasting) (P = 0.001); tmax 4.5 h (antacid), 2.9 h (fasting) (P < 0.001).",Pharmacokinetics of tenidap sodium administered with food or antacid in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7547087/),h,4.5,178331,DB01370,Aluminium
,7547087,tmax,"However, co-administration with the antacid significantly decreased both the mean rate and extent of absorption of tenidap compared with the fasting state: AUC, 420.93 micrograms ml-1 h (antacid), 476.31 micrograms ml-1 h (fasting) (P = 0.026); Cmax 14.3 micrograms ml-1 (antacid), 18.0 micrograms ml-1 (fasting) (P = 0.001); tmax 4.5 h (antacid), 2.9 h (fasting) (P < 0.001).",Pharmacokinetics of tenidap sodium administered with food or antacid in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7547087/),h,2.9,178332,DB01370,Aluminium
,7863246,bioavailability,"Antacid ingestion decreased the bioavailability of famotidine, ranitidine and cimetidine by 20-25%, and the bioavailability of nizatidine by 12%.",Drug interactions of H2-receptor antagonists. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7863246/),,12,179873,DB01370,Aluminium
,3665393,AUC,"The ranges of mean (+/- S.D.) values were 113.97 +/- 21.5 to 127.53 +/- 29.3 micrograms.hr/mL for AUC, 35.30 +/- 6.40 to 41.00 +/- 10.00 micrograms/mL for Cmax, 0.95 +/- 0.30 to 1.28 +/- 0.54 hr for tmax, and 0.346 +/- 0.026 to 0.388 +/- 0.040 hr-1 for k.",Effect of antacid suspension on the pharmacokinetics of ibuprofen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665393/),[h·μg] / [ml],113.97,187949,DB01370,Aluminium
,3665393,AUC,"The ranges of mean (+/- S.D.) values were 113.97 +/- 21.5 to 127.53 +/- 29.3 micrograms.hr/mL for AUC, 35.30 +/- 6.40 to 41.00 +/- 10.00 micrograms/mL for Cmax, 0.95 +/- 0.30 to 1.28 +/- 0.54 hr for tmax, and 0.346 +/- 0.026 to 0.388 +/- 0.040 hr-1 for k.",Effect of antacid suspension on the pharmacokinetics of ibuprofen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665393/),[h·μg] / [ml],127.53,187950,DB01370,Aluminium
,3665393,Cmax,"The ranges of mean (+/- S.D.) values were 113.97 +/- 21.5 to 127.53 +/- 29.3 micrograms.hr/mL for AUC, 35.30 +/- 6.40 to 41.00 +/- 10.00 micrograms/mL for Cmax, 0.95 +/- 0.30 to 1.28 +/- 0.54 hr for tmax, and 0.346 +/- 0.026 to 0.388 +/- 0.040 hr-1 for k.",Effect of antacid suspension on the pharmacokinetics of ibuprofen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665393/),[μg] / [ml],35.30,187951,DB01370,Aluminium
,3665393,Cmax,"The ranges of mean (+/- S.D.) values were 113.97 +/- 21.5 to 127.53 +/- 29.3 micrograms.hr/mL for AUC, 35.30 +/- 6.40 to 41.00 +/- 10.00 micrograms/mL for Cmax, 0.95 +/- 0.30 to 1.28 +/- 0.54 hr for tmax, and 0.346 +/- 0.026 to 0.388 +/- 0.040 hr-1 for k.",Effect of antacid suspension on the pharmacokinetics of ibuprofen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665393/),[μg] / [ml],41.00,187952,DB01370,Aluminium
,3665393,tmax,"The ranges of mean (+/- S.D.) values were 113.97 +/- 21.5 to 127.53 +/- 29.3 micrograms.hr/mL for AUC, 35.30 +/- 6.40 to 41.00 +/- 10.00 micrograms/mL for Cmax, 0.95 +/- 0.30 to 1.28 +/- 0.54 hr for tmax, and 0.346 +/- 0.026 to 0.388 +/- 0.040 hr-1 for k.",Effect of antacid suspension on the pharmacokinetics of ibuprofen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665393/),h,0.95,187953,DB01370,Aluminium
,3665393,tmax,"The ranges of mean (+/- S.D.) values were 113.97 +/- 21.5 to 127.53 +/- 29.3 micrograms.hr/mL for AUC, 35.30 +/- 6.40 to 41.00 +/- 10.00 micrograms/mL for Cmax, 0.95 +/- 0.30 to 1.28 +/- 0.54 hr for tmax, and 0.346 +/- 0.026 to 0.388 +/- 0.040 hr-1 for k.",Effect of antacid suspension on the pharmacokinetics of ibuprofen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665393/),h,1.28,187954,DB01370,Aluminium
,3665393,k,"The ranges of mean (+/- S.D.) values were 113.97 +/- 21.5 to 127.53 +/- 29.3 micrograms.hr/mL for AUC, 35.30 +/- 6.40 to 41.00 +/- 10.00 micrograms/mL for Cmax, 0.95 +/- 0.30 to 1.28 +/- 0.54 hr for tmax, and 0.346 +/- 0.026 to 0.388 +/- 0.040 hr-1 for k.",Effect of antacid suspension on the pharmacokinetics of ibuprofen. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665393/),1/[h],0.346,187955,DB01370,Aluminium
,3665393,k,"The ranges of mean (+/- S.D.) values were 113.97 +/- 21.5 to 127.53 +/- 29.3 micrograms.hr/mL for AUC, 35.30 +/- 6.40 to 41.00 +/- 10.00 micrograms/mL for Cmax, 0.95 +/- 0.30 to 1.28 +/- 0.54 hr for tmax, and 0.346 +/- 0.026 to 0.388 +/- 0.040 hr-1 for k.",Effect of antacid suspension on the pharmacokinetics of ibuprofen. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665393/),1/[h],0.388,187956,DB01370,Aluminium
,3413794,Systemic clearance,"Systemic clearance of Al was less in renally impaired rabbits (39 vs. 53 ml/hr/kg), as were the steady-state volume of distribution (516 vs. 1175 ml/kg), the half-life of elimination (14 vs. 27 hr), and the mean residence time of Al (14 vs. 25 hr).","Influence of renal impairment, chemical form, and serum protein binding on intravenous and oral aluminum kinetics in the rabbit. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3413794/),[ml] / [h·kg],39,188028,DB01370,Aluminium
,3413794,Systemic clearance,"Systemic clearance of Al was less in renally impaired rabbits (39 vs. 53 ml/hr/kg), as were the steady-state volume of distribution (516 vs. 1175 ml/kg), the half-life of elimination (14 vs. 27 hr), and the mean residence time of Al (14 vs. 25 hr).","Influence of renal impairment, chemical form, and serum protein binding on intravenous and oral aluminum kinetics in the rabbit. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3413794/),[ml] / [h·kg],53,188029,DB01370,Aluminium
,3413794,steady-state volume of distribution,"Systemic clearance of Al was less in renally impaired rabbits (39 vs. 53 ml/hr/kg), as were the steady-state volume of distribution (516 vs. 1175 ml/kg), the half-life of elimination (14 vs. 27 hr), and the mean residence time of Al (14 vs. 25 hr).","Influence of renal impairment, chemical form, and serum protein binding on intravenous and oral aluminum kinetics in the rabbit. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3413794/),[ml] / [kg],516,188030,DB01370,Aluminium
,3413794,steady-state volume of distribution,"Systemic clearance of Al was less in renally impaired rabbits (39 vs. 53 ml/hr/kg), as were the steady-state volume of distribution (516 vs. 1175 ml/kg), the half-life of elimination (14 vs. 27 hr), and the mean residence time of Al (14 vs. 25 hr).","Influence of renal impairment, chemical form, and serum protein binding on intravenous and oral aluminum kinetics in the rabbit. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3413794/),[ml] / [kg],1175,188031,DB01370,Aluminium
,3413794,half-life of elimination,"Systemic clearance of Al was less in renally impaired rabbits (39 vs. 53 ml/hr/kg), as were the steady-state volume of distribution (516 vs. 1175 ml/kg), the half-life of elimination (14 vs. 27 hr), and the mean residence time of Al (14 vs. 25 hr).","Influence of renal impairment, chemical form, and serum protein binding on intravenous and oral aluminum kinetics in the rabbit. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3413794/),h,14,188032,DB01370,Aluminium
,3413794,half-life of elimination,"Systemic clearance of Al was less in renally impaired rabbits (39 vs. 53 ml/hr/kg), as were the steady-state volume of distribution (516 vs. 1175 ml/kg), the half-life of elimination (14 vs. 27 hr), and the mean residence time of Al (14 vs. 25 hr).","Influence of renal impairment, chemical form, and serum protein binding on intravenous and oral aluminum kinetics in the rabbit. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3413794/),h,27,188033,DB01370,Aluminium
,3413794,mean residence time,"Systemic clearance of Al was less in renally impaired rabbits (39 vs. 53 ml/hr/kg), as were the steady-state volume of distribution (516 vs. 1175 ml/kg), the half-life of elimination (14 vs. 27 hr), and the mean residence time of Al (14 vs. 25 hr).","Influence of renal impairment, chemical form, and serum protein binding on intravenous and oral aluminum kinetics in the rabbit. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3413794/),h,14,188034,DB01370,Aluminium
,3413794,mean residence time,"Systemic clearance of Al was less in renally impaired rabbits (39 vs. 53 ml/hr/kg), as were the steady-state volume of distribution (516 vs. 1175 ml/kg), the half-life of elimination (14 vs. 27 hr), and the mean residence time of Al (14 vs. 25 hr).","Influence of renal impairment, chemical form, and serum protein binding on intravenous and oral aluminum kinetics in the rabbit. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3413794/),h,25,188035,DB01370,Aluminium
,3413794,Oral bioavailability,Oral bioavailability of Al in renally intact rabbits ranged from 0.3 to 2.2% (Al borate less than glycinate less than hydroxide less than chloride less than sucralfate less than lactate less than nitrate less than citrate).,"Influence of renal impairment, chemical form, and serum protein binding on intravenous and oral aluminum kinetics in the rabbit. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3413794/),%,0.3 to 2.2,188036,DB01370,Aluminium
less,3413794,ultrafilterability,"In vitro and in vivo determination of Al ultrafilterability (less than 30,000 D) as an estimate of serum protein binding suggested a greater percentage of ultrafilterable Al species in renally impaired rabbit serum than in control rabbit serum.","Influence of renal impairment, chemical form, and serum protein binding on intravenous and oral aluminum kinetics in the rabbit. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3413794/),d,"30,000",188037,DB01370,Aluminium
,11451211,elimination half-life,The elimination half-life was 10-15 h.,The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11451211/),h,10-15,189075,DB01370,Aluminium
,11451211,Renal clearance,"Renal clearance (0.5-0.7 l/h) was independent of dose, accounting for approximately 9-12% of an oral dose.",The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11451211/),[l] / [h],0.5-0.7,189076,DB01370,Aluminium
,11451211,absolute bioavailability,The absolute bioavailability of olmesartan from olmesartan medoxomil tablets was 28.6%.,The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11451211/),%,28.6,189077,DB01370,Aluminium
,9222077,area under the curve (AUC),"After treatments A and C, mean area under the curve (AUC) was reduced by 66% and 28% (14.2 and 30.2 mg.h/L), respectively, and mean T(1/2) declined by 33% and 31% (8.3 and 8.5 h), respectively, relative to the values after B (42.1 mg.h/L; 12.4 h).",Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222077/),[h·mg] / [l],14.2,190917,DB01370,Aluminium
,9222077,area under the curve (AUC),"After treatments A and C, mean area under the curve (AUC) was reduced by 66% and 28% (14.2 and 30.2 mg.h/L), respectively, and mean T(1/2) declined by 33% and 31% (8.3 and 8.5 h), respectively, relative to the values after B (42.1 mg.h/L; 12.4 h).",Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222077/),[h·mg] / [l],30.2,190918,DB01370,Aluminium
,9222077,T(1/2),"After treatments A and C, mean area under the curve (AUC) was reduced by 66% and 28% (14.2 and 30.2 mg.h/L), respectively, and mean T(1/2) declined by 33% and 31% (8.3 and 8.5 h), respectively, relative to the values after B (42.1 mg.h/L; 12.4 h).",Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222077/),h,8.3,190919,DB01370,Aluminium
,9222077,T(1/2),"After treatments A and C, mean area under the curve (AUC) was reduced by 66% and 28% (14.2 and 30.2 mg.h/L), respectively, and mean T(1/2) declined by 33% and 31% (8.3 and 8.5 h), respectively, relative to the values after B (42.1 mg.h/L; 12.4 h).",Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222077/),h,8.5,190920,DB01370,Aluminium
,9222077,T(1/2),"After treatments A and C, mean area under the curve (AUC) was reduced by 66% and 28% (14.2 and 30.2 mg.h/L), respectively, and mean T(1/2) declined by 33% and 31% (8.3 and 8.5 h), respectively, relative to the values after B (42.1 mg.h/L; 12.4 h).",Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222077/),[h·mg] / [l],42.1,190921,DB01370,Aluminium
,9222077,T(1/2),"After treatments A and C, mean area under the curve (AUC) was reduced by 66% and 28% (14.2 and 30.2 mg.h/L), respectively, and mean T(1/2) declined by 33% and 31% (8.3 and 8.5 h), respectively, relative to the values after B (42.1 mg.h/L; 12.4 h).",Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222077/),h,12.4,190922,DB01370,Aluminium
,9222077,Kel-corrected relative bioavailabilities,"The mean Kel-corrected relative bioavailabilities for A and C were 50% and 104%, respectively, suggesting a large reduction in the initial absorption of trovafloxacin with A.",Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222077/),%,50,190923,DB01370,Aluminium
,9222077,Kel-corrected relative bioavailabilities,"The mean Kel-corrected relative bioavailabilities for A and C were 50% and 104%, respectively, suggesting a large reduction in the initial absorption of trovafloxacin with A.",Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222077/),%,104,190924,DB01370,Aluminium
,9222077,relative bioavailability,The mean relative bioavailability after D was 82%.,Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9222077/),%,82,190925,DB01370,Aluminium
,3755676,AUC48,The phenytoin AUC48 was reduced from 173.6 +/- 22.6 mg .,Effect of sucralfate on phenytoin bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3755676/),mg,173.6,191442,DB01370,Aluminium
,3755676,AUC120,"h/L to 157.1 +/- 19.6 mg . h/L (p less than 0.02), and the phenytoin AUC120 was reduced from 200.5 +/- 31.9 mg .",Effect of sucralfate on phenytoin bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3755676/),mg,200.5,191443,DB01370,Aluminium
,2890459,absolute oral bioavailability,"The absolute oral bioavailability, relative to that after intravenous administration, was 98% +/- 14%.",Absorption studies of the H2-blocker nizatidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2890459/),%,98,192484,DB01370,Aluminium
,34405290,drug loading (DL %,The drug loading (DL %) and entrapment efficiency (EE %) of Gal-Res NPs were 46.80% and 88.06%.,"Preparation, Characterization, and In Vitro/In Vivo Evaluation of 3-O-β-D-Galactosylated Resveratrol-Loaded Polydopamine Nanoparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34405290/),%,46.80,192499,DB01370,Aluminium
,34405290,entrapment efficiency (EE %),The drug loading (DL %) and entrapment efficiency (EE %) of Gal-Res NPs were 46.80% and 88.06%.,"Preparation, Characterization, and In Vitro/In Vivo Evaluation of 3-O-β-D-Galactosylated Resveratrol-Loaded Polydopamine Nanoparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34405290/),%,88.06,192500,DB01370,Aluminium
,34405290,particle,"The average particle size, polydispersity index (PDI), and Zeta potential of Gal-Res NPs were 179.38 ± 2.83 nm, 0.129 ± 0.013, and - 28.05 ± 0.36 mV, respectively.","Preparation, Characterization, and In Vitro/In Vivo Evaluation of 3-O-β-D-Galactosylated Resveratrol-Loaded Polydopamine Nanoparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34405290/),nm,179.38,192501,DB01370,Aluminium
,34405290,polydispersity index (PDI),"The average particle size, polydispersity index (PDI), and Zeta potential of Gal-Res NPs were 179.38 ± 2.83 nm, 0.129 ± 0.013, and - 28.05 ± 0.36 mV, respectively.","Preparation, Characterization, and In Vitro/In Vivo Evaluation of 3-O-β-D-Galactosylated Resveratrol-Loaded Polydopamine Nanoparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34405290/),mv,0.129,192502,DB01370,Aluminium
,34405290,Zeta potential,"The average particle size, polydispersity index (PDI), and Zeta potential of Gal-Res NPs were 179.38 ± 2.83 nm, 0.129 ± 0.013, and - 28.05 ± 0.36 mV, respectively.","Preparation, Characterization, and In Vitro/In Vivo Evaluation of 3-O-β-D-Galactosylated Resveratrol-Loaded Polydopamine Nanoparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34405290/),mv,-,192503,DB01370,Aluminium
,34405290,Zeta potential,"The average particle size, polydispersity index (PDI), and Zeta potential of Gal-Res NPs were 179.38 ± 2.83 nm, 0.129 ± 0.013, and - 28.05 ± 0.36 mV, respectively.","Preparation, Characterization, and In Vitro/In Vivo Evaluation of 3-O-β-D-Galactosylated Resveratrol-Loaded Polydopamine Nanoparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34405290/),mv,28.05,192504,DB01370,Aluminium
,3770957,plasma level,The mean fluoride plasma level before the shift was 23 ng/ml (1.2 microM/l) and increased on average to 48 ng/ml (range 14-151 ng/ml) at the end of the shift.,Occupational fluoride exposure and plasma fluoride levels in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3770957/),[ng] / [ml],23,194594,DB01370,Aluminium
,3770957,plasma level,The mean fluoride plasma level before the shift was 23 ng/ml (1.2 microM/l) and increased on average to 48 ng/ml (range 14-151 ng/ml) at the end of the shift.,Occupational fluoride exposure and plasma fluoride levels in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3770957/),[ng] / [ml],48,194595,DB01370,Aluminium
,1910052,"time to reach the peak plasma concentration, Tmax,","After the oral 10-mg dose, the average time to reach the peak plasma concentration, Tmax, was 4.4 +/- 2.2 hours in these uremic patients, with a range of 2 to 8 hours.",Pharmacokinetics of ritanserin in patients undergoing hemodialysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1910052/),h,4.4,197066,DB01370,Aluminium
,1910052,peak plasma concentration,The average peak plasma concentration was 73.6 +/- 26.9 ng/mL (range: 54.6-120.0 ng/mL).,Pharmacokinetics of ritanserin in patients undergoing hemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1910052/),[ng] / [ml],73.6,197067,DB01370,Aluminium
,1910052,area under the plasma concentration-time curve,The mean area under the plasma concentration-time curve for ritanserin (2031 +/- 636 ng.hr/mL) was 47% lower compared with that in healthy volunteers (3867 +/- 1413 ng.hr/mL).,Pharmacokinetics of ritanserin in patients undergoing hemodialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1910052/),[h·ng] / [ml],2031,197068,DB01370,Aluminium
,1910052,area under the plasma concentration-time curve,The mean area under the plasma concentration-time curve for ritanserin (2031 +/- 636 ng.hr/mL) was 47% lower compared with that in healthy volunteers (3867 +/- 1413 ng.hr/mL).,Pharmacokinetics of ritanserin in patients undergoing hemodialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1910052/),[h·ng] / [ml],3867,197069,DB01370,Aluminium
,1910052,terminal half-life,"The regular hemodialysis sessions every 2-3 days did not affect the elimination rate of ritanserin, as the terminal half-life in these patients (39 +/- 23 hr) is similar to that in healthy volunteers (41 +/- 14 hr).",Pharmacokinetics of ritanserin in patients undergoing hemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1910052/),h,39,197070,DB01370,Aluminium
,1910052,terminal half-life,"The regular hemodialysis sessions every 2-3 days did not affect the elimination rate of ritanserin, as the terminal half-life in these patients (39 +/- 23 hr) is similar to that in healthy volunteers (41 +/- 14 hr).",Pharmacokinetics of ritanserin in patients undergoing hemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1910052/),h,41,197071,DB01370,Aluminium
,2920479,bioavailability,"Absorption of norfloxacin, ciprofloxacin, and enoxacin is incomplete, whereas the bioavailability of pefloxacin, ofloxacin and fleroxacin is almost 100%.",The pharmacokinetics and tissue penetration of the fluoroquinolones. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),%,100,197116,DB01370,Aluminium
,2920479,Maximum serum concentrations,Maximum serum concentrations vary between 1.5 and 10.7 micrograms/ml depending on the dose and antibiotic given.,The pharmacokinetics and tissue penetration of the fluoroquinolones. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),[μg] / [ml],1.5,197117,DB01370,Aluminium
,2920479,Maximum serum concentrations,Maximum serum concentrations vary between 1.5 and 10.7 micrograms/ml depending on the dose and antibiotic given.,The pharmacokinetics and tissue penetration of the fluoroquinolones. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),[μg] / [ml],10.7,197118,DB01370,Aluminium
,2920479,AUC's,Respective AUC's of 78 and 5.5 micrograms/ml-h are observed following the administration of 400 mg of either fleroxacin or norfloxacin.,The pharmacokinetics and tissue penetration of the fluoroquinolones. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),[μg] / [ml-h],78,197119,DB01370,Aluminium
,2920479,AUC's,Respective AUC's of 78 and 5.5 micrograms/ml-h are observed following the administration of 400 mg of either fleroxacin or norfloxacin.,The pharmacokinetics and tissue penetration of the fluoroquinolones. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),[μg] / [ml-h],5.5,197120,DB01370,Aluminium
,2920479,apparent volume of distribution,Protein binding is low (less than or equal to 30%) and apparent volume of distribution is between 1.5 and 3.1 liters/kg.,The pharmacokinetics and tissue penetration of the fluoroquinolones. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),[l] / [kg],1.5 and 3.1,197121,DB01370,Aluminium
,2920479,half-lives,"Norfloxacin and ciprofloxacin have the shortest half-lives (+/- 4h), while fleroxacin and pefloxacin have the longest (10-12h).",The pharmacokinetics and tissue penetration of the fluoroquinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),h,10-12,197122,DB01370,Aluminium
,10408394,plasma half-life,"This dye showed a prolonged plasma half-life (6.8 h) as compared to AlClPc (2.6 h) and AlPc-PEG (23 min), lower retention by liver and spleen and higher tumour-to-skin and tumour-to-muscle ratios.",Water-soluble aluminium phthalocyanine-polymer conjugates for PDT: photodynamic activities and pharmacokinetics in tumour-bearing mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10408394/),h,6.8,198480,DB01370,Aluminium
,10408394,plasma half-life,"This dye showed a prolonged plasma half-life (6.8 h) as compared to AlClPc (2.6 h) and AlPc-PEG (23 min), lower retention by liver and spleen and higher tumour-to-skin and tumour-to-muscle ratios.",Water-soluble aluminium phthalocyanine-polymer conjugates for PDT: photodynamic activities and pharmacokinetics in tumour-bearing mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10408394/),h,2.6,198481,DB01370,Aluminium
,10408394,plasma half-life,"This dye showed a prolonged plasma half-life (6.8 h) as compared to AlClPc (2.6 h) and AlPc-PEG (23 min), lower retention by liver and spleen and higher tumour-to-skin and tumour-to-muscle ratios.",Water-soluble aluminium phthalocyanine-polymer conjugates for PDT: photodynamic activities and pharmacokinetics in tumour-bearing mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10408394/),min,23,198482,DB01370,Aluminium
,2627821,overall healing rates,The overall healing rates after 8 weeks for the groups taking cimetidine alone and cimetidine plus antacid were 80.0% and 92.6% respectively with no significant difference.,[Effect of antacids on the bioavailability and therapeutic efficacy of cimetidine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2627821/),%,80.0,198599,DB01370,Aluminium
,2627821,overall healing rates,The overall healing rates after 8 weeks for the groups taking cimetidine alone and cimetidine plus antacid were 80.0% and 92.6% respectively with no significant difference.,[Effect of antacids on the bioavailability and therapeutic efficacy of cimetidine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2627821/),%,92.6,198600,DB01370,Aluminium
,2610502,area under the concentration-time curve,"However, the antacid caused a significant (P less than 0.01) reduction in the gastrointestinal absorption of doxycycline (area under the concentration-time curve, 38.6 +/- 22.7 mg.h/liter, fasting; 6.0 +/- 3.2 mg.h/liter, with antacid), resulting in subtherapeutic levels of doxycycline.","Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2610502/),[h·mg] / [l],38.6,198791,DB01370,Aluminium
,2610502,area under the concentration-time curve,"However, the antacid caused a significant (P less than 0.01) reduction in the gastrointestinal absorption of doxycycline (area under the concentration-time curve, 38.6 +/- 22.7 mg.h/liter, fasting; 6.0 +/- 3.2 mg.h/liter, with antacid), resulting in subtherapeutic levels of doxycycline.","Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2610502/),[h·mg] / [l],6.0,198792,DB01370,Aluminium
,14506591,elimination half-life,"Porfimer sodium exhibited a longer elimination half-life (175.3 hr), slower clearance (0.0028 L/kg/hr), and a larger area under the curve (1075 microg/g/hr) in tumors than did tin ethyl etiopurpurin or aluminum chlorophthalocyanine.",Biodistribution of three photosensitizers in dogs with spontaneous tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14506591/),h,175.3,199966,DB01370,Aluminium
,14506591,clearance,"Porfimer sodium exhibited a longer elimination half-life (175.3 hr), slower clearance (0.0028 L/kg/hr), and a larger area under the curve (1075 microg/g/hr) in tumors than did tin ethyl etiopurpurin or aluminum chlorophthalocyanine.",Biodistribution of three photosensitizers in dogs with spontaneous tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14506591/),[l] / [h·kg],0.0028,199967,DB01370,Aluminium
,14506591,area under the curve,"Porfimer sodium exhibited a longer elimination half-life (175.3 hr), slower clearance (0.0028 L/kg/hr), and a larger area under the curve (1075 microg/g/hr) in tumors than did tin ethyl etiopurpurin or aluminum chlorophthalocyanine.",Biodistribution of three photosensitizers in dogs with spontaneous tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14506591/),[μg] / [g·h],1075,199968,DB01370,Aluminium
,7965657,Cmax,"The tablet and solution formulations were bioequivalent, as confirmed by similarities in mean Cmax (26.3 vs 27.7 ng/mL), Tmax (1.79 vs 1.70 h), and AUC (166.0 vs 167.3 ng.h/mL) values.","Ondansetron absorption in adults: effect of dosage form, food, and antacids. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7965657/),[ng] / [ml],26.3,202368,DB01370,Aluminium
,7965657,Cmax,"The tablet and solution formulations were bioequivalent, as confirmed by similarities in mean Cmax (26.3 vs 27.7 ng/mL), Tmax (1.79 vs 1.70 h), and AUC (166.0 vs 167.3 ng.h/mL) values.","Ondansetron absorption in adults: effect of dosage form, food, and antacids. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7965657/),[ng] / [ml],27.7,202369,DB01370,Aluminium
,7965657,Tmax,"The tablet and solution formulations were bioequivalent, as confirmed by similarities in mean Cmax (26.3 vs 27.7 ng/mL), Tmax (1.79 vs 1.70 h), and AUC (166.0 vs 167.3 ng.h/mL) values.","Ondansetron absorption in adults: effect of dosage form, food, and antacids. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7965657/),h,1.79,202370,DB01370,Aluminium
,7965657,Tmax,"The tablet and solution formulations were bioequivalent, as confirmed by similarities in mean Cmax (26.3 vs 27.7 ng/mL), Tmax (1.79 vs 1.70 h), and AUC (166.0 vs 167.3 ng.h/mL) values.","Ondansetron absorption in adults: effect of dosage form, food, and antacids. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7965657/),h,1.70,202371,DB01370,Aluminium
,7965657,AUC,"The tablet and solution formulations were bioequivalent, as confirmed by similarities in mean Cmax (26.3 vs 27.7 ng/mL), Tmax (1.79 vs 1.70 h), and AUC (166.0 vs 167.3 ng.h/mL) values.","Ondansetron absorption in adults: effect of dosage form, food, and antacids. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7965657/),[h·ng] / [ml],166.0,202372,DB01370,Aluminium
,7965657,AUC,"The tablet and solution formulations were bioequivalent, as confirmed by similarities in mean Cmax (26.3 vs 27.7 ng/mL), Tmax (1.79 vs 1.70 h), and AUC (166.0 vs 167.3 ng.h/mL) values.","Ondansetron absorption in adults: effect of dosage form, food, and antacids. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7965657/),[h·ng] / [ml],167.3,202373,DB01370,Aluminium
,7965657,AUC,"In another randomized, open-label, crossover study in 12 healthy male subjects, the bioavailability of an 8-mg ondansetron tablet administered 5 min after a standard meal was slightly but significantly greater than in fasted subjects, as indicated by comparative mean AUC values [201.4 ng.h/mL (fed) vs 172.5 ng.h/mL (fasted)].","Ondansetron absorption in adults: effect of dosage form, food, and antacids. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7965657/),[h·ng] / [ml],201.4,202374,DB01370,Aluminium
,7965657,AUC,"In another randomized, open-label, crossover study in 12 healthy male subjects, the bioavailability of an 8-mg ondansetron tablet administered 5 min after a standard meal was slightly but significantly greater than in fasted subjects, as indicated by comparative mean AUC values [201.4 ng.h/mL (fed) vs 172.5 ng.h/mL (fasted)].","Ondansetron absorption in adults: effect of dosage form, food, and antacids. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7965657/),[h·ng] / [ml],172.5,202375,DB01370,Aluminium
,3499163,time taken to reach peak,5 Food lengthened the time taken to reach peak tenoxicam concentrations (5.82 +/- 4.6 vs 1.84 +/- 1.0 h in the fasting state; P less than 0.02) and marginally reduced the peak concentrations achieved.,Effect of food and various antacids on the absorption of tenoxicam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3499163/),h,5.82,203346,DB01370,Aluminium
,3499163,time taken to reach peak,5 Food lengthened the time taken to reach peak tenoxicam concentrations (5.82 +/- 4.6 vs 1.84 +/- 1.0 h in the fasting state; P less than 0.02) and marginally reduced the peak concentrations achieved.,Effect of food and various antacids on the absorption of tenoxicam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3499163/),h,1.84,203347,DB01370,Aluminium
,3735104,fraction absorbed orally,"The fraction absorbed orally (mean +/- SEM) was 0.27 +/- 0.03; the half-life was 5.29 +/- 0.47 h; the steady-state volume of distribution was 38.4 +/- 6.4 mL/kg, and the clearance was 8.87 +/- 1.76 mL X h-1 X kg-1.",Absorption and disposition of aluminum in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735104/),,0.27,203733,DB01370,Aluminium
,3735104,half-life,"The fraction absorbed orally (mean +/- SEM) was 0.27 +/- 0.03; the half-life was 5.29 +/- 0.47 h; the steady-state volume of distribution was 38.4 +/- 6.4 mL/kg, and the clearance was 8.87 +/- 1.76 mL X h-1 X kg-1.",Absorption and disposition of aluminum in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735104/),h,5.29,203734,DB01370,Aluminium
,3735104,steady-state volume of distribution,"The fraction absorbed orally (mean +/- SEM) was 0.27 +/- 0.03; the half-life was 5.29 +/- 0.47 h; the steady-state volume of distribution was 38.4 +/- 6.4 mL/kg, and the clearance was 8.87 +/- 1.76 mL X h-1 X kg-1.",Absorption and disposition of aluminum in the rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735104/),[ml] / [kg],38.4,203735,DB01370,Aluminium
,3735104,clearance,"The fraction absorbed orally (mean +/- SEM) was 0.27 +/- 0.03; the half-life was 5.29 +/- 0.47 h; the steady-state volume of distribution was 38.4 +/- 6.4 mL/kg, and the clearance was 8.87 +/- 1.76 mL X h-1 X kg-1.",Absorption and disposition of aluminum in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735104/),[ml] / [h·kg],8.87,203736,DB01370,Aluminium
,3735104,Plasma protein binding,Plasma protein binding was determined to be approximately 98%.,Absorption and disposition of aluminum in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735104/),%,98,203737,DB01370,Aluminium
,1487550,maximum peak plasma concentration (Cmax),"The pharmacokinetic parameters for droxicam given alone were: maximum peak plasma concentration (Cmax) = 1.53 +/- .21 micrograms/mL (mean +/- SD), time to peak concentration (Tmax) = 7.5 +/- 2.1 hr, t1/2a = 1.38 +/- .82 hour, t1/2el = 53.3 +/- 11.9 hr, Cl/F = 2.98 +/- .71 mL/min, volume of distribution (Vd/F) = 13.2 +/- 1.8 L and area under the curve (AUC) = 117.6 +/- 26.8 micrograms/hour/mL.",The effect of antacid and ranitidine on droxicam pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487550/),[μg] / [ml],1.53,207156,DB01370,Aluminium
,1487550,time to peak concentration (Tmax),"The pharmacokinetic parameters for droxicam given alone were: maximum peak plasma concentration (Cmax) = 1.53 +/- .21 micrograms/mL (mean +/- SD), time to peak concentration (Tmax) = 7.5 +/- 2.1 hr, t1/2a = 1.38 +/- .82 hour, t1/2el = 53.3 +/- 11.9 hr, Cl/F = 2.98 +/- .71 mL/min, volume of distribution (Vd/F) = 13.2 +/- 1.8 L and area under the curve (AUC) = 117.6 +/- 26.8 micrograms/hour/mL.",The effect of antacid and ranitidine on droxicam pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487550/),h,7.5,207157,DB01370,Aluminium
,1487550,t1/2a,"The pharmacokinetic parameters for droxicam given alone were: maximum peak plasma concentration (Cmax) = 1.53 +/- .21 micrograms/mL (mean +/- SD), time to peak concentration (Tmax) = 7.5 +/- 2.1 hr, t1/2a = 1.38 +/- .82 hour, t1/2el = 53.3 +/- 11.9 hr, Cl/F = 2.98 +/- .71 mL/min, volume of distribution (Vd/F) = 13.2 +/- 1.8 L and area under the curve (AUC) = 117.6 +/- 26.8 micrograms/hour/mL.",The effect of antacid and ranitidine on droxicam pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487550/),h,1.38,207158,DB01370,Aluminium
,1487550,t1/2el,"The pharmacokinetic parameters for droxicam given alone were: maximum peak plasma concentration (Cmax) = 1.53 +/- .21 micrograms/mL (mean +/- SD), time to peak concentration (Tmax) = 7.5 +/- 2.1 hr, t1/2a = 1.38 +/- .82 hour, t1/2el = 53.3 +/- 11.9 hr, Cl/F = 2.98 +/- .71 mL/min, volume of distribution (Vd/F) = 13.2 +/- 1.8 L and area under the curve (AUC) = 117.6 +/- 26.8 micrograms/hour/mL.",The effect of antacid and ranitidine on droxicam pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487550/),h,53.3,207159,DB01370,Aluminium
,1487550,Cl/F,"The pharmacokinetic parameters for droxicam given alone were: maximum peak plasma concentration (Cmax) = 1.53 +/- .21 micrograms/mL (mean +/- SD), time to peak concentration (Tmax) = 7.5 +/- 2.1 hr, t1/2a = 1.38 +/- .82 hour, t1/2el = 53.3 +/- 11.9 hr, Cl/F = 2.98 +/- .71 mL/min, volume of distribution (Vd/F) = 13.2 +/- 1.8 L and area under the curve (AUC) = 117.6 +/- 26.8 micrograms/hour/mL.",The effect of antacid and ranitidine on droxicam pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487550/),[ml] / [min],2.98,207160,DB01370,Aluminium
,1487550,volume of distribution (Vd/F),"The pharmacokinetic parameters for droxicam given alone were: maximum peak plasma concentration (Cmax) = 1.53 +/- .21 micrograms/mL (mean +/- SD), time to peak concentration (Tmax) = 7.5 +/- 2.1 hr, t1/2a = 1.38 +/- .82 hour, t1/2el = 53.3 +/- 11.9 hr, Cl/F = 2.98 +/- .71 mL/min, volume of distribution (Vd/F) = 13.2 +/- 1.8 L and area under the curve (AUC) = 117.6 +/- 26.8 micrograms/hour/mL.",The effect of antacid and ranitidine on droxicam pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487550/),l,13.2,207161,DB01370,Aluminium
,1487550,area under the curve (AUC),"The pharmacokinetic parameters for droxicam given alone were: maximum peak plasma concentration (Cmax) = 1.53 +/- .21 micrograms/mL (mean +/- SD), time to peak concentration (Tmax) = 7.5 +/- 2.1 hr, t1/2a = 1.38 +/- .82 hour, t1/2el = 53.3 +/- 11.9 hr, Cl/F = 2.98 +/- .71 mL/min, volume of distribution (Vd/F) = 13.2 +/- 1.8 L and area under the curve (AUC) = 117.6 +/- 26.8 micrograms/hour/mL.",The effect of antacid and ranitidine on droxicam pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1487550/),[μg] / [h·ml],117.6,207162,DB01370,Aluminium
,2858279,terminal t1/2,"In the remaining subjects, temazepam elimination was biphasic, with the terminal t1/2 ranging from 11 to 77 hours.",Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2858279/),h,11 to 77,208543,DB01370,Aluminium
,2858279,percent free,The percent free temazepam in plasma from dialysis subjects ranged from 4.4% to 8.8% (mean = 5.9%).,Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2858279/),,4,208544,DB01370,Aluminium
,2858279,percent free,The percent free temazepam in plasma from dialysis subjects ranged from 4.4% to 8.8% (mean = 5.9%).,Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2858279/),,8.,208545,DB01370,Aluminium
,2858279,percent free,The percent free temazepam in plasma from dialysis subjects ranged from 4.4% to 8.8% (mean = 5.9%).,Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2858279/),,5,208546,DB01370,Aluminium
,8494374,nonrenal clearance,The mean nonrenal clearance increased from 13.27 +/- 3.33 to 15.68 +/- 2.35 liters/h (18.2%) following the antacid regimen.,Effect of oral antacids on disposition of intravenous enoxacin. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8494374/),[l] / [h],13.27,209158,DB01370,Aluminium
,8494374,nonrenal clearance,The mean nonrenal clearance increased from 13.27 +/- 3.33 to 15.68 +/- 2.35 liters/h (18.2%) following the antacid regimen.,Effect of oral antacids on disposition of intravenous enoxacin. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8494374/),[l] / [h],15.68,209159,DB01370,Aluminium
,2334155,bioavailabilities,"When norfloxacin was given 5 min after Maalox and Titralac, the bioavailabilities were 9.02 and 37.5%, respectively, relative to that for 400 mg of norfloxacin alone.",Inhibition of norfloxacin absorption by antacids. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2334155/),%,9.02,215906,DB01370,Aluminium
,2334155,bioavailabilities,"When norfloxacin was given 5 min after Maalox and Titralac, the bioavailabilities were 9.02 and 37.5%, respectively, relative to that for 400 mg of norfloxacin alone.",Inhibition of norfloxacin absorption by antacids. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2334155/),%,37.5,215907,DB01370,Aluminium
,2334155,relative bioavailability,"When Maalox was given 2 h after norfloxacin, maximal concentrations of norfloxacin in plasma occurred between 1 and 1.5 h postdose, and absorption was reduced to a lesser extent, with a relative bioavailability of 81.31%.",Inhibition of norfloxacin absorption by antacids. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2334155/),%,81.31,215908,DB01370,Aluminium
,9204774,friability,Hard spherical beads of aluminum alginate and aluminum carboxymethylcellulose with a narrow particle size distribution (1.60 +/- 0.12 and 3.10 +/- 0.20 mm) and low friability (0.5 and 1.4%) respectively were obtained with high yield (80-90%) and a drug content approaching 70-80%.,Comparative study of in-vitro release and bioavailability of sustained release diclofenac sodium from certain hydrophilic polymers and commercial tablets in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9204774/),%,0.5,218180,DB01370,Aluminium
,9204774,friability,Hard spherical beads of aluminum alginate and aluminum carboxymethylcellulose with a narrow particle size distribution (1.60 +/- 0.12 and 3.10 +/- 0.20 mm) and low friability (0.5 and 1.4%) respectively were obtained with high yield (80-90%) and a drug content approaching 70-80%.,Comparative study of in-vitro release and bioavailability of sustained release diclofenac sodium from certain hydrophilic polymers and commercial tablets in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9204774/),%,1.4,218181,DB01370,Aluminium
,9204774,Kel,"They showed Kel values of 0.02 +/- 0.01 and 0.3 +/- 0.01 h-1 and these correspond to t1/2 of 34.65 and 27.70 for the Na-alginate and NaCMC beads, respectively.",Comparative study of in-vitro release and bioavailability of sustained release diclofenac sodium from certain hydrophilic polymers and commercial tablets in beagle dogs. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9204774/),1/[h],0.02,218182,DB01370,Aluminium
,9204774,Kel,"They showed Kel values of 0.02 +/- 0.01 and 0.3 +/- 0.01 h-1 and these correspond to t1/2 of 34.65 and 27.70 for the Na-alginate and NaCMC beads, respectively.",Comparative study of in-vitro release and bioavailability of sustained release diclofenac sodium from certain hydrophilic polymers and commercial tablets in beagle dogs. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9204774/),1/[h],0.3,218183,DB01370,Aluminium
,9204774,t1/2,"They showed Kel values of 0.02 +/- 0.01 and 0.3 +/- 0.01 h-1 and these correspond to t1/2 of 34.65 and 27.70 for the Na-alginate and NaCMC beads, respectively.",Comparative study of in-vitro release and bioavailability of sustained release diclofenac sodium from certain hydrophilic polymers and commercial tablets in beagle dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9204774/),,34.65,218184,DB01370,Aluminium
,9204774,t1/2,"They showed Kel values of 0.02 +/- 0.01 and 0.3 +/- 0.01 h-1 and these correspond to t1/2 of 34.65 and 27.70 for the Na-alginate and NaCMC beads, respectively.",Comparative study of in-vitro release and bioavailability of sustained release diclofenac sodium from certain hydrophilic polymers and commercial tablets in beagle dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9204774/),,27.70,218185,DB01370,Aluminium
,9204774,mean residence time (MRT),"They also showed mean residence time (MRT) values of 9.56 +/- 2.5 and 7.86 +/- 0.54 h, respectively.",Comparative study of in-vitro release and bioavailability of sustained release diclofenac sodium from certain hydrophilic polymers and commercial tablets in beagle dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9204774/),h,9.56,218186,DB01370,Aluminium
,9204774,mean residence time (MRT),"They also showed mean residence time (MRT) values of 9.56 +/- 2.5 and 7.86 +/- 0.54 h, respectively.",Comparative study of in-vitro release and bioavailability of sustained release diclofenac sodium from certain hydrophilic polymers and commercial tablets in beagle dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9204774/),h,7.86,218187,DB01370,Aluminium
,9204774,relative bioavailability,"The relative bioavailability of the two formulations were 59.01 and 47.96%, respectively, relative to that of the commercial Voltaren Retard tablets of Ciba-Geigy which showed a Kel of 0.044 h-1 corresponding to a t1/2 of 15.75 h and MRT of 7.45 +/- 1.10 h.",Comparative study of in-vitro release and bioavailability of sustained release diclofenac sodium from certain hydrophilic polymers and commercial tablets in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9204774/),%,59.01,218188,DB01370,Aluminium
,9204774,relative bioavailability,"The relative bioavailability of the two formulations were 59.01 and 47.96%, respectively, relative to that of the commercial Voltaren Retard tablets of Ciba-Geigy which showed a Kel of 0.044 h-1 corresponding to a t1/2 of 15.75 h and MRT of 7.45 +/- 1.10 h.",Comparative study of in-vitro release and bioavailability of sustained release diclofenac sodium from certain hydrophilic polymers and commercial tablets in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9204774/),%,47.96,218189,DB01370,Aluminium
,9204774,Kel,"The relative bioavailability of the two formulations were 59.01 and 47.96%, respectively, relative to that of the commercial Voltaren Retard tablets of Ciba-Geigy which showed a Kel of 0.044 h-1 corresponding to a t1/2 of 15.75 h and MRT of 7.45 +/- 1.10 h.",Comparative study of in-vitro release and bioavailability of sustained release diclofenac sodium from certain hydrophilic polymers and commercial tablets in beagle dogs. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9204774/),1/[h],0.044,218190,DB01370,Aluminium
,9204774,t1/2,"The relative bioavailability of the two formulations were 59.01 and 47.96%, respectively, relative to that of the commercial Voltaren Retard tablets of Ciba-Geigy which showed a Kel of 0.044 h-1 corresponding to a t1/2 of 15.75 h and MRT of 7.45 +/- 1.10 h.",Comparative study of in-vitro release and bioavailability of sustained release diclofenac sodium from certain hydrophilic polymers and commercial tablets in beagle dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9204774/),h,15.75,218191,DB01370,Aluminium
,9204774,MRT,"The relative bioavailability of the two formulations were 59.01 and 47.96%, respectively, relative to that of the commercial Voltaren Retard tablets of Ciba-Geigy which showed a Kel of 0.044 h-1 corresponding to a t1/2 of 15.75 h and MRT of 7.45 +/- 1.10 h.",Comparative study of in-vitro release and bioavailability of sustained release diclofenac sodium from certain hydrophilic polymers and commercial tablets in beagle dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9204774/),h,7.45,218192,DB01370,Aluminium
,8658538,unbound distribution,"The extent of unbound distribution (an indicator of the mechanism of BBB permeation) was 0.9 and 1.2 for the frontal cortex and lateral ventricle for CP20, and was 1.1 and 1.6 for CP94, suggesting diffusion across the BBB.","The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2 dimethly-, 1,2 diethyl-, and 1-[ethan-1'ol]-2-methyl-3-hydroxypyridin-4-one in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8658538/),,0.9,220027,DB01370,Aluminium
,8658538,unbound distribution,"The extent of unbound distribution (an indicator of the mechanism of BBB permeation) was 0.9 and 1.2 for the frontal cortex and lateral ventricle for CP20, and was 1.1 and 1.6 for CP94, suggesting diffusion across the BBB.","The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2 dimethly-, 1,2 diethyl-, and 1-[ethan-1'ol]-2-methyl-3-hydroxypyridin-4-one in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8658538/),,1.2,220028,DB01370,Aluminium
,8658538,unbound distribution,"The extent of unbound distribution (an indicator of the mechanism of BBB permeation) was 0.9 and 1.2 for the frontal cortex and lateral ventricle for CP20, and was 1.1 and 1.6 for CP94, suggesting diffusion across the BBB.","The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2 dimethly-, 1,2 diethyl-, and 1-[ethan-1'ol]-2-methyl-3-hydroxypyridin-4-one in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8658538/),,1.1,220029,DB01370,Aluminium
,8658538,unbound distribution,"The extent of unbound distribution (an indicator of the mechanism of BBB permeation) was 0.9 and 1.2 for the frontal cortex and lateral ventricle for CP20, and was 1.1 and 1.6 for CP94, suggesting diffusion across the BBB.","The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2 dimethly-, 1,2 diethyl-, and 1-[ethan-1'ol]-2-methyl-3-hydroxypyridin-4-one in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8658538/),,1.6,220030,DB01370,Aluminium
,8658538,unbound distribution,"The extent of unbound distribution of CP40 was 0.2 for both the frontal cortex and lateral ventricle, suggesting the presence of a transporter moving it out of brain extracellular fluid.","The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2 dimethly-, 1,2 diethyl-, and 1-[ethan-1'ol]-2-methyl-3-hydroxypyridin-4-one in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8658538/),,0.2,220031,DB01370,Aluminium
,1759833,total amount of ofloxacin excreted in urine,"The total amount of ofloxacin excreted in urine had a mean value of 163.59 +/- 22.13 mg when ofloxacin was administered alone, 152.41 +/- 18.76 mg when it was administered with Al3+, and 146.49 +/- 14.85 mg when it was administered with Fe2+.",Effects of two cations on gastrointestinal absorption of ofloxacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1759833/),mg,163.59,220352,DB01370,Aluminium
,1759833,total amount of ofloxacin excreted in urine,"The total amount of ofloxacin excreted in urine had a mean value of 163.59 +/- 22.13 mg when ofloxacin was administered alone, 152.41 +/- 18.76 mg when it was administered with Al3+, and 146.49 +/- 14.85 mg when it was administered with Fe2+.",Effects of two cations on gastrointestinal absorption of ofloxacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1759833/),mg,152.41,220353,DB01370,Aluminium
,1759833,total amount of ofloxacin excreted in urine,"The total amount of ofloxacin excreted in urine had a mean value of 163.59 +/- 22.13 mg when ofloxacin was administered alone, 152.41 +/- 18.76 mg when it was administered with Al3+, and 146.49 +/- 14.85 mg when it was administered with Fe2+.",Effects of two cations on gastrointestinal absorption of ofloxacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1759833/),mg,146.49,220354,DB01370,Aluminium
,7938042,half-lives,"The half-lives of aluminum in liver (56 vs 17 days), muscle (33 vs 16 days), and serum (12 vs 8 days) were significantly greater in anemic than normal rats, respectively.",Tissue turnover of aluminum and Ga-67: effect of iron status. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7938042/),d,56,222455,DB01370,Aluminium
,7938042,half-lives,"The half-lives of aluminum in liver (56 vs 17 days), muscle (33 vs 16 days), and serum (12 vs 8 days) were significantly greater in anemic than normal rats, respectively.",Tissue turnover of aluminum and Ga-67: effect of iron status. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7938042/),d,17,222456,DB01370,Aluminium
,7938042,half-lives,"The half-lives of aluminum in liver (56 vs 17 days), muscle (33 vs 16 days), and serum (12 vs 8 days) were significantly greater in anemic than normal rats, respectively.",Tissue turnover of aluminum and Ga-67: effect of iron status. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7938042/),d,33,222457,DB01370,Aluminium
,7938042,half-lives,"The half-lives of aluminum in liver (56 vs 17 days), muscle (33 vs 16 days), and serum (12 vs 8 days) were significantly greater in anemic than normal rats, respectively.",Tissue turnover of aluminum and Ga-67: effect of iron status. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7938042/),d,16,222458,DB01370,Aluminium
,7938042,half-lives,"The half-lives of aluminum in liver (56 vs 17 days), muscle (33 vs 16 days), and serum (12 vs 8 days) were significantly greater in anemic than normal rats, respectively.",Tissue turnover of aluminum and Ga-67: effect of iron status. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7938042/),d,12,222459,DB01370,Aluminium
,7938042,half-lives,"The half-lives of aluminum in liver (56 vs 17 days), muscle (33 vs 16 days), and serum (12 vs 8 days) were significantly greater in anemic than normal rats, respectively.",Tissue turnover of aluminum and Ga-67: effect of iron status. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7938042/),d,8,222460,DB01370,Aluminium
,7938042,half-life,"The turnover of Ga-67 from the first compartment was rapid (half-life = 0.8 and 0.6 days) in anemic and normal rats, respectively, and was similar to the turnover of Ga-67 from the Gl tract (half-life = 0.7 and 0.6 days in anemic and normal rats, respectively).",Tissue turnover of aluminum and Ga-67: effect of iron status. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7938042/),d,0.8,222461,DB01370,Aluminium
,7938042,half-life,"The turnover of Ga-67 from the first compartment was rapid (half-life = 0.8 and 0.6 days) in anemic and normal rats, respectively, and was similar to the turnover of Ga-67 from the Gl tract (half-life = 0.7 and 0.6 days in anemic and normal rats, respectively).",Tissue turnover of aluminum and Ga-67: effect of iron status. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7938042/),d,0.6,222462,DB01370,Aluminium
,7938042,half-life,"The turnover of Ga-67 from the first compartment was rapid (half-life = 0.8 and 0.6 days) in anemic and normal rats, respectively, and was similar to the turnover of Ga-67 from the Gl tract (half-life = 0.7 and 0.6 days in anemic and normal rats, respectively).",Tissue turnover of aluminum and Ga-67: effect of iron status. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7938042/),d,0.7,222463,DB01370,Aluminium
,7938042,turnover,"The turnover of Ga-67 from the second compartment was also rapid (2.8 vs 4.0 days in anemic and normal rats, respectively).",Tissue turnover of aluminum and Ga-67: effect of iron status. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7938042/),d,2.8,222464,DB01370,Aluminium
,7938042,turnover,"The turnover of Ga-67 from the second compartment was also rapid (2.8 vs 4.0 days in anemic and normal rats, respectively).",Tissue turnover of aluminum and Ga-67: effect of iron status. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7938042/),d,4.0,222465,DB01370,Aluminium
,7999822,Peak plasma concentrations (Cmax),Peak plasma concentrations (Cmax) were +PB: 22.7 mg/L (15.3-32.6) (median and range) and -PB: 23.2 mg/L (18.9-27.4).,Phosphate binders do not reduce bioavailability of oral cefuroxime-axetil in patients on peritoneal dialysis treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7999822/),[mg] / [l],22.7,223242,DB01370,Aluminium
,7999822,Peak plasma concentrations (Cmax),Peak plasma concentrations (Cmax) were +PB: 22.7 mg/L (15.3-32.6) (median and range) and -PB: 23.2 mg/L (18.9-27.4).,Phosphate binders do not reduce bioavailability of oral cefuroxime-axetil in patients on peritoneal dialysis treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7999822/),[mg] / [l],23.2,223243,DB01370,Aluminium
,7999822,area under the curve (AUC),The area under the curve (AUC) of the plasma levels was +PB: 364 mg h/L (247-530) and -PB: 368 mg h/L (296-438).,Phosphate binders do not reduce bioavailability of oral cefuroxime-axetil in patients on peritoneal dialysis treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7999822/),[h·mg] / [l],364,223244,DB01370,Aluminium
,7999822,area under the curve (AUC),The area under the curve (AUC) of the plasma levels was +PB: 364 mg h/L (247-530) and -PB: 368 mg h/L (296-438).,Phosphate binders do not reduce bioavailability of oral cefuroxime-axetil in patients on peritoneal dialysis treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7999822/),[h·mg] / [l],368,223245,DB01370,Aluminium
,7999822,plasma elimination half-life (t1/2),The plasma elimination half-life (t1/2) was +PB: 13.9 h (11.5-14.6) and -PB: 13.8 h (12.2-15.4).,Phosphate binders do not reduce bioavailability of oral cefuroxime-axetil in patients on peritoneal dialysis treatment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7999822/),h,13.9,223246,DB01370,Aluminium
,7999822,plasma elimination half-life (t1/2),The plasma elimination half-life (t1/2) was +PB: 13.9 h (11.5-14.6) and -PB: 13.8 h (12.2-15.4).,Phosphate binders do not reduce bioavailability of oral cefuroxime-axetil in patients on peritoneal dialysis treatment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7999822/),h,13.8,223247,DB01370,Aluminium
,7999822,concentrations,Cefuroxime concentrations in the peritoneal effluent from the first exchange were 1.9 mg/L (0.5-6.2) (+PB) and 3.4 mg/L (2.1-4.7) (-PB).,Phosphate binders do not reduce bioavailability of oral cefuroxime-axetil in patients on peritoneal dialysis treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7999822/),[mg] / [l],1.9,223248,DB01370,Aluminium
,7999822,concentrations,Cefuroxime concentrations in the peritoneal effluent from the first exchange were 1.9 mg/L (0.5-6.2) (+PB) and 3.4 mg/L (2.1-4.7) (-PB).,Phosphate binders do not reduce bioavailability of oral cefuroxime-axetil in patients on peritoneal dialysis treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7999822/),[mg] / [l],3.4,223249,DB01370,Aluminium
,2982276,fractional excretion of,"In the presence of endogenous PTH, the fractional excretion of phosphate (FEPi) increased significantly after 3 h of Al infusion (6.1 +/- 0.9 to 15.0 +/- 1.8%, P less than 0.05, n = 8), but not in controls (n = 7), while plasma calcium and Pi decreased, suggesting a PTH effect.",Effect of aluminum on the renal handling of phosphate in the rat. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2982276/),,6.1,224997,DB01370,Aluminium
,2982276,fractional excretion of,"In the presence of endogenous PTH, the fractional excretion of phosphate (FEPi) increased significantly after 3 h of Al infusion (6.1 +/- 0.9 to 15.0 +/- 1.8%, P less than 0.05, n = 8), but not in controls (n = 7), while plasma calcium and Pi decreased, suggesting a PTH effect.",Effect of aluminum on the renal handling of phosphate in the rat. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2982276/),,15.0,224998,DB01370,Aluminium
,7742805,CL,The CL with normal renal function was 0.178 (l/h/kg).,Premarketing population pharmacokinetic study of levofloxacin in normal subjects and patients with infectious diseases. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7742805/),[l] / [h·kg],0.178,225026,DB01370,Aluminium
,7742805,apparent volume of distribution (Vd),The apparent volume of distribution (Vd) was calculated to be 1.46 (l/kg).,Premarketing population pharmacokinetic study of levofloxacin in normal subjects and patients with infectious diseases. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7742805/),[l] / [kg],1.46,225027,DB01370,Aluminium
,11295258,bioavailability,Oral Al bioavailability averaged 0.28%.,Aluminum bioavailability from drinking water is very low and is not appreciably influenced by stomach contents or water hardness. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295258/),%,0.28,225803,DB01370,Aluminium
,11295258,oral bioavailability,"The present and published results suggest oral bioavailability of Al from drinking water is very low, about 0.3%.",Aluminum bioavailability from drinking water is very low and is not appreciably influenced by stomach contents or water hardness. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295258/),%,0.3,225804,DB01370,Aluminium
,7940560,steady state volumes of distribution,"The Al-HP steady state volumes of distribution ranged from 220 to 871 ml/kg, suggesting that each complex distributed out of the vascular compartment (which should have been approximately 65 ml/kg).",Pharmacokinetics of aluminum 3-hydroxypyridin-4-one complexes: implications for aluminum redistribution subsequent to chelation therapy. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7940560/),[ml] / [kg],220 to 871,226141,DB01370,Aluminium
,7940560,Systemic clearances,Systemic clearances ranged from 189 to 906 ml/h per kg.,Pharmacokinetics of aluminum 3-hydroxypyridin-4-one complexes: implications for aluminum redistribution subsequent to chelation therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7940560/),[ml] / [h·kg],189 to 906,226142,DB01370,Aluminium
,7940560,Elimination half-lives (t1/2),"Elimination half-lives (t1/2) and mean residence times ranged from 0.36 to 0.84 and 0.52 to 1.20 h, respectively.",Pharmacokinetics of aluminum 3-hydroxypyridin-4-one complexes: implications for aluminum redistribution subsequent to chelation therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7940560/),h,0.36 to 0.84,226143,DB01370,Aluminium
,7940560,mean residence times,"Elimination half-lives (t1/2) and mean residence times ranged from 0.36 to 0.84 and 0.52 to 1.20 h, respectively.",Pharmacokinetics of aluminum 3-hydroxypyridin-4-one complexes: implications for aluminum redistribution subsequent to chelation therapy. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7940560/),h,0.52 to 1.20,226144,DB01370,Aluminium
,30295193,bioavailability enhancement,"Enhanced in vitro dissolution rate of optimized solid SMEDDS manifested in bioavailability enhancement of 167.54% and 188.98%, as compared to pure drug and marketed product.",Role of Porous Carriers in the Biopharmaceutical Performance of Solid SMEDDS of Canagliflozin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30295193/),%,167.54,226367,DB01370,Aluminium
,30295193,bioavailability enhancement,"Enhanced in vitro dissolution rate of optimized solid SMEDDS manifested in bioavailability enhancement of 167.54% and 188.98%, as compared to pure drug and marketed product.",Role of Porous Carriers in the Biopharmaceutical Performance of Solid SMEDDS of Canagliflozin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30295193/),%,188.98,226368,DB01370,Aluminium
,6489427,Concentrations,Concentrations across the membrane fall from 120 ng/ml to 10 ng/ml.,Sequestration of fentanyl by the cardiopulmonary bypass (CPBP). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489427/),[ng] / [ml],120,232885,DB01370,Aluminium
,6489427,Concentrations,Concentrations across the membrane fall from 120 ng/ml to 10 ng/ml.,Sequestration of fentanyl by the cardiopulmonary bypass (CPBP). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489427/),[ng] / [ml],10,232886,DB01370,Aluminium
,10049268,maximum concentration of drug in serum (Cmax),"Both fasting conditions produced similar results: a mean (+/- standard deviation) EMB maximum concentration of drug in serum (Cmax) of 4.5 +/- 1.0 micrograms/ml, time to maximum concentration of drug in serum (Tmax) of 2.5 +/- 0.9 h, and area under the concentration-time curve from 0 h to infinity (AUC0-infinity) of 28.9 +/- 4.7 micrograms.h/ml.","Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10049268/),[μg] / [ml],4.5,233519,DB01370,Aluminium
,10049268,time to maximum concentration of drug in serum (Tmax),"Both fasting conditions produced similar results: a mean (+/- standard deviation) EMB maximum concentration of drug in serum (Cmax) of 4.5 +/- 1.0 micrograms/ml, time to maximum concentration of drug in serum (Tmax) of 2.5 +/- 0.9 h, and area under the concentration-time curve from 0 h to infinity (AUC0-infinity) of 28.9 +/- 4.7 micrograms.h/ml.","Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10049268/),h,2.5,233520,DB01370,Aluminium
,10049268,area under the concentration-time curve from 0 h to infinity (AUC0-infinity),"Both fasting conditions produced similar results: a mean (+/- standard deviation) EMB maximum concentration of drug in serum (Cmax) of 4.5 +/- 1.0 micrograms/ml, time to maximum concentration of drug in serum (Tmax) of 2.5 +/- 0.9 h, and area under the concentration-time curve from 0 h to infinity (AUC0-infinity) of 28.9 +/- 4.7 micrograms.h/ml.","Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10049268/),[h·μg] / [ml],28.9,233521,DB01370,Aluminium
,10049268,Cmax,"In the presence of antacids, subjects had a mean Cmax of 3.3 +/- 0.5 micrograms/ml, Tmax of 2.9 +/- 1.2 h, and AUC0-infinity of 27.5 +/- 5.9 micrograms.h/ml.","Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10049268/),[μg] / [ml],3.3,233522,DB01370,Aluminium
,10049268,Tmax,"In the presence of antacids, subjects had a mean Cmax of 3.3 +/- 0.5 micrograms/ml, Tmax of 2.9 +/- 1.2 h, and AUC0-infinity of 27.5 +/- 5.9 micrograms.h/ml.","Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10049268/),h,2.9,233523,DB01370,Aluminium
,10049268,AUC0-infinity,"In the presence of antacids, subjects had a mean Cmax of 3.3 +/- 0.5 micrograms/ml, Tmax of 2.9 +/- 1.2 h, and AUC0-infinity of 27.5 +/- 5.9 micrograms.h/ml.","Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10049268/),[h·μg] / [ml],27.5,233524,DB01370,Aluminium
,10049268,Cmax,"In the presence of the Food and Drug Administration high-fat meal, subjects had a mean Cmax of 3.8 +/- 0.8 micrograms/ml, Tmax of 3.2 +/- 1.3 h, and AUC0-infinity of 29.6 +/- 4.7 micrograms.h/ml.","Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10049268/),[μg] / [ml],3.8,233525,DB01370,Aluminium
,10049268,Tmax,"In the presence of the Food and Drug Administration high-fat meal, subjects had a mean Cmax of 3.8 +/- 0.8 micrograms/ml, Tmax of 3.2 +/- 1.3 h, and AUC0-infinity of 29.6 +/- 4.7 micrograms.h/ml.","Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10049268/),h,3.2,233526,DB01370,Aluminium
,10049268,AUC0-infinity,"In the presence of the Food and Drug Administration high-fat meal, subjects had a mean Cmax of 3.8 +/- 0.8 micrograms/ml, Tmax of 3.2 +/- 1.3 h, and AUC0-infinity of 29.6 +/- 4.7 micrograms.h/ml.","Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10049268/),[h·μg] / [ml],29.6,233527,DB01370,Aluminium
,9176037,urinary,"3. The 5 h urinary 26Al excretion amounted to 0.1 +/- 0.02, 0.7 +/- 0.2, 5.1 +/- 1.5 and 0.1 +/- 0.1% of administered dose in the four groups respectively.",Intestinal absorption of trace amounts of aluminium in rats studied with 26aluminium and accelerator mass spectrometry. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176037/),%,0.1,238312,DB01370,Aluminium
,9176037,urinary,"3. The 5 h urinary 26Al excretion amounted to 0.1 +/- 0.02, 0.7 +/- 0.2, 5.1 +/- 1.5 and 0.1 +/- 0.1% of administered dose in the four groups respectively.",Intestinal absorption of trace amounts of aluminium in rats studied with 26aluminium and accelerator mass spectrometry. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176037/),%,0.7,238313,DB01370,Aluminium
,9176037,urinary,"3. The 5 h urinary 26Al excretion amounted to 0.1 +/- 0.02, 0.7 +/- 0.2, 5.1 +/- 1.5 and 0.1 +/- 0.1% of administered dose in the four groups respectively.",Intestinal absorption of trace amounts of aluminium in rats studied with 26aluminium and accelerator mass spectrometry. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176037/),%,5.1,238314,DB01370,Aluminium
,9176037,urinary,"3. The 5 h urinary 26Al excretion amounted to 0.1 +/- 0.02, 0.7 +/- 0.2, 5.1 +/- 1.5 and 0.1 +/- 0.1% of administered dose in the four groups respectively.",Intestinal absorption of trace amounts of aluminium in rats studied with 26aluminium and accelerator mass spectrometry. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176037/),%,0.1,238315,DB01370,Aluminium
,9176037,26Al excretion,"3. The 5 h urinary 26Al excretion amounted to 0.1 +/- 0.02, 0.7 +/- 0.2, 5.1 +/- 1.5 and 0.1 +/- 0.1% of administered dose in the four groups respectively.",Intestinal absorption of trace amounts of aluminium in rats studied with 26aluminium and accelerator mass spectrometry. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176037/),%,0.1,238316,DB01370,Aluminium
,9176037,26Al excretion,"3. The 5 h urinary 26Al excretion amounted to 0.1 +/- 0.02, 0.7 +/- 0.2, 5.1 +/- 1.5 and 0.1 +/- 0.1% of administered dose in the four groups respectively.",Intestinal absorption of trace amounts of aluminium in rats studied with 26aluminium and accelerator mass spectrometry. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176037/),%,0.7,238317,DB01370,Aluminium
,9176037,26Al excretion,"3. The 5 h urinary 26Al excretion amounted to 0.1 +/- 0.02, 0.7 +/- 0.2, 5.1 +/- 1.5 and 0.1 +/- 0.1% of administered dose in the four groups respectively.",Intestinal absorption of trace amounts of aluminium in rats studied with 26aluminium and accelerator mass spectrometry. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176037/),%,5.1,238318,DB01370,Aluminium
,9176037,26Al excretion,"3. The 5 h urinary 26Al excretion amounted to 0.1 +/- 0.02, 0.7 +/- 0.2, 5.1 +/- 1.5 and 0.1 +/- 0.1% of administered dose in the four groups respectively.",Intestinal absorption of trace amounts of aluminium in rats studied with 26aluminium and accelerator mass spectrometry. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176037/),%,0.1,238319,DB01370,Aluminium
,9176037,fractional intestinal absorption,4. We conclude that the fractional intestinal absorption of trace oral doses of aluminium hydroxide is at least 0.1% (compared with the previous estimate of 0.01% using large 27Al oral loads).,Intestinal absorption of trace amounts of aluminium in rats studied with 26aluminium and accelerator mass spectrometry. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176037/),%,0.1,238320,DB01370,Aluminium
,9176037,fractional intestinal absorption,4. We conclude that the fractional intestinal absorption of trace oral doses of aluminium hydroxide is at least 0.1% (compared with the previous estimate of 0.01% using large 27Al oral loads).,Intestinal absorption of trace amounts of aluminium in rats studied with 26aluminium and accelerator mass spectrometry. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176037/),%,0.01,238321,DB01370,Aluminium
,9176037,Absorption,"Absorption of aluminium citrate given alone is significantly greater (0.7%) and is further increased to 5% by the accompanying sodium citrate, consistent with an enhancing effect of added citrate upon mucosal aluminium permeability.",Intestinal absorption of trace amounts of aluminium in rats studied with 26aluminium and accelerator mass spectrometry. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176037/),%,0.7,238322,DB01370,Aluminium
,9176037,Absorption,"Absorption of aluminium citrate given alone is significantly greater (0.7%) and is further increased to 5% by the accompanying sodium citrate, consistent with an enhancing effect of added citrate upon mucosal aluminium permeability.",Intestinal absorption of trace amounts of aluminium in rats studied with 26aluminium and accelerator mass spectrometry. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176037/),%,5,238323,DB01370,Aluminium
,8696074,fractional,"Using a urinary excretion factor based on the results of previous studies, the fractional aluminium uptake from each of the species was calculated: aluminium citrate, 5.23 x 10(-3); aluminium hydroxide, 1.04 x 10(-4); aluminium hydroxide with citrate, 1.36 x 10(-3).",The bioavailability of 26Al-labelled aluminium citrate and aluminium hydroxide in volunteers. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8696074/),,5.23 x 10(-3),239534,DB01370,Aluminium
,8696074,fractional,"Using a urinary excretion factor based on the results of previous studies, the fractional aluminium uptake from each of the species was calculated: aluminium citrate, 5.23 x 10(-3); aluminium hydroxide, 1.04 x 10(-4); aluminium hydroxide with citrate, 1.36 x 10(-3).",The bioavailability of 26Al-labelled aluminium citrate and aluminium hydroxide in volunteers. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8696074/),,1.04 x 10(-4),239535,DB01370,Aluminium
,8696074,fractional,"Using a urinary excretion factor based on the results of previous studies, the fractional aluminium uptake from each of the species was calculated: aluminium citrate, 5.23 x 10(-3); aluminium hydroxide, 1.04 x 10(-4); aluminium hydroxide with citrate, 1.36 x 10(-3).",The bioavailability of 26Al-labelled aluminium citrate and aluminium hydroxide in volunteers. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8696074/),,1.36 x 10(-3),239536,DB01370,Aluminium
,2324845,half-life,Serum fluoride concentrations decreased with a half-life of 3.3 to 6.9 hours after work.,"Fluoride, aluminum, and phosphate kinetics in cryolite workers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2324845/),h,3.3 to 6.9,239781,DB01370,Aluminium
,2324845,clearance,Fluoride clearance was 40.5 to 76.5 mL/min at urinary flow rates of 0.89 to 2.21 mL/min.,"Fluoride, aluminum, and phosphate kinetics in cryolite workers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2324845/),[ml] / [min],40.5 to 76.5,239782,DB01370,Aluminium
,2324845,urinary flow rates,Fluoride clearance was 40.5 to 76.5 mL/min at urinary flow rates of 0.89 to 2.21 mL/min.,"Fluoride, aluminum, and phosphate kinetics in cryolite workers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2324845/),[ml] / [min],0.89 to 2.21,239783,DB01370,Aluminium
,32383076,IC50(αvβ6),"Both demonstrated excellent affinity and selectivity for integrin αvβ6 by ELISA (IC50(αvβ6) = 3-7 nM vs IC50(αvβ3) > 10 μM) and in cell binding studies (51.0 ± 0.7 % and 47.2 ± 0.7 % of total radioactivity bound to DX3puroβ6 cells at 1 h, respectively, vs. ≤ 1.2 % to DX3puro for both compounds).",The Effects of an Albumin Binding Moiety on the Targeting and Pharmacokinetics of an Integrin αvβ6-Selective Peptide Labeled with Aluminum [18F]Fluoride. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32383076/),nM,3-7,244109,DB01370,Aluminium
>,32383076,IC50(αvβ3),"Both demonstrated excellent affinity and selectivity for integrin αvβ6 by ELISA (IC50(αvβ6) = 3-7 nM vs IC50(αvβ3) > 10 μM) and in cell binding studies (51.0 ± 0.7 % and 47.2 ± 0.7 % of total radioactivity bound to DX3puroβ6 cells at 1 h, respectively, vs. ≤ 1.2 % to DX3puro for both compounds).",The Effects of an Albumin Binding Moiety on the Targeting and Pharmacokinetics of an Integrin αvβ6-Selective Peptide Labeled with Aluminum [18F]Fluoride. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32383076/),μM,10,244110,DB01370,Aluminium
,32383076,uptake,"In vivo studies confirmed the effect of the ABM on blood circulation (≤ 0.1 % ID/g remaining in blood for [18F]AlF 1 as soon as 1 h p.i. vs. > 2 % ID/g for [18F]AlF 2 at 6 h p.i.) and higher αvβ6(+) tumor uptake (4 h: DX3puroβ6; [18F]AlF 1: 3.0 ± 0.7 % ID/g, [18F]AlF 2: 7.2 ± 0.7 % ID/g; BxPC-3; [18F]AlF 2: 10.2 ± 0.1 % ID/g).",The Effects of an Albumin Binding Moiety on the Targeting and Pharmacokinetics of an Integrin αvβ6-Selective Peptide Labeled with Aluminum [18F]Fluoride. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32383076/),%,3.0,244111,DB01370,Aluminium
,32383076,uptake,"In vivo studies confirmed the effect of the ABM on blood circulation (≤ 0.1 % ID/g remaining in blood for [18F]AlF 1 as soon as 1 h p.i. vs. > 2 % ID/g for [18F]AlF 2 at 6 h p.i.) and higher αvβ6(+) tumor uptake (4 h: DX3puroβ6; [18F]AlF 1: 3.0 ± 0.7 % ID/g, [18F]AlF 2: 7.2 ± 0.7 % ID/g; BxPC-3; [18F]AlF 2: 10.2 ± 0.1 % ID/g).",The Effects of an Albumin Binding Moiety on the Targeting and Pharmacokinetics of an Integrin αvβ6-Selective Peptide Labeled with Aluminum [18F]Fluoride. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32383076/),%,7.2,244112,DB01370,Aluminium
,32383076,uptake,"In vivo studies confirmed the effect of the ABM on blood circulation (≤ 0.1 % ID/g remaining in blood for [18F]AlF 1 as soon as 1 h p.i. vs. > 2 % ID/g for [18F]AlF 2 at 6 h p.i.) and higher αvβ6(+) tumor uptake (4 h: DX3puroβ6; [18F]AlF 1: 3.0 ± 0.7 % ID/g, [18F]AlF 2: 7.2 ± 0.7 % ID/g; BxPC-3; [18F]AlF 2: 10.2 ± 0.1 % ID/g).",The Effects of an Albumin Binding Moiety on the Targeting and Pharmacokinetics of an Integrin αvβ6-Selective Peptide Labeled with Aluminum [18F]Fluoride. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32383076/),%,10.2,244113,DB01370,Aluminium
,10460103,Cmax,"Both fasting conditions produced similar results: a mean INH Cmax of 5.53 +/- 2.92 microg/ml, Tmax of 1.02 +/- 1.10 hours, and AUC0-infinity of 20.16 +/- 12.45 microg x hr/ml.","Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460103/),[μg] / [ml],5.53,246003,DB01370,Aluminium
,10460103,Tmax,"Both fasting conditions produced similar results: a mean INH Cmax of 5.53 +/- 2.92 microg/ml, Tmax of 1.02 +/- 1.10 hours, and AUC0-infinity of 20.16 +/- 12.45 microg x hr/ml.","Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460103/),h,1.02,246004,DB01370,Aluminium
,10460103,AUC0-infinity,"Both fasting conditions produced similar results: a mean INH Cmax of 5.53 +/- 2.92 microg/ml, Tmax of 1.02 +/- 1.10 hours, and AUC0-infinity of 20.16 +/- 12.45 microg x hr/ml.","Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460103/),[h·μg] / [ml],20.16,246005,DB01370,Aluminium
,10460103,Cmax,"Antacids did not alter these parameters significantly (Cmax of 5.62 +/- 2.53 microg/ml, Tmax of 0.71 +/- 0.56 hours, and AUC0-infinity of 20.27 +/- 11.39 microg x hr/ml).","Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460103/),[μg] / [ml],5.62,246006,DB01370,Aluminium
,10460103,Tmax,"Antacids did not alter these parameters significantly (Cmax of 5.62 +/- 2.53 microg/ml, Tmax of 0.71 +/- 0.56 hours, and AUC0-infinity of 20.27 +/- 11.39 microg x hr/ml).","Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460103/),h,0.71,246007,DB01370,Aluminium
,10460103,AUC0-infinity,"Antacids did not alter these parameters significantly (Cmax of 5.62 +/- 2.53 microg/ml, Tmax of 0.71 +/- 0.56 hours, and AUC0-infinity of 20.27 +/- 11.39 microg x hr/ml).","Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460103/),[h·μg] / [ml],20.27,246008,DB01370,Aluminium
,10460103,Cmax,"In contrast, the high-fat meal recommended by the Food and Drug Administration reduced INH Cmax by 51% (2.73 +/- 1.70 microg/ml), nearly doubled Tmax (1.93 +/- 1.61 hours), and reduced AUC0-infinity by 12% (17.72 +/- 10.32 microg x hr/ml).","Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460103/),[μg] / [ml],2.73,246009,DB01370,Aluminium
,10460103,Tmax,"In contrast, the high-fat meal recommended by the Food and Drug Administration reduced INH Cmax by 51% (2.73 +/- 1.70 microg/ml), nearly doubled Tmax (1.93 +/- 1.61 hours), and reduced AUC0-infinity by 12% (17.72 +/- 10.32 microg x hr/ml).","Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460103/),h,1.93,246010,DB01370,Aluminium
,10460103,AUC0-infinity,"In contrast, the high-fat meal recommended by the Food and Drug Administration reduced INH Cmax by 51% (2.73 +/- 1.70 microg/ml), nearly doubled Tmax (1.93 +/- 1.61 hours), and reduced AUC0-infinity by 12% (17.72 +/- 10.32 microg x hr/ml).","Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460103/),[h·μg] / [ml],17.72,246011,DB01370,Aluminium
,11413863,Tmax,Tmax of crushed pantoprazole was earlier as compared to the intact tablet (0.5 h vs. 3 h) and Cmax was approximately 10% higher due to faster absorption.,Bioavailability of a crushed pantoprazole tablet after buffering with sodium hydrogencarbonate or magaldrate relative to the intact enteric coated pantoprazole tablet. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11413863/),h,0.5,247800,DB01370,Aluminium
,11413863,Tmax,Tmax of crushed pantoprazole was earlier as compared to the intact tablet (0.5 h vs. 3 h) and Cmax was approximately 10% higher due to faster absorption.,Bioavailability of a crushed pantoprazole tablet after buffering with sodium hydrogencarbonate or magaldrate relative to the intact enteric coated pantoprazole tablet. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11413863/),h,3,247801,DB01370,Aluminium
,11413863,bioavailability,"The bioavailability of the crushed pantoprazole tablet relative to the intact pantoprazole tablet was 93% when using sodium hydrogencarbonate as the buffering agent, and 88% when using magaldrate.",Bioavailability of a crushed pantoprazole tablet after buffering with sodium hydrogencarbonate or magaldrate relative to the intact enteric coated pantoprazole tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11413863/),%,93,247802,DB01370,Aluminium
,11413863,bioavailability,"The bioavailability of the crushed pantoprazole tablet relative to the intact pantoprazole tablet was 93% when using sodium hydrogencarbonate as the buffering agent, and 88% when using magaldrate.",Bioavailability of a crushed pantoprazole tablet after buffering with sodium hydrogencarbonate or magaldrate relative to the intact enteric coated pantoprazole tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11413863/),%,88,247803,DB01370,Aluminium
,32458378,total radioactivity recovered,"In the human mass balance study, mean total radioactivity recovered was 98.3% of the dose administered (53.1% and 45.2% excreted via urine and feces, respectively).","Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32458378/),,98.,248833,DB01370,Aluminium
,32458378,total radioactivity recovered,"In the human mass balance study, mean total radioactivity recovered was 98.3% of the dose administered (53.1% and 45.2% excreted via urine and feces, respectively).","Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32458378/),%,53.1,248834,DB01370,Aluminium
,32458378,total radioactivity recovered,"In the human mass balance study, mean total radioactivity recovered was 98.3% of the dose administered (53.1% and 45.2% excreted via urine and feces, respectively).","Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32458378/),%,45.2,248835,DB01370,Aluminium
,6896647,serum half-life,After i.v. injection in rats the 14C-radioactivity has a very short serum half-life of 1 h and is excreted almost completely by the kidneys.,"Sucralfate: pharmacokinetics, metabolism and selective binding to experimental gastric and duodenal ulcers in animals. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6896647/),h,1,249487,DB01370,Aluminium
,6747022,Absolute bioavailability,Absolute bioavailability of DZ-SR averaged 0.98 +/- 0.06.,Absolute bioavailability and effect of food and antacid on diazepam absorption from a slow-release preparation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6747022/),,0.98,250391,DB01370,Aluminium
,9925057,maximal serum concentration (Cmax),"Both fasting conditions produced similar results: a mean RIF maximal serum concentration (Cmax) of 10.54+/-3.18 microg/mL, the time at which it occurred (Tmax) of 2.42+/-1.32 h, and the area under the curve from time zero to infinity (AUC0-infinity) of 57.15+/-13.41 microg x h/mL.","Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9925057/),[μg] / [ml],10.54,252957,DB01370,Aluminium
,9925057,time at which it occurred (Tmax),"Both fasting conditions produced similar results: a mean RIF maximal serum concentration (Cmax) of 10.54+/-3.18 microg/mL, the time at which it occurred (Tmax) of 2.42+/-1.32 h, and the area under the curve from time zero to infinity (AUC0-infinity) of 57.15+/-13.41 microg x h/mL.","Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9925057/),h,2.42,252958,DB01370,Aluminium
,9925057,area under the curve from time zero to infinity (AUC0-infinity),"Both fasting conditions produced similar results: a mean RIF maximal serum concentration (Cmax) of 10.54+/-3.18 microg/mL, the time at which it occurred (Tmax) of 2.42+/-1.32 h, and the area under the curve from time zero to infinity (AUC0-infinity) of 57.15+/-13.41 microg x h/mL.","Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9925057/),[h·μg] / [ml],57.15,252959,DB01370,Aluminium
,9925057,Cmax,"Antacids did not alter these parameters (Cmax of 10.89+/-5.22 microg/mL, Tmax of 2.36+/-1.28 h, and AUC0-infinity of 58.37+/-18.49 microg x h/mL).","Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9925057/),[μg] / [ml],10.89,252960,DB01370,Aluminium
,9925057,Tmax,"Antacids did not alter these parameters (Cmax of 10.89+/-5.22 microg/mL, Tmax of 2.36+/-1.28 h, and AUC0-infinity of 58.37+/-18.49 microg x h/mL).","Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9925057/),h,2.36,252961,DB01370,Aluminium
,9925057,AUC0-infinity,"Antacids did not alter these parameters (Cmax of 10.89+/-5.22 microg/mL, Tmax of 2.36+/-1.28 h, and AUC0-infinity of 58.37+/-18.49 microg x h/mL).","Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9925057/),[h·μg] / [ml],58.37,252962,DB01370,Aluminium
,9925057,Cmax,"In contrast, the Food and Drug Administration high-fat meal reduced RIF Cmax by 36% (7.27+/-2.29 microg/mL), nearly doubled Tmax (4.43+/-1.09 h), but reduced AUC0-infinity by only 6% (55.20+/-14.48 microg x h/mL).","Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9925057/),[μg] / [ml],7.27,252963,DB01370,Aluminium
,9925057,Tmax,"In contrast, the Food and Drug Administration high-fat meal reduced RIF Cmax by 36% (7.27+/-2.29 microg/mL), nearly doubled Tmax (4.43+/-1.09 h), but reduced AUC0-infinity by only 6% (55.20+/-14.48 microg x h/mL).","Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9925057/),h,4.43,252964,DB01370,Aluminium
,9925057,AUC0-infinity,"In contrast, the Food and Drug Administration high-fat meal reduced RIF Cmax by 36% (7.27+/-2.29 microg/mL), nearly doubled Tmax (4.43+/-1.09 h), but reduced AUC0-infinity by only 6% (55.20+/-14.48 microg x h/mL).","Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9925057/),[h·μg] / [ml],55.20,252965,DB01370,Aluminium
,3094570,Absolute bioavailability,Absolute bioavailability of oral flecainide averaged 70% (range 60-86%).,"Flecainide: single and multiple oral dose kinetics, absolute bioavailability and effect of food and antacid in man. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094570/),%,70,254852,DB01370,Aluminium
,3094570,apparent volume of distribution,The apparent volume of distribution of 5.5 +/- 0.3 l kg-1 indicates wide distribution of flecainide in tissues.,"Flecainide: single and multiple oral dose kinetics, absolute bioavailability and effect of food and antacid in man. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094570/),[l] / [kg],5.5,254853,DB01370,Aluminium
,3094570,elimination half-lives,"Estimated elimination half-lives from plasma data averaged 9.3 to 12.4 h (single oral dose studies), 11.8 h (single i.v. dose), and 11.5 h (multiple oral dose).","Flecainide: single and multiple oral dose kinetics, absolute bioavailability and effect of food and antacid in man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094570/),h,9.3 to 12.4,254854,DB01370,Aluminium
,3094570,elimination half-lives,"Estimated elimination half-lives from plasma data averaged 9.3 to 12.4 h (single oral dose studies), 11.8 h (single i.v. dose), and 11.5 h (multiple oral dose).","Flecainide: single and multiple oral dose kinetics, absolute bioavailability and effect of food and antacid in man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094570/),h,11.8,254855,DB01370,Aluminium
,3094570,elimination half-lives,"Estimated elimination half-lives from plasma data averaged 9.3 to 12.4 h (single oral dose studies), 11.8 h (single i.v. dose), and 11.5 h (multiple oral dose).","Flecainide: single and multiple oral dose kinetics, absolute bioavailability and effect of food and antacid in man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094570/),h,11.5,254856,DB01370,Aluminium
,3094570,CLNR,Following i.v. dosing CLNR and CLR averaged respectively 3.24 +/- 0.80 and 2.38 +/- 0.49 ml min-1 kg-1.,"Flecainide: single and multiple oral dose kinetics, absolute bioavailability and effect of food and antacid in man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094570/),[ml] / [kg·min],3.24,254857,DB01370,Aluminium
,3094570,CLR,Following i.v. dosing CLNR and CLR averaged respectively 3.24 +/- 0.80 and 2.38 +/- 0.49 ml min-1 kg-1.,"Flecainide: single and multiple oral dose kinetics, absolute bioavailability and effect of food and antacid in man. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094570/),[ml] / [kg·min],2.38,254858,DB01370,Aluminium
,3094570,trough,"After 200 mg twice daily oral treatment steady state was reached within 3-4 days with trough and peak plasma levels on day 8 of 457 and 662 ng ml-1, which are well within the therapeutic range.","Flecainide: single and multiple oral dose kinetics, absolute bioavailability and effect of food and antacid in man. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094570/),[ng] / [ml],457,254859,DB01370,Aluminium
,3094570,peak plasma levels,"After 200 mg twice daily oral treatment steady state was reached within 3-4 days with trough and peak plasma levels on day 8 of 457 and 662 ng ml-1, which are well within the therapeutic range.","Flecainide: single and multiple oral dose kinetics, absolute bioavailability and effect of food and antacid in man. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094570/),[ng] / [ml],662,254860,DB01370,Aluminium
,3753709,PR,"With phosphorus restriction, the serum concentration of 1,25-(OH)2D increased by 80% from a mean of 38 +/- 3 to 68 +/- 6 pg/ml, P less than 0.001; the PR increased from 1.8 +/- 0.2 to 3.8 +/- 0.6 micrograms/d, P less than 0.005; the MCR did not change significantly.","Oral intake of phosphorus can determine the serum concentration of 1,25-dihydroxyvitamin D by determining its production rate in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3753709/),,1,260591,DB01370,Aluminium
,3753709,PR,"With phosphorus restriction, the serum concentration of 1,25-(OH)2D increased by 80% from a mean of 38 +/- 3 to 68 +/- 6 pg/ml, P less than 0.001; the PR increased from 1.8 +/- 0.2 to 3.8 +/- 0.6 micrograms/d, P less than 0.005; the MCR did not change significantly.","Oral intake of phosphorus can determine the serum concentration of 1,25-dihydroxyvitamin D by determining its production rate in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3753709/),,3,260592,DB01370,Aluminium
,3753709,PR,"The PR decreased to 1.3 +/- 0.2 micrograms/d, P less than 0.05; the MCR did not change significantly.","Oral intake of phosphorus can determine the serum concentration of 1,25-dihydroxyvitamin D by determining its production rate in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3753709/),,1,260593,DB01370,Aluminium
,2316233,area under the concentration-time curve (AUC),"The mean area under the concentration-time curve (AUC) (23.11 +/- 5.21 mg.h/L), time to reach maximum concentration (tmax) (3.13 +/- 0.64 h), maximum serum concentration (1.44 +/- 0.41 mg/L), and elimination rate constant (0.069 +/- 0.010-h) observed during the control phase of the trial did not differ significantly (p greater than 0.05) from values obtained during the coadministration of aluminum hydroxide with quinidine gluconate (23.91 +/- 4.48 mg.h/L, 4.13 +/- 2.12 h, 1.53 +/- 0.34 mg/L, and 0.077 +/- 0.013-h, respectively).",Effect of aluminum hydroxide gel on quinidine gluconate absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316233/),[h·mg] / [l],23.11,261161,DB01370,Aluminium
,2316233,time to reach maximum concentration (tmax),"The mean area under the concentration-time curve (AUC) (23.11 +/- 5.21 mg.h/L), time to reach maximum concentration (tmax) (3.13 +/- 0.64 h), maximum serum concentration (1.44 +/- 0.41 mg/L), and elimination rate constant (0.069 +/- 0.010-h) observed during the control phase of the trial did not differ significantly (p greater than 0.05) from values obtained during the coadministration of aluminum hydroxide with quinidine gluconate (23.91 +/- 4.48 mg.h/L, 4.13 +/- 2.12 h, 1.53 +/- 0.34 mg/L, and 0.077 +/- 0.013-h, respectively).",Effect of aluminum hydroxide gel on quinidine gluconate absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316233/),h,3.13,261162,DB01370,Aluminium
,2316233,maximum serum concentration,"The mean area under the concentration-time curve (AUC) (23.11 +/- 5.21 mg.h/L), time to reach maximum concentration (tmax) (3.13 +/- 0.64 h), maximum serum concentration (1.44 +/- 0.41 mg/L), and elimination rate constant (0.069 +/- 0.010-h) observed during the control phase of the trial did not differ significantly (p greater than 0.05) from values obtained during the coadministration of aluminum hydroxide with quinidine gluconate (23.91 +/- 4.48 mg.h/L, 4.13 +/- 2.12 h, 1.53 +/- 0.34 mg/L, and 0.077 +/- 0.013-h, respectively).",Effect of aluminum hydroxide gel on quinidine gluconate absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316233/),[mg] / [l],1.44,261163,DB01370,Aluminium
,2316233,maximum serum concentration,"The mean area under the concentration-time curve (AUC) (23.11 +/- 5.21 mg.h/L), time to reach maximum concentration (tmax) (3.13 +/- 0.64 h), maximum serum concentration (1.44 +/- 0.41 mg/L), and elimination rate constant (0.069 +/- 0.010-h) observed during the control phase of the trial did not differ significantly (p greater than 0.05) from values obtained during the coadministration of aluminum hydroxide with quinidine gluconate (23.91 +/- 4.48 mg.h/L, 4.13 +/- 2.12 h, 1.53 +/- 0.34 mg/L, and 0.077 +/- 0.013-h, respectively).",Effect of aluminum hydroxide gel on quinidine gluconate absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316233/),[h·mg] / [l],23.91,261164,DB01370,Aluminium
,2316233,maximum serum concentration,"The mean area under the concentration-time curve (AUC) (23.11 +/- 5.21 mg.h/L), time to reach maximum concentration (tmax) (3.13 +/- 0.64 h), maximum serum concentration (1.44 +/- 0.41 mg/L), and elimination rate constant (0.069 +/- 0.010-h) observed during the control phase of the trial did not differ significantly (p greater than 0.05) from values obtained during the coadministration of aluminum hydroxide with quinidine gluconate (23.91 +/- 4.48 mg.h/L, 4.13 +/- 2.12 h, 1.53 +/- 0.34 mg/L, and 0.077 +/- 0.013-h, respectively).",Effect of aluminum hydroxide gel on quinidine gluconate absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316233/),h,4.13,261165,DB01370,Aluminium
,2316233,elimination rate constant,"The mean area under the concentration-time curve (AUC) (23.11 +/- 5.21 mg.h/L), time to reach maximum concentration (tmax) (3.13 +/- 0.64 h), maximum serum concentration (1.44 +/- 0.41 mg/L), and elimination rate constant (0.069 +/- 0.010-h) observed during the control phase of the trial did not differ significantly (p greater than 0.05) from values obtained during the coadministration of aluminum hydroxide with quinidine gluconate (23.91 +/- 4.48 mg.h/L, 4.13 +/- 2.12 h, 1.53 +/- 0.34 mg/L, and 0.077 +/- 0.013-h, respectively).",Effect of aluminum hydroxide gel on quinidine gluconate absorption. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316233/),,0.069,261166,DB01370,Aluminium
,9191556,retention,"26AI retention in brain and liver were approximately 4 x 10(-8) and 2 x 10(-6), respectively.","Gastrointestinal absorption, tissue retention, and urinary excretion of dietary aluminum in rats determined by using 26Al. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9191556/),,4 x 10(-8),266286,DB01370,Aluminium
,9191556,retention,"26AI retention in brain and liver were approximately 4 x 10(-8) and 2 x 10(-6), respectively.","Gastrointestinal absorption, tissue retention, and urinary excretion of dietary aluminum in rats determined by using 26Al. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9191556/),,2 x 10(-6),266287,DB01370,Aluminium
,2610509,Maximum cefixime concentrations,"Maximum cefixime concentrations in serum for regimens i through iv were (mean +/- standard deviation) 4.9 +/- 1.4, 5.7 +/- 1.3, 5.1 +/- 1.0, and 5.5 +/- 1.5 micrograms/ml, respectively.",Influence of an antacid containing aluminum and magnesium on the pharmacokinetics of cefixime. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2610509/),[μg] / [ml],4.9,269413,DB01370,Aluminium
,2610509,Maximum cefixime concentrations,"Maximum cefixime concentrations in serum for regimens i through iv were (mean +/- standard deviation) 4.9 +/- 1.4, 5.7 +/- 1.3, 5.1 +/- 1.0, and 5.5 +/- 1.5 micrograms/ml, respectively.",Influence of an antacid containing aluminum and magnesium on the pharmacokinetics of cefixime. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2610509/),[μg] / [ml],5.7,269414,DB01370,Aluminium
,2610509,Maximum cefixime concentrations,"Maximum cefixime concentrations in serum for regimens i through iv were (mean +/- standard deviation) 4.9 +/- 1.4, 5.7 +/- 1.3, 5.1 +/- 1.0, and 5.5 +/- 1.5 micrograms/ml, respectively.",Influence of an antacid containing aluminum and magnesium on the pharmacokinetics of cefixime. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2610509/),[μg] / [ml],5.1,269415,DB01370,Aluminium
,2610509,Maximum cefixime concentrations,"Maximum cefixime concentrations in serum for regimens i through iv were (mean +/- standard deviation) 4.9 +/- 1.4, 5.7 +/- 1.3, 5.1 +/- 1.0, and 5.5 +/- 1.5 micrograms/ml, respectively.",Influence of an antacid containing aluminum and magnesium on the pharmacokinetics of cefixime. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2610509/),[μg] / [ml],5.5,269416,DB01370,Aluminium
,2610509,area under the serum concentration-time curve extrapolated to infinity,"Corresponding values for area under the serum concentration-time curve extrapolated to infinity were 38.3 +/- 14.5, 42.8 +/- 13.9, 38.5 +/- 9.8, and 41.6 +/- 16.7 micrograms.h/ml.",Influence of an antacid containing aluminum and magnesium on the pharmacokinetics of cefixime. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2610509/),[h·μg] / [ml],38.3,269417,DB01370,Aluminium
,2610509,area under the serum concentration-time curve extrapolated to infinity,"Corresponding values for area under the serum concentration-time curve extrapolated to infinity were 38.3 +/- 14.5, 42.8 +/- 13.9, 38.5 +/- 9.8, and 41.6 +/- 16.7 micrograms.h/ml.",Influence of an antacid containing aluminum and magnesium on the pharmacokinetics of cefixime. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2610509/),[h·μg] / [ml],42.8,269418,DB01370,Aluminium
,2610509,area under the serum concentration-time curve extrapolated to infinity,"Corresponding values for area under the serum concentration-time curve extrapolated to infinity were 38.3 +/- 14.5, 42.8 +/- 13.9, 38.5 +/- 9.8, and 41.6 +/- 16.7 micrograms.h/ml.",Influence of an antacid containing aluminum and magnesium on the pharmacokinetics of cefixime. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2610509/),[h·μg] / [ml],38.5,269419,DB01370,Aluminium
,2610509,area under the serum concentration-time curve extrapolated to infinity,"Corresponding values for area under the serum concentration-time curve extrapolated to infinity were 38.3 +/- 14.5, 42.8 +/- 13.9, 38.5 +/- 9.8, and 41.6 +/- 16.7 micrograms.h/ml.",Influence of an antacid containing aluminum and magnesium on the pharmacokinetics of cefixime. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2610509/),[h·μg] / [ml],41.6,269420,DB01370,Aluminium
,2000958,half-lives,"Until now, tracer studies of aluminum kinetics have not been possible because aluminum has only two isotopes, with half-lives of 6.5 min (29Al) and 7 x 10(5) yr (26Al), neither of which is suitable for conventional studies.",Accelerator mass spectrometry: application to study of aluminum kinetics in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2000958/),min,6.5,269945,DB01370,Aluminium
,2000958,half-lives,"Until now, tracer studies of aluminum kinetics have not been possible because aluminum has only two isotopes, with half-lives of 6.5 min (29Al) and 7 x 10(5) yr (26Al), neither of which is suitable for conventional studies.",Accelerator mass spectrometry: application to study of aluminum kinetics in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2000958/),yr,7 x 10(5),269946,DB01370,Aluminium
,2000958,Renal clearance,Renal clearance of 26Al was approximately 0.75 ml.min-1.kg body wt-1 in both rats.,Accelerator mass spectrometry: application to study of aluminum kinetics in the rat. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2000958/),[kg·ml] / [min],0.75,269947,DB01370,Aluminium
,1663108,Cmax,"The Cmax and AUC0-9 in saliva were generally in the range 1.05-1.40 mg/L and 4.89-6.16 mg.h/L, respectively, and were unaffected (P less than 0.05) by the metallic drugs, except aluminium hydroxide which lowered these values.",Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1663108/),[mg] / [l],1.05-1.40,272807,DB01370,Aluminium
,1663108,AUC0-9,"The Cmax and AUC0-9 in saliva were generally in the range 1.05-1.40 mg/L and 4.89-6.16 mg.h/L, respectively, and were unaffected (P less than 0.05) by the metallic drugs, except aluminium hydroxide which lowered these values.",Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1663108/),[h·mg] / [l],4.89-6.16,272808,DB01370,Aluminium
,9068926,peak drug plasma concentration (Cmax),"Plasma concentrations in healthy volunteers reach a mean peak drug plasma concentration (Cmax) of approximately 2.8 and 5.2 mg/L within 1 to 2 hours after oral administration of levofloxacin 250 and 500mg tablets, respectively.",The clinical pharmacokinetics of levofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[mg] / [l],2.8,273446,DB01370,Aluminium
,9068926,peak drug plasma concentration (Cmax),"Plasma concentrations in healthy volunteers reach a mean peak drug plasma concentration (Cmax) of approximately 2.8 and 5.2 mg/L within 1 to 2 hours after oral administration of levofloxacin 250 and 500mg tablets, respectively.",The clinical pharmacokinetics of levofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[mg] / [l],5.2,273447,DB01370,Aluminium
,9068926,bioavailability,The bioavailability of oral levofloxacin approaches 100% and is little affected by the administration with food.,The clinical pharmacokinetics of levofloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),%,100,273448,DB01370,Aluminium
,9068926,Cmax,"Single oral doses of levofloxacin 50 to 1000mg produce a mean Cmax and area under the concentration-time curve (AUC) ranging from approximately 0.6 to 9.4 mg/L and 4.7 to 108 mg.h/L, respectively, both increasing linearly in a dose-proportional fashion.",The clinical pharmacokinetics of levofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[mg] / [l],0.6 to 9.4,273449,DB01370,Aluminium
,9068926,area under the concentration-time curve (AUC),"Single oral doses of levofloxacin 50 to 1000mg produce a mean Cmax and area under the concentration-time curve (AUC) ranging from approximately 0.6 to 9.4 mg/L and 4.7 to 108 mg.h/L, respectively, both increasing linearly in a dose-proportional fashion.",The clinical pharmacokinetics of levofloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[h·mg] / [l],4.7 to 108,273450,DB01370,Aluminium
,9068926,volume of distribution,"Levofloxacin is widely distributed throughout the body, with a mean volume of distribution of 1.1 L/kg, and penetrates well into most body tissues and fluids.",The clinical pharmacokinetics of levofloxacin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[l] / [kg],1.1,273451,DB01370,Aluminium
,9068926,plasma elimination half-life (t1/2 beta),The plasma elimination half-life (t1/2 beta) ranges from 6 to 8 hours in individuals with normal renal function.,The clinical pharmacokinetics of levofloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),h,6 to 8,273452,DB01370,Aluminium
